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Abstract 
Gastrointestinal (GI) motility disorders such as irritable bowel syndrome (IBS) occur when 
coordinated smooth muscle contractile activity is disrupted. Although much is known about 
the ionic conductances responsible for GI smooth muscle contraction, comparably little is 
known about the underlying potassium (K+) channels responsible for suppressing smooth 
muscle contractility and promoting GI tract relaxation. Using a mouse model, quantitative 
real-time PCR was used to establish the expression profiles of 93 K+ channel α- and β-
subunit genes in ileum and colon. Immunostaining of selected K2P channel proteins, 
informed from the qPCR, revealed distinctive expression patterns. Specifically, the 
mechano-gated K2P channel, mTREK-1, was exclusively localised to smooth muscle of ileum 
and colon whereas the expression of related TREK-2 and TRAAK channel proteins was 
limited to enteric neurons. To assess the contribution of these K+ channels to the regulation 
of longitudinal smooth muscle tone, ileum and colon tissues were exposed to a variety of 
K2P channels modulators including BL-1249, CDC and riluzole using an organ bath 
preparation. Activation of mechano-gated K2P channels resulted in significant relaxation of 
both KCl and CCh pre-contracted ileum and colon tissues and reduced the amplitude of 
spontaneous contractions. Relaxation occurred in the presence of TTX, indicating a direct 
smooth muscle action of the K2P modulators. Given their prominent role in determining GI 
tract smooth muscle contractility, mouse homologues of the mechano-gated subfamily of 
channels were investigated further. Cloned mouse TREK-1, TREK-2 and TRAAK channels 
exhibited similar biophysical properties to their human homologues, with comparable 
sensitivity to well-known K2P activators AA, CDC and BL-1249. In contrast to previous 
findings, I reveal the proposed TREK-1 blocker, spadin, to possess the pharmacological 
2 
 
characteristics of an antagonist. Spadin specifically antagonised the activation of cloned 
TREK-1 channels by the polyunsaturated fatty acid, arachidonic acid (AA), but not by other 
pharmacological activators. The generation of a chimera with the spadin insensitive 
mTREK-2 channel indicated that the mechanism of action of spadin does not involve the C-
terminus directly, and likely works via an allosteric mechanism distinct from the AA binding 
site. This study has provided a new insight into the potassium channel subtype expression 
profile and function in mouse intestine, and highlights the mechano-gated K2P channel 
TREK-1 as a potential target for future drug development treating hypermotility GI 
disorders.  
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1.1 Gastrointestinal (GI) tract  
1.1.1 Anatomy and function of the GI tract 
The Gastrointestinal (GI) tract, also called the digestive tract, is a continuous pathway 
encompasses several organs within multicellular animals that allows the mixing and 
propulsion of intraluminal contents to enable efficient digestion of food, a progressive 
absorption of nutrients, and finally an excretion of residues. These functions are achieved 
through a series of organs with distinct roles from mouth to anus (Figure 1.1) (Greenwood-
Van Meerveld et al., 2017). The mouth, also known as the oral cavity, is the beginning of 
the GI tract. There are many accessory organs such as tongue, teeth and salivary glands 
that results in the initial phase of food digestion. Teeth masticate the food into small pieces, 
moistened by saliva before the tongue and other muscles push the food into the pharynx. 
The oesophagus is a muscular tube that takes the food bolus from the pharynx to the 
stomach. The major role of the stomach is firstly to act as a storage tank for holding food, 
but also to churn and break down food particles using hydrochloric acid and digestive 
enzymes secreted from the stomach wall to continue the process of digestion of food. The 
rest of non-liquefiable remnants are released from the stomach and pass through the small 
intestines to be eliminated (Tortora and Derrickson, 2009). The small intestine can be 
anatomically subdivided into three distinct regions, including duodenum, jejunum and 
ileum, which are principally responsible for digestion and absorption, a process 
incorporating both physical and chemical mechanisms, and almost 90% of digestion and 
absorption occurs here. Moreover, the digestive enzymes used in small intestine are 
released by the pancreas and bile from the liver, which both organs act as the accessory 
organ of GI tract. The large intestine is the last part of our digestive system, containing 
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proximal colon and distal colon, which are primarily concerned with desiccation and 
compaction of waste, with storage in the sigmoid colon and rectum prior to elimination 
(Cheng et al., 2010). 
 
Figure 1.1: The anatomy of human GI tract.  
 
1.1.2 Histology of the GI tract 
There are four layers of tissue in the GI tract, including mucosa, submucosa, muscularis and 
serosa (Figure 1.2). The mucosa is a mucous membrane making up the innermost layer of 
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the gut wall, lining the entire GI tract and can be subdivided into epithelium, lamina propria 
and muscularis mucosa. The epithelium in the small intestine and large intestine are 
composed of simple columnar epithelial cells. The intestinal gland (also called intestinal 
crypt) are found in the intestinal epithelium and contains multiple types of the cells: stem 
cell, Paneth cell, goblet cell, Tuft cell, enterocytes and enteroendocrine cells. These cells 
secrete mucous and enzymes such as cholecystokinin and secretin, and other bio-chemicals 
such as anti-microbial peptides that either protect the mucosa or aid in digestion (Clevers, 
2013). The submucosa is a connective tissue layer containing blood vessels, lymphatic 
vessels, submucosal glands and the submucosal plexus (also called the Meissner’s plexus). 
The submucosal plexus is a network of nerves derived from the myenteric plexus, 
containing neuronal cells that influence the contraction and relaxation of the circular 
smooth muscle. The muscularis is a muscle layer consists of an outer longitudinal and an 
inner circular muscle layer (Reed and Wickham, 2009), sandwiching another nerve network 
called the myenteric plexus (also known as the Auerbach’s plexus) which coordinates 
muscularis smooth muscle contractility (Furness et al., 2014). In addition, interstitial cells 
of Cajal (ICC), also known as pacemaker cells, are located around the circumference of the 
myenteric plexus, and through communication with enteric neurons and smooth muscle 
cells induce propagating electrical slow wave potentials leading to smooth muscle 
depolarisation, and thus helping to regulate the phasic contractile activity of GI smooth 
muscle that underlies peristalsis (Al-Shboul, 2013). The outermost layer of the gut wall is 
the serosa (or adventitia) containing a layer of connective tissue and a layer of cells that 
secrete serous fluid in order to reduces friction from muscle movement. 
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Figure 1.2: Diagram shows the layers of the GI tract identifying the sub-parts of the mucosa, 
submucosa, muscularis and serosa (Adapated from Tortora and Derrickson, 2009).  
 
1.2 Enteric nervous system (ENS)  
In vertebrates the nervous system consists of two main anatomical subdivisions, the central 
nervous system (CNS) and the peripheral nervous system (PNS). The CNS encompasses the 
brain and spinal cord, whereas the PNS can be divided into three subsystems; the somatic 
nervous system (SNS), the autonomic nervous system (ANS) and the enteric nervous 
system (ENS). The ENS is the largest and most complex unit of the PNS, and is the only 
substantial grouping of neurons that form a nervous system to generate activity 
independent of the CNS, unlike other autonomic neurons whose functions rely on signals 
transmitted from the CNS. Therefore, ENS is also referred to as the ‘‘second brain’’ in the 
body (Wood et al., 1999).  However, ENS activity can be modulated by the CNS through the 
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influence of parasympathetic and sympathetic inputs. It is this coordinated bidirectional 
communication of the CNS and the ENS which is largely responsible for the neuronal control 
of GI motility and its secretory activity (Rao and Gershon, 2018).  
 
Many properties of the ENS resemble the CNS and the conceptual model is the same 
(Figure 1.3). Similar to the CNS, the ENS consists of three major types of neurons which 
form neuronal microcircuits; sensory neurons (also referred to as intrinsic primary afferent 
neurons (IPANs)), interneurons and motor neurons. Sensory neurons have receptor regions 
responsible for detecting thermal, mechanical or chemical stimuli and translating them into 
signals, coded by action potentials, to other points in the nervous system. Interneurons are 
linked by synapses into networks that process information received from sensory neurons 
and control the kinetics of motor neurons.  Motor neurons will finally transmit the response 
signal to the effector systems by initiating appropriate reflex control of motility, secretion 
and blood flow (Furness, 2007). This diverse ENS neuronal network innervates the GI tract, 
and thus provides the intrinsic neuronal control and integration of virtually all GI functions. 
As such, dysregulation of the ENS has been shown to be implicated in multiple GI disorders, 
such as Irritable Bowel Syndrome (IBS), gastroparesis and chronic intestinal pseudo-
obstruction (Rao and Gershon, 2016). Furthermore, the ENS also communicates with many 
other cell types beyond muscular and secretory cells types, such as intestinal epithelial, 
endocrine and immune cells, to influence gut motility, intestinal infection and  even in sites 
distal from an initial pathogen entry (Rao and Gershon, 2018).  
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Figure 1.3: The conceptual model for the ENS is analagous to the CNS. Sensory neurons, 
interneurons and motor neurons are connected synaptically to form neuronal 
microcircuits. Information flow from sensory neurons to interneuronal integrative 
networks to motor neurons to effector systems ( Adapated from Wood et al., 1999).    
 
1.2.1 Anatomy of the ENS 
A vast amount of neurons are contained in the ENS, estimated to range between 200-600 
million cells in humans, which are required for programmatic control of  GI functions, and 
is comparable with  the number of neurons estimated in the spinal cord (Furness, 2007, 
Wood, 2012). The ENS of the GI tract is formed of a number of interconnected signalling 
networks containing neurons, axons and enteric glial cells which are positioned inside the 
muscle wall of the GI tract. These neurons and glial cells are generally grouped into clusters, 
known as enteric ganglia, which in turn are connected by fibre tracts to form ganglionated 
plexuses. Interganglionic fibre tracts contain projections from ganglion cell bodies in one 
ganglion that connect synaptically with neurons in neighbouring ganglia (Furness, 2008). 
Moreover, the cell bodies of ENS neurons are not like other autonomic ganglia which form 
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in grape-like clusters, they can be observed histologically to lay edge-to-edge like a single 
layer of coins in a 2-dimensional plane (Hanani et al., 1998).  
 
There are two major plexus in the ENS, the myenteric plexus located between the 
longitudinal and circular muscle layers, and the submucosal plexus located between the 
circular muscle and mucosa layer (Figure 1.4) (Furness, 2007). The network of the 
myenteric plexus is continuous around the circumference and along the GI tract, providing 
the neural regulation of contractions for both the longitudinal and circular smooth muscles, 
and thus primarily involved in the physiology of GI motility. In addition, most of the motor 
neurons that innervate the circular and longitudinal muscles cells which are located in the 
myenteric plexus (Brookes, 2001). Conversely, ganglion cells in the submucosal plexus 
mainly supply motor innervation to epithelial cells, secretory glands, blood vessels and 
inflammatory cells in the epithelial layer and also to the smooth muscle layer in the 
muscularis mucosae. As such, the submucosal plexus is mainly responsible for providing 
the neural regulation of mucosal function in the GI tract (Kunze and Furness, 1999).  
Furthermore, the submucosal plexus and myenteric plexus form an interplexus connection 
and reciprocally project to one another. For example, neurons in myenteric plexus project 
synaptic input from axons to the submucosal plexus, meanwhile received the fibres 
projecting from the submucosal plexus (Wood, 2012).  
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Figure 1.4: Anatomy of the enteric nervous system. Representation of the ENS in whole-
mount section (A) and cross sections (B) ( Adapated from Furness, 2007).  
 
1.2.2 Types of neurons in the ENS 
The ENS of humans consists of over 500 million neuron cells which make it the largest 
collection of neurons outside of brain (Furness, 2007). ENS neurons are diverse in terms of 
their combinations of features, such as morphology, neurochemical properties and 
functional activities. ENS neurons with distinct roles in GI function can be classified as 1) 
excitatory and inhibitory motor neurons, 2) interneurons and 3) Intrinsic primary afferent 
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neurons (IPANs), based on their morphologies, their projections, and the primary 
neurotransmitters they utilise (Figure 1.5 and Table 1.1). 
 
All the enteric neurons can be first sub-divided into 2 types by their morphology: Dogiel 
type I and Dogiel type II, as described by Jan von Dogiel in 1899 (Furness et al., 1998). Both 
types are present within the submucosal plexus as well as the myenteric plexus. Neurons 
with lamellar dendrites and a single axon are known as Dogiel type I neurons, which have 
been associated with motor neurons and interneurons. In contrast, Dogiel type II neurons 
have large round or oval cell bodies and multiple long axons and processes, which are 
processed by IPANs (Furness et al., 1998, Clerc et al., 1998, Costa et al., 2000).  
 
Over 30 functionally distinct types of neurons have been discovered which communicate 
using more than 25 different neurotransmitters in ENS. Neurotransmitters are a type of 
chemical messenger which transmit signals across a chemical synapse from one neuron to 
another ‘‘target cell’’ such as neuron, smooth muscle cell or gland cell, and affect gut 
motility, nutrient absorption, GI innate immune system, and the microbiome. (Mittal et al., 
2017). Moreover, the mechanism of chemically regulated synaptic transmission in the ENS 
is seemingly as complex as in the CNS. Enteric neurotransmitters include small molecules 
(e.g. acetylcholine (ACh) and glutamate), the mono-amine (e.g. noradrenaline (NA), 
serotonin (5-HT) and dopamine (DA)), large molecules (vasoactive intestinal peptide (VIP)), 
and gaseous signalling molecules (nitric oxide (NO) and carbon monoxide) (Lomax and 
Furness, 2000, Hansen, 2003). In general, neurons that secrete ACh and substance P (SP) 
are excitatory, which stimulate smooth muscle contraction, increase intestinal secretions, 
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release enteric hormones, and dilate blood vessels. In contrast, neurons that secrete NO 
and VIP are inhibitory, which stimulate smooth muscle relaxation (Nezami and Srinivasan, 
2010).  
 
Enteric neurons are also classified in terms of their function. IPANs function as sensory 
neurons and together with endocrine and immune cells establish a surveillance network 
which is essential for controlling digestion, the sensation of pain and energy and fluid 
homoeostasis in ENS (Holzer, 2002). Electrophysiological studies using intracellular 
recordings of myenteric neurons of the guinea-pig ileum indicate that there are two 
physiologically distinct enteric neuronal cell-types known as S (synaptic) and AH (after-
hyperpolarization) neurons (Hirst et al., 1974, Nishi and North, 1973). IPANs are thought to 
be AH neurons, which as a component of the action potential is carried by Ca2+ and a 
delayed and longer lasting after-hyperpolarizing (AHP) potential. Relatively, interneurons 
and motor neurons are known as S neurons, which have relatively high excitability and 
classified as tonically firing and are followed by a fast AHP (Furness, 2000, Smith et al., 
1999). Regarding interneurons, there is one type of ascending and three types descending 
interneurons which have been characterised in the small intestine (Table 1.1), of which 
most are the descending type. Unlike descending interneurons which are associated with 
a complex of neurotransmitters including 5-HT, ACh, NO and VIP, ascending interneurons 
are mainly cholinergic (Kunze and Furness, 1999, Hansen, 2003). Finally, excitatory and 
inhibitory muscle motor neurons receive innervation signals from ascending or descending 
interneurons, leading to neurotransmitter release, provoking contraction or relaxation of 
longitudinal and circular smooth muscles (Figure 1.5). 
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Figure 1.5: Schematic illustrating the major neuronal subtypes found in the enteric plexuses 
and highlighting the subset that forms the peristaltic reflex microcircuit. Luminal distention 
or mucosal deformation triggers direct activation of mechanoreceptive endings of intrinsic 
primary afferent neurons (IPANs) as well as indirect activation of IPANs upon serotonin (5-
HT) release by enterochromaffin cells (ECs) in the epithelium. IPANs release acetylcholine 
(ACh) to activate ascending and descending interneurons, which excite excitatory and 
inhibitory motor neurons, respectively. Motor neuron activity results in oral contraction 
and anal relaxation of intestinal smooth muscle, which propels luminal contents in the 
proximal–distal direction. Ascending interneurons express enkephalin (Enk) and 
descending interneurons release ACh and 5-HT. Excitatory motor neurons secrete ACh and 
substance P (SP), whereas inhibitory motor neurons secrete nitric oxide (NO), vasoactive 
intestinal peptide (VIP) and the purine β-nicotinamide adenine dinucleotide (βNAD). 
Secretomotor and vasomotor neurons of the submucosal plexus (SMP) secrete ACh or VIP. 
Taken from (Rao and Gershon, 2018). 
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Table 1.1: Types of neurons in the enteric nervous system. This table lists the neuron types 
that are found in the guinea-pig small intestine, some of their defining characteristics, and 
percentage occurrence in each of the ganglionated plexuses. I have also listed three types 
of motor neuron that are found in other parts of the tubular digestive tract, marked by 
asterisks*. Taken from (Furness, 2000).  
 
 
1.2.3 Enteric glia 
Enteric glia including enteric astrocytes, like their counterparts in the central nervous 
system provide structural and metabolic support for enteric neurons (Rao et al., 2015). 
There are two types of glial found in the enteric plexuses, the intramuscular glia, which are 
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interactive with nerve fibres coursing through the muscularis externa, and the mucosal glia, 
which located in the underneath the epithelium (Rao and Gershon, 2018). Recently, enteric 
glia have been suggested to be active contributors to the ENS and therefore GI tract 
functions, such as preventing inflammation and maintaining intestinal epithelial barrier 
integrity (Gulbransen and Sharkey, 2012). Furthermore, individual glia within the myenteric 
ganglion are electrically coupled to each other through gap junctions, allowing the cells to 
transmit Ca2+ waves.  It has been revealed that disruption of these Ca2+ signals can modify 
GI motility, indicating glia are actively involved in GI functioning and homeostasis (Maudlej 
and Hanani, 1992, McClain et al., 2015).  
 
1.3 Smooth muscle   
Smooth muscle cells are found in the walls of various organs and tubular structures of the 
body, including blood vessels in cardiovascular system, the GI tract, airways in the 
respiratory system, and in the urogenital system. In the GI tract, smooth muscles are 
organized into two layers, the circular smooth muscle layer and the longitudinal smooth 
muscle layer. Both smooth and cardiac muscle tissue are usually activated involuntarily, 
whereas skeletal muscle is considered voluntary which can be made to contract or relax by 
conscious control (Tortora and Derrickson, 2009).  Individual smooth muscle cells form both 
mechanical and electrical junctions with neighbouring cells to create a syncytium that 
underlies the coordination of contractions, forcing the food, water and waste to move 
though the gut, in a process called peristalsis (Sanders et al., 2012b). Peristaltic movement 
in GI tract comprises relaxation of circular smooth muscles, followed by their contraction 
to keep the substances from moving backward, then longitudinal contraction to push it 
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moving forward. These contractions manifest as either tonic and/or phasic contractions 
and are regulated by hormones, autonomic/involuntary nervous regulatory input and other 
local chemical signals (e.g. calcium ions). Moreover, smooth muscle contraction and 
relaxation is vastly slower and lasts much longer than skeletal muscle twitch or cardiac 
muscle contraction, and allows the muscle tone  to retain partial contraction thereby 
sustain long-term tone. This property is important in controlling blood pressure in the 
cardiovascular system and functioning of the GI tract, where the walls of blood vessels 
called arterioles and intestine, which maintain a steady pressure of blood, and a steady 
pressure on the contents of the tract, respectively (Keynes et al., 2011, Tortora and 
Derrickson, 2009).  
 
1.3.1 The role of interstitial cells  
GI smooth muscles are ‘‘autonomous’’ and produce spontaneous pacemaker activity 
(electrical slow waves). This intrinsic pacemaker activity generated from interstitial cells of 
Cajal (ICC), which are electrically coupled to smooth muscle cells via gap junction resulting 
in depolarization which initiates Ca2+ entry and contraction. A combination of intracellular 
timing of ICC and ion conductance generate the pacemaker currents which underlie slow 
waves and produces a continuous rhythmic cycle of depolarisation and repolarisation of 
smooth muscle cell membrane potential. This activity is characterised by spontaneous 
phasic contractions which are the foundation for peristaltic and segmental motility 
patterns (Koh et al., 2012, Sanders et al., 2016). Slow waves in the GI tract is independent 
of neural or hormonal inputs, although the frequency and force of contractions is highly 
dependent on neural and other regulatory inputs (Hennig et al., 2010). There are two types 
38 
 
of ICC found in the GI tract, myenteric ICC (ICC-MY) and intramuscular ICC (ICC-IM). ICC-IM 
pacemaker cells mediate the excitation of smooth muscle cells through receptor activation 
by neurotransmitters such as ACh and NO (Sanders et al., 2016, Sanders et al., 2006). Both 
inhibitory and excitatory neurons can regulate the amplitude of contractions, as basal 
spontaneous contractions have low amplitude contractions (Sanders et al., 2012b). As such, 
ICCs are hypothesised to be the cellular links between ENS neurons and intestinal smooth 
muscle cells (Sanders and Ward, 2006).  
 
1.3.2 The mechanism of smooth muscle contraction 
The contraction of smooth muscle is regulated mainly by external inputs from the 
autonomic nervous system via receptor activation or directly through mechanical stretch 
of the GI tract itself. These stimuli inducing a change in smooth muscle cell membrane 
potential permitting transmembrane influx of calcium ions (Ca2+) through both TRPC 
channels (Tsvilovskyy et al., 2009) and voltage-dependent calcium channels (VDCC) such as 
L-type Ca2+ channels (Ambudkar, 2009, Wegener et al., 2006). The mechanisms by which 
an increase in intracellular calcium stimulates GI smooth muscle contraction is illustrated 
in the Figure 1.6. Autonomic control of GI tract function occurs via neurotransmitter 
released from either parasympathetic nervous system (PNAS) or sympathetic nervous 
system (SNS) and receptor activation. Action potential induced exocytosis of acetylcholine 
(ACh) from parasympathetic post ganglionic neurons, triggers activation of G-protein 
coupled, metabotropic cholinergic receptors, the muscarinic receptor subtype 2 (M2) and 
subtype 3 (M3) located on post-synaptic smooth muscle cells. Stimulation of M2 receptors 
cause activation of pertussis toxin (PTX)-sensitive Gi/o proteins which opens TRPC4 channel 
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for Ca2+ influx. While the M3 is coupled to PTX-insensitive Gq/11 proteins that stimulate 
phospholipase C (PLC) and leads to hydrolyse phosphatidylinositol 4,5-bisphosphate (PIP2) 
to diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This IP3 signalling triggers 
intracellular Ca2+ release from intracellular Ca2+ stores called sarcoplasmic reticulum (SR) 
while DAG activates TRPC6 channels to cause Ca2+ influx from extracellular fluid. The 
activation of TRPC4/6 channels (Beech et al., 2004, Tsvilovskyy et al., 2009) depolarises 
membrane potential and leads to activation of VDCC, allowing further Ca2+ influx to the cell. 
The ensuing influx of Ca2+ cause the formation of Ca2+/calmodulin complex which activates 
myosin light chain kinase (MLCK), an enzyme that is capable of phosphorylating myosin 
light chains (MLC) in the presence of adenosine triphosphate (ATP). The myosin-binding 
subunit, when phosphorylated, inhibits the enzymatic activity of MLC phosphatase, 
allowing the light chain of myosin to remain phosphorylated, thereby promoting smooth 
muscle contraction. Finally, VDCC in the cell membrane will stay on opening in response to 
membrane depolarization that induced by mechanical stretch of the smooth muscle cells 
(Webb, 2003, Ambudkar, 2009).  
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Figure 1.6: Mechanism pathway of GI smooth muscle contraction. Various agonists 
(neurotransmitters, hormones, etc.) bind to specific receptors to activate contraction in 
smooth muscle. Dotted lines indicates inhibition, solid lines indicates stimulation.  
 
1.3.3 The mechanism of smooth muscle relaxation 
Smooth muscle relaxation lead to a reduction of intracellular Ca2+ concentration through 
closing of VDCC. However, direct regulation of VDCC is not typical in GI smooth muscle cells 
(Sanders et al., 2012a). As such, other conductance leading to membrane depolarization or 
hyperpolarization of GI smooth muscles are targeted by regulating opening of VDCC. 
Potassium ion (K+) channels play an important role in regulating membrane potential. The 
fundamental purpose of K+ channels is to regulate the intracellular concentration of Ca2+ 
by controlling the closure of VDCC, thus promote smooth muscle relaxation. As shown in 
41 
 
Figure 1.7, activation of K+ channels by cell membrane depolarisation leads to K+ efflux from 
the cell, which causes membrane potential (Em) to hyperpolarized towards resting 
membrane potential and the subsequent voltage-dependent closure of VDCC. This activity 
results in a reduced intracellular free Ca2+ levels, causing the smooth muscle relaxation. 
Conversely, inhibition of K+ channels would result in cell depolarization (Em becoming more 
positive), leading to the opening of VDCC and increased intracellular Ca2+ levels, thus 
promoting smooth muscle contraction. Therefore, the potassium channels act as a major 
regulator of GI smooth muscle cells activity. 
 
Figure 1.7: How K+ regulates the smooth relaxation/contraction. Schematic illustration of 
the key events involved in the smooth muscle response to potassium ion channel activation 
(left) or inhibition (right) ( Adapated from Sobey, 2001). 
 
The relaxation of smooth muscle also could be triggered directly via neurotransmitter 
released from SNS. Sympathetic neurons release noradrendaline (NA) that binds to β2-
adrenergic receptor activating Gs protein leading to increased activity of adenylate cyclase 
(AC). Stimulation of AC converts adenosine triphosphate (ATP) to cyclic adenosine 
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monophosphate (cAMP) cause increase of intracellular cAMP, which activates protein 
kinase A (PKA). The activation of PKA leads to inhibition of PIP2 hydrolysis, increased Ca2+ 
uptake by internal store SR via SERCA pump, inactivation of myosin light chain kinase, and 
activation of cell membrane ion channels and transports such as K+ channel and NCX. The 
net effect of these processed would be to reduce intracellular Ca2+ concentration and 
thereby producing smooth muscle relaxation (Knox and Tattersfield, 1995, Billington et al., 
2013). Furthermore, sympathetic transmission via nitric oxide (NO) from nitrenergic nerves 
in the GI tract could also induce smooth muscle relaxation. The release of NO from nitric 
oxide synthase (NOS) activates soluble guanylyl cyclase (GC) in smooth muscle cells that 
produce cyclic GMP (cGMP), triggers activation of K+ channels and uptake intracellular Ca2+ 
by internal store SR and NCX. This processes leads to a reduced intracellular free Ca2+ levels 
and mimic smooth muscle cell membrane hyperpolarization, causing the smooth muscle 
relaxation (Toda and Herman, 2005).   
 
1.3.4 GI motility disorders and current treatment 
GI motility is a highly complex physiological process involving the coordinated contractions 
of the circular and longitudinal smooth muscle cells. Disruption to the natural rhythm of 
intestinal contractions can lead to common hypo- or hyper-motility pathologies such as 
Irritable bowel syndrome (IBS) (Beyder and Farrugia, 2012) which affects 1 in 5 people in 
the UK and 11% of the population globally, and is twice as common in woman as men 
(Canavan et al., 2014). IBS is a common functional GI disorder characterised by recurrent 
abdominal discomfort or pain, the onset of which is associated with abnormal defecation, 
alternating between constipation, diarrhoea and mixed symptoms (Curro, 2014). Although 
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IBS causes no pathological damage to the bowel wall, it can cause pain and affect a patient’s 
quality of life significantly. As we discussed above, muscle contraction is a calcium 
dependent process, and thus ion channels are favourable targets given their prominent 
role in the contraction/relaxation process and their plasma membrane location. Calcium 
channels have already been targeted (such as nifedipine, verapamil and dilitaizem) (Opie, 
1997) and given their targeting in other pathologies (neuronal and cardiac disorders) (Shaw 
and Colecraft, 2013, Ortner and Striessnig, 2016) present good potential drug targets in GI 
tract for GI disorders involving muscle dysfunction.   
 
The aetiology of IBS has not been elucidated fully adding to the difficultly of directly curing 
the disorder, nonetheless it is believed environmental factors such as diet, stress, ageing 
and microbial flora may play a key role in effecting GI motility (Marynowski et al., 2015). 
Although there is no cure for IBS, treatment is mainly focused on preventing and relieving 
symptoms of pain, constipation, diarrhoea and discomfort. Dietary and lifestyle 
modification, such as high-fibre diet, regular exercise or drinking more water are usually 
recommended for treating mild symptoms (Camilleri and Ford, 2017). For 
pharmacotherapy, anticholingergics target, such as laxatives, is given to increase gut 
motility in patients suffering with constipation (Saha, 2014).  Selective serotonin reuptake 
inhibitors (SSRI) antidepressants, such as fluoxetine (Prozac), are also commonly used to 
produce an antidepressant effect by blocking the neuronal reuptake of serotonin, in order 
to relief the abdominal pain and constipation (Talley, 2003). Moreover, an anti-diarrheal 
drugs like loperamide, an opioid receptor agonist which decreases the frequency of 
diarrhoea can be taken. Ion channel modulators, such as otilonium bromide, could either 
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inhibit the action of ACh at muscarinic receptors or block calcium channels on GI smooth 
muscle to alter contractility of GI smooth muscle (Camilleri and Ford, 2017).  
 
Collectively, most of the currently identified therapeutic targets for the treatment of GI 
disorders within the ENS are neurotransmitter and hormone receptors (Furness, 2008), and 
thus some of these drugs have limited use due to their adverse effects, such as nausea, 
headache, dizziness and drowsiness. Therefore, a safer and more specific targets on 
smooth muscle contraction cycles could be a novel target to investigate. Given the 
important contribution of K+ channels to the process of excitation contraction coupling and 
their plasma membrane location, they could be potential therapeutic targets for treating 
GI motility disorders such as irritable bowel syndromes, which have not been significantly 
targeted at present. For instance, K+ channel activators could be used to relieve symptoms 
of GI tract hypermotility, and blockers could be used to relieve of symptoms of 
constipation. Before considering K+ channels as a potential therapeutic target, their 
structural, functional and pharmacological diversity should be understand first. 
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1.4 Potassium ion channels   
1.4.1 Ion channel signalling   
Electricity plays an essential role in cell physiology. The movement of inorganic ions, 
including Na+, K+, Ca2+, Mg2+ Cl- and H+, across cell membranes and constitutes an electrical 
current that produces a voltage difference across them, which leads to mediating a diverse 
range of processes in excitable cells, such as neuronal transmission, muscle contraction and 
cell proliferation (Kew and Davies, 2010). In excitable cells, fast electrical signalling is made 
possible by mechanisms that establish an asymmetric ionic distribution of various ions 
across the plasma membrane. This charge separation creates a chemical driving force for 
movement of ions across the membrane though ion channels following natural laws of 
thermodynamics. Though all ions are asymmetrically distributed across the membrane, 
only K+ ions are permitted to cross the membrane at rest. There is an outflow of K+ ions 
which tries to equilibrate the differential concentration difference across the membrane 
and leads to a negative resting membrane potential (the inside of the cell is less positive 
relative to the outside). The movement of K+ ions continues until equilibrium is reached, 
where the tendency for ions to move down their chemical concentration gradient is offset 
by the matching electrical gradient (named the equilibrium potential) induced by the 
movement of K+ ions themselves. Maintenance of ion concentration asymmetry across the 
membrane is achieved by active transport. This process is largely carried by the ATP-driven 
Na+/K+ pump, which constantly transport 3 Na+ out of the cell, and 2 K+ ions into the cell, 
and thus, indirectly, plays a critical role in maintaining the resting membrane potential 
(Hille, 2001, Kew and Davies, 2010, Dubyak, 2004).  
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When the cell has been stimulated, these specialized electrical signalling produce the 
action potential, a distinctive and rapid electrical signal that is propagated along the nerve 
fibre (Hille, 2001, Rasband, 2010). The action potential is made by a rapid feedback process 
involving the direct action of voltage changes due to the passive diffusion of charged ions 
through gated ion channels. As shown in Figure 1.8, a change in membrane potential 
induced by an external stimulus causes opening of voltage-gated Na+ channels. This allows 
Na+ ions to flow passively down their electrochemical gradient into the cell. This influx of 
cations into the interior of the cell creates an increasingly more positive electrical 
environment (less negative) relative to the outside of the cell, a process known as 
depolarization. The extent of this depolarisation is limited by two processes; firstly, the 
continuation of Na+ conductance across the plasma membrane through voltage-gated 
sodium channels is halted via the rapid onset of an intrinsic gating mechanism called 
inactivation (Hille, 2001), secondly the delayed (compared to sodium channel activation) 
opening of voltage-gated K+ channels causes K+ ion efflux from the cell down its own 
electrochemical gradient resulting in a re-establishment of a negative electrical 
environment (relative to the outside of the cell), a process known as repolarization. This 
repolarisation of the membrane potential may be extended more negatively beyond the 
normal homeostatic level of resting membrane potential, a hyperpolarisation of the 
membrane potential. During this period, voltage-gated potassium channels close, sodium 
channels recover in a time- and voltage-dependent manner from their inactivated state 
and constitutively open background/leak potassium conductances along with active 
processes allow an equilibration of potassium ions across the membrane back to 
homeostatic levels equalling the K+ reversal potential (Krev) (Yellen, 2002, Goldstein et al., 
2001). The action potential is the basis for transmitting signals in excitable cells, for 
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example to initiate muscle contraction or hormone/neurotransmitter release. Therefore, 
potassium ion channels, constitute the physical substrates that underlie neuronal and 
muscular signalling.  
 
Figure 1.8: A ‘‘Schematic’’ diagram of action potential. The membrane potential starts out 
at −70 mV. When stimulus is applied, the membrane potential increase above the threshold 
potential. Followed by the opening of voltage-gated Na+ channels triggers rapid 
depolarization of the cell membrane. This is followed by a transient outward repolarization 
induced by activation of voltage-gated K+ channels. After this, K+ conductances return the 
membrane potential to hyperpolarized values, where the balance of depolarizing and 
hyperpolarizing stimuli will determine the next action potential.    
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1.4.2 K+ channel superfamily 
K+ channels form the largest family of ion channels, with more than 90 genes in the human 
genome. K+ channels allow the selective and passive movement of K+ ions into or out of the 
cell along their electrochemical gradients. K+ channels are formed as multimeric complexes 
via the assembly of principle (α) subunits containing various transmembrane spanning 
domains (TM) with intracellular facing n and c termini, and a semi-hydrophobic loop (P) 
that partially spans the lipid bilayer. Some K+ channels are also formed with auxiliary β 
subunits which can alter channel structure, function, pharmacology and regulation (Tian et 
al., 2014). Structurally, α subunits can be classified into the following three main families: 
2TM-1P, 6/7TM-1P and 4TM-2P (Figure 1.9). As expected, K+ channels belonging to the 
same family present similar structure and biophysical activities, and thus they can also be 
categorised based on functional attributes such as  how they open and close (referred to 
as “gating”) which can be regulated by variety of stimuli including changes in pH, 
temperature, membrane voltage, ligands and mechanical stretch. Structural and functional 
analyses of K+ channels, particularly crystallisation, have elucidated a much deeper 
understanding of the molecular mechanisms behind ion selectivity, conduction and gating.  
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Figure 1.9: K+ channel families. Phylogenetic tree of human K+ channels. The insets 
correspond to the typical structure presented by subunits of each of the tree families. For 
simplicity, the letter code for K+ channels (KCN) has been omitted (e.g., KCNA1 is depicted 
as A1), the ‘‘words’’ refer to different subtype of K+ channels (e.g., ‘‘KCNQ’’ indicates the Kv 
7 subfamily)  (Heitzmann and Warth, 2008).  
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1.4.3 Selectivity filter of K+ channels 
K+ channels possess a unique structural hallmark, which singularly defines its functional 
phenotype, the selectivity filter sequence. A common feature present at their pore-lining 
P-loops of K+ channels which is a conserved sequence of amino acids known now as the ‘‘K+ 
channel sequence signature’’ (Yellen, 2002). Mutation of these amino acids disrupts the 
ability of the channel to distinguish between K+ and Na+  ions (Heginbotham et al., 1994) or 
indeed to pass ions at all. K+ ions can pass through the selective filter at an extremely fast 
rate, around 107 to 108 K+ ions per second (Morais-Cabral et al., 2001). These high diffusion 
rates are essential during rapid opening and closing channel transitions, since a typical 
action potentials in neurons requires millions of ions to flow in a millisecond timescale 
(Yellen, 2002, Doyle et al., 1998). To catalyse K+ ion flow through the pore almost as fast as 
they are able to diffuse up to it, the energetic barriers in the channel have to be very low 
or equal to K+ ions diffusing through water. This is all achieved while discriminating 
between K+ ions, which have an atomic radius of 1.33Å and Na+ ions with an atomic radius 
of 0.95Å (MacKinnon, 2004).  
 
Crystallisation of the bacterial ion channels KcsA generated the first accurate structure of 
selectively filter and led to confirmation of how K+ channels discriminate between K+ and 
Na+ ions at such high conductance rates. The ion pathway of KcsA was found to be long and 
wide, with a length in 18Å and a cavity in the region of 10Å in diameter (Doyle et al., 1998). 
Each α subunit was found to direct the negatively charged C-terminal end of its pore loop 
towards a K+ ion thereby the pore helices are stabilising the K+ ion in the cavity (Figure 
1.10A) (Roux and MacKinnon, 1999). Figure 1.10B shows the structure formed by the 
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selectively filter, which present in their pore-lining P-loops located towards the 
extracellular face of the ion conduction pathway. It consists of a consensus amino acid 
signature sequences ‘‘TxGxG’’ (Heginbotham et al., 1994), where the x between the two 
glycines (G) is usually an aromatic tyrosine (Y), phenylalanine (F) or a hydrophobic leucine 
(L) (Heginbotham et al., 1994, Schewe et al., 2016). The glycine residues provide the 
dihedral angles, the threonine residues provides the hydroxy oxygen atom to coordinates 
the K+ ion and the tyrosine and valine side-chains provide geometric constraint (Roux and 
MacKinnon, 1999). This features allows their main chain carbonyl oxygen atoms to the 
inside and towards the ions, which forms a narrow tube with 4 equally spaced K+ binding 
sites with eight oxygen atoms (MacKinnon, 2004). The oxygen atoms surrounding the K+ 
ions in the selectivity filter mimic the environment of K+ in an aqueous solution. Therefore, 
the ability of K+ channels to discriminate between K+ and Na+ ions is a results of the binding 
sites compensating the energetic cost of the dehydration of the K+ ions, which cannot be 
accomplished for Na+ as it is too small (Zhou et al., 2001b, Morais-Cabral et al., 2001).  
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Figure 1.10: Schematic of the KcsA K+ channel. (a) Molecular structure representation of 
the KcsA channel. K+ (green) bind at four locations in the selectivity filter (yellow). (b) Close-
up view of the selectivity filter in ball-and stick representation. K+ are numbered as 1-4 to 
indicate the location of binding sites in the filter. Position 1 is closest to the extracellular 
solution and position 4 is closest to the cavity. Taken from (Morais-Cabral et al., 2001).  
 
1.4.4 2TM-1P channel family 
Inwardly rectifying channels (Kir) represent the simplest architecture among K+ channels, 
comprising two transmembrane spanning domains separated by a single pore loop domain 
and flanked by cytoplasmic amino and carboxyl terminal domains (Figure 1.11a). Functional 
channels are formed by homo or heteromeric tetramerisation of subunits. There are 15 Kir 
genes expressed in humans encoding 15 different alpha subunits. Homotetrameric 
assembly leads to 7 different subfamilies (Kir1-7) that can be further classified into four 
general functional groups: 1) classical Kir channels (Kir2.x), 2) G-protein gated (Kir3.x), 3) K+-
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transport channels (Kir1.x, Kir4.x, Kir5.x, and Kir7.x), 4) ATP-sensitive K+ channels (Kir6.x) (Kew 
and Davies, 2010).  
 
Heteromerisation of channel subunits normally occurs between channels of the same 
subfamily, for instance Kir2.1 can form functional subunits with any other Kir2.x family 
member (Preisig-Muller et al., 2002). However, some subfamilies, such as Kir4.1 have been 
reported to assemble functional channels with other families, such as Kir5.1 (Hibino et al., 
2004). The characteristic inward rectification of Kir channels results primarily from a 
voltage-dependent chronic pore obstruction by intracellular polyamines and charged Mg2+ 
ions, which physically blocks the conduction pathway during depolarization, thereby 
impending the outward flow of K+. This pore block is relieved at negative potentials allowing 
voltage-independent large inward K+ currents at potentials negative to Ek (where there is 
no block and influx overcomes block) compared to the smaller K+ currents at potential more 
positive to EK (where intracellular block overcomes outward ionic flux; see Figure 1.11b & 
c) (Hille, 2001, Osawa et al., 2009). Thus, the voltage at which rectification occurs is 
controlled by the equilibrium potential for K+, which is defined by transmembrane K+ 
concentration gradients, and therefore not by voltage per se (fig 1.13c). Due to these 
properties, Kir channels are predominantly responsible for maintaining the resting 
membrane potential of the cell, and are particularly active at hyperpolarised potentials, 
and in regulation of the action potential duration and receptor-dependent inhibition of 
cellular excitability (Osawa et al., 2009). 
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Figure 1.11: Characterisation of 2TM-1P channels. (a) Membrane topology of a typical 2TM-
1P family. Transmembrane domains are labelled M1-M2, with the pore loop labelled P. (b) 
Example current traces based on Kir4.2. (c) Current-voltage relationship for Kir channels 
under physiological K+ concentration (blue line) and symmetrical K+ concentration (dotted 
green line). Taken from (Goldstein et al., 2001). 
 
Kir channels have various functions in multiple cell types including macrophages, cardiac 
myocytes, endothelial cells and CNS cells. For example, in cardiac myocytes, Kir2.x, Kir3.x 
and Kir6.x with SUR subunits (also known as KATP) subfamilies are important for 
maintenance of prolonged action potential by slowing membrane repolarisation 
(Anumonwo and Lopatin, 2010). In endothelial cells, vascular smooth muscle cells and 
pericytes, Kir2.1 and KATP channels participate in dilation, induced by elevated extracellular 
K+ (Jackson, 2005). In pancreatic β cells, KATP channel activity is inversely correlated with 
insulin secretion,  conditions tending to reduce channel activity will stimulate insulin 
secretion above normal leading to hypoglycaemia, while increasing channel activity will 
attenuate insulin secretion, leading to hyperglycaemia (Kew and Davies, 2010). 
Furthermore, Kir2.x, Kir3.x and KATP subfamilies are also expressed GI tract. Activation of Kir 
currents would lead to reduce the amplitude of conducting slow waves and reduce the 
tendency of slow waves to initiate Ca2+ action potentials in smooth muscle cells (Koh et al., 
2012).  
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Blockers most commonly used for Kir channels are Ba2+ and Cs+ (Franchini et al., 2004, 
Hagiwara et al., 1976), while tetraethylammonium (TEA) and 4-aminopyridine (4-AP) are 
known as the classic blockers for Kv channels, but have little effect on Kir channels (Oonuma 
et al., 2002, Hagiwara et al., 1976). There are also other compounds available that can 
affect particular types of Kir channels. A small-molecule named as VU590 has been reported 
that potently block Kir1.1 and Kir7.1 channels by crossing the membrane to access an 
intracellular binding site (Lewis et al., 2009). Tertiapin is a toxin that was isolated from 
honey bee venom which blocks G-protein gated Kir (Kir3.x) and Kir1.1 channels (Jin and Lu, 
1998). The oxidation-resistant tertiapinQ blocks G-protein gated Kir current, but not KATP 
current (Hibino et al., 2010). The majority of reagents affecting KATP channel activity react 
on the auxiliary pancreatic sulfonylurea receptor (SUR) subunits. A number of chemically 
diverse agents are able to bind to SUR and activate KATP channels, including diazoxide, 
cromakalim, pinacidil and aprikalim (Kew and Davies, 2010). Moreover, Kir channels could 
be also modified by regulatory factors. For instance,  the phosphatidylinositol 4,5-
bisphosphate (PIP2) has been reported that activate the Kir channels by activation of ATP-
dependent lipid kinases (Hilgemann and Ball, 1996, Hilgemann et al., 2001), which are 
thought to bind to positively charged residues along the C-terminus (Huang et al., 1998, 
Lopes et al., 2002). In addition, some Kir channels (such as Kir1.1, Kir2.3 and Kir4.1) are 
regulated by pH levels of intracellular or extracellular (Dahlmann et al., 2004), while others 
such as Kir3.2 and Kir3.4 can be regulated by intracellular Na+ (Ho and Murrell-Lagnado, 
1999, Zhang et al., 1999).  
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1.4.5 6TM-1P channel family 
6TM-1P channels represent the largest sub-family of K+ channels, encoded by at least 40 
different genes in human genome, with additional diversity produced by alternative 
splicing and heteromultimerization (Yellen, 2002). 6TM-1P channel subunits consist of a 
series of six transmembrane spanning domains with a single semi-hydrophobic loop 
between TM5 and TM6, and intracellular facing N and C terminus. Their hallmark is a 
voltage-sensing domain formed by TM1-TM4 with the forth TM acting primarily as the 
voltage sensor. TM4 has conserved positively charged residues (lysine or arginine) at every 
third or fourth position that allow a mechanical response to changes in transmembrane 
potential to trigger channel opening (Figure 1.12 a) (Goldstein et al., 2001, Hille, 2001). 
Fully assembled 6TM-1P channel are formed by homo- or heterotetramers of α-subunits, 
with the four pore loop domains of each subunit coming together to form the four-fold 
symmetric conduction pathway across the bilayer. The functional 6TM-1P channel can 
often be further functionally, biophysically  and pharmacologically diversified through 
association with accessory subunits, also called auxiliary subunits or β-subunits (Heitzmann 
and Warth, 2008). The opening of K+ channels leads to currents that tend to drive the 
membrane potential towards the equilibrium potential for K+, and thus in general are 
inhibitory. Physiologically, these voltage-dependent K+ channels are activated by 
membrane depolarization, and play a fundamental role in repolarization of membrane 
potential, a critical signalling process in excitable tissues comprising neurons or muscle 
(Figure 1.12 b & c).  
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Figure 1.12: Characterisation of 6TM-1P channels. (a) Membrane topology of a typical 6TM-
1P family subunit. Transmembrane domains are labelled S1-S6, with the pore loop labelled 
P. The channels are noted for their positively charged TM4 (S4) that acts as the primary 
voltage sensor for detecting changes in the membrane potential.  (b) An example current 
trace based on KCNQ1. (c) Current-voltage relationship for Kv channels under physiological 
K+ concentration (blue line) and symmetrical K+ concentration (dotted green line). Taken 
from (Goldstein et al., 2001). 
 
The α-subunits of 6TM-1P K+ channels can be divided into 12 classes within 3 major groups 
of proteins, according to their functional attributes and sequence homology. These groups 
are: 1) Kv1–Kv6 and Kv8-Kv9 subfamilies, which are components of voltage-gated K+ 
channels with fast kinetics; 2) Kv7 subfamily (often called the KCNQ family) which are pore-
forming subunits of voltage-gated K+ channels with slow kinetics; 3) Kv10-Kv12 subfamilies 
(also known as EAG family), like Kv7 subfamily, that activate relatively slowly upon 
membrane depolarization (Kew and Davies, 2010). For example, the subunits of the Kv7 
subfamily form the M-type K+ channels responsible for M current (IM), which is activated at 
a lower-threshold membrane potential than would normally activate neuronal cells, 
hyperpolarizes the cell membrane, and consequently reduces the firing of action potential 
(Santini and Porter, 2010). The protein of EAG family, such as Kv11.1, contribute to the 
cardiac current (IKr), which is important for cardiac repolarization.  
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1.4.5.1 Kv 1-4 channels 
Kv 1.x, Kv 2.x, Kv 3.x and Kv 4.x are homologues to the Drosophila melanogaster (fruit fly) 
genes as shaker, shab, shaw and shal respectively (Covarrubias et al., 1991). There are 8 
genes in Kv1 subfamily: Kv1.1–Kv1.8. All Kv1 proteins are capable of forming heteromeric 
channel complex. In addition, most native Kv1 channel complex may include at least one 
type of Kvβ subunit. This β-subunits binds to the domain where located in the N-terminal 
region of the channel pore-forming subunits, constructing channel complexes of eight 
polypeptides, which play diverse roles in modulating the gating, stability, and trafficking of 
Kv1 channels (Long et al., 2005a). For instance, crystallisation of Kv1.2 channel complex 
exhibits a tetramer of Kv1.2 pore-forming subunits associated with a tetramer of Kvβ 
proteins (Long et al., 2005b). Moreover, in cultured hippocampal neurons, Kvβ subunit co-
expression led to axonal targeting of Kv1.2, recapitulating the Kv1.2 localization observed in 
many brain neurons (Campomanes et al., 2002). Kv1 channels can be delayed rectifiers 
channels that show different degrees of inactivation, except Kv1.4 which fully inactivates 
creating an A-type current due to fast voltage-dependent inactivation by an N-terminal 
blocking peptide. Kv1.4 channels also show a slow recovery from inactivation (MacKinnon 
et al., 1993). All Kv1 subunits are voltage-dependent channels that tend to activate faster 
and at lower membrane potentials than other Kv channel subfamilies. They produce 
significant current at voltages below spike threshold (between -50 and -55 mV), and thus 
are thought to be associated with the subthreshold activity of neurons (Kew and Davies, 
2010). The expression of Kv1 are widely distributed throughout the body, mainly in brain, 
but some subunits with important roles in immune cells (Kv1.3) (Kazama, 2015), in heart 
(Kv1.4 and Kv1.5) (Matsubara et al., 1993), and in smooth muscle (Kv1.5) (Yuan et al., 1998). 
Furthermore, all Kv1 channels are highly sensitive to 4-AP with IC50 ~ 500 µM, except Kv1.8 
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which exhibit inhibition effects with IC50 above 1 mM (Kew and Davies, 2010), whereas the 
voltage-gated channel blocker TEA does not inhibit the Kv1.x channel activity (Hopkins, 
1998).  
 
Kv2 channels constitute Kv2.1 and Kv2.2 subunits and are delayed rectifiers that play a 
significant role in membrane excitability, particularly the repolarisation of action potentials 
in neurons (Peng and Wu, 2007). Kv2 subunits are unique in that they are able to form 
functional heteromeric channels with other Kv subunits, including Kv5, Kv6, Kv8 and Kv9. 
These associations influence the voltage-dependence and dynamics of activation, 
deactivation and inactivation, as well as their pharmacological characteristics (Kew and 
Davies, 2010). For example, co-expression of Kv2.1 with Kv9.1 slows the rate of activation, 
leads to a hyperpolarizing shift in the voltage-dependence of activation and inactivation 
and changes sensitivity to TEA, compared to Kv2.1 channel alone (Richardson and 
Kaczmarek, 2000). The expression of Kv2.1 and Kv2.2 are both largely expressed across brain 
tissue (Hwang et al., 1993). Kv2 channels are blocked by high concentrations of the classical 
K+ channel pore blocker TEA (IC50: 5-10 mM) but are less-sensitive to 4-AP (Shieh and Kirsch, 
1994).  
 
Kv3 channels are predominately expressed in CNS neurons, particularly interneurons and 
are responsible for generating high firing frequencies. Kv3.1 and Kv3.2 activate and 
deactivate very fast, with little or no inactivation, a prerequisite feature for fast neuronal 
firing. Kv3 channels have also been suggested to play an essential role in neurotransmitter 
release due to their distribution in axons and presynaptic terminals of neurons (Brooke et 
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al., 2004, Ishikawa et al., 2003). Moreover, the activity of Kv3 channels become more 
apparent at more positive potentials in comparison to other Kv channels, not really 
becoming apparent until potentials more positive than -20 - -10 mV. Interestingly, Kv3.4 
channels, which show significant inactivation are rarely expressed in the neurons where 
the other three Kv3 genes (Kv3.1-3.3) are usually expressed (Weiser et al., 1994), instead 
they have been shown to have important roles in skeletal muscle physiology (Abbott et al., 
2001). Kv3 channels are blocked by classical K+ channel blocker TEA (IC50: 0.1-0.3 mM) and 
4-AP (IC50: 0.6-1 mM) (Kew and Davies, 2010), and also blood depressing substance (BDS) 
toxin BDS I and BDS II with high sensitive with IC50 ~ 1 µM (Yeung et al., 2005).  
 
Kv4 channels are defined by their fast inactivation and recovery from inactivation, and are 
known as A-type K+ currents. These features make these channels (particularly those 
formed by Kv4.2 and Kv4.3 subunits) key components of the transient outward K+ currents 
in human heart (Wettwer et al., 1993, Nadal et al., 2001). Kv4 channels may associate with 
specific β-subunits: cytoplasmic Kv channel interacting proteins (KChIPs) and membrane-
spanning dipeptidyl aminopeptidase-related proteins (DPPs) (Nadal et al., 2003, An et al., 
2000, Barghaan et al., 2008). KChIPs slow Kv4 current decay kinetics, promote recovery 
from inactivation and shift the voltage dependence of steady-state inactivation to more 
positive potentials (An et al., 2000). DPPs promote both current inactivation and recovery 
kinetics and shift both activation and inactivation curves of Kv4 channels to more negative 
potentials (Nadal et al., 2003). All members from Kv4 subfamily are sensitive to 4-AP (5-10 
mM) and display differential sensitivity to block by toxins (e.g. phrixotoxins and 
stromatoxin) (Kew and Davies, 2010, Diochot et al., 1999, Escoubas et al., 2002).  
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1.4.5.2 Kv 5, 6, 8 and 9 channels 
Kv 5, 6, 8 and 9 channels are collectively referred to as electrically silent Kv (KvS) channels 
because they fail to generate functional ion channel protein by themselves. There are 10 
KvS subunits that have been identified to date: Kv5.1, Kv6.1-6.4, Kv8.1, Kv8.2, and Kv9.1-9.3, 
which all display three features in common; 1) they are unable to form functional channels 
at the plasma membrane as homotetramers or heterotetramers within the KvS family 
because of retention in the endoplasmic reticulum, 2) they only associated with Kv2.x as 
heterotetramers to form functional channels and not with members of the Kv1.x, Kv3.x and 
Kv4.x subfamilies, and 3) they can modulate the biophysical properties of Kv2 channels. 
Therefore, Kv2/KvS heterotetramers display shifts in the voltage-dependence of activation 
and/or the voltage dependence of inactivation; changes in the activation, deactivation, 
and/or inactivation kinetics; and alterations in the current density in comparison with Kv2 
homotetramers (Bocksteins, 2016). In addition, Kv6.1 has been shown to decrease the  TEA 
sensitivity when co-expressed with Kv2.1 (Post et al., 1996).  
 
1.4.5.3 Kv 7 channels 
The Kv7 channel subfamily consists of five subunits, Kv7.1 to Kv7.5. They can form functional 
homomeric and heteromeric channels within the Kv7 subfamily. Kv7.1, also known as 
KCNQ1 or KvLQT1 because of it is association with a form of long QT syndrome, forms the 
functional basis for the slowly activating K+ (Iks) current in the heart (Barhanin et al., 1996). 
The other members of Kv7 (Kv7.2-7.5 or KCNQ2-5) are expressed throughout the central 
and peripheral nervous system (Kew and Davies, 2010). Unlike Kv7.1 which forms 
preferentially homomeric channels, other Kv7 channel members co-associate to form 
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physiologically important currents.  Kv7.2, Kv7.3 and Kv7.5 (through co-assembly with Kv7.3) 
are thought to be the molecular correlate for the neuronal M-current (Wickenden et al., 
2001, Wang et al., 1998). Mutations to either Kv7.2 or Kv7.3 are suspected to play a 
significant role in the hereditary form of juvenile epilepsy (Robbins, 2001, Biervert et al., 
1998). Moreover, Kv7.4 and Kv7.5 have been reported to be expressed in vascular and 
intestinal smooth muscle cells, and also play an important role in regulating the smooth 
muscle contractility (Jepps et al., 2009, Greenwood and Ohya, 2009, Stott et al., 2014). 
Members of the Kv7 family have been documented to interact with accessory subunits 
encoded by KCNE genes. There are five KCNE genes that have been identified, KCNE1-
KCNE5. These genes encode proteins with a single transmembrane domain, intracellular N-
terminus and an extracellular C-terminus and can significantly affect the activation of 
threshold Kv7 channels (Dedek and Waldegger, 2001). Message for both Kv7.1 and KCNE1 
(also known as minK) have been detected in epithelial cells of gut and exocrine pancreas 
(Heitzmann and Warth, 2008). Meanwhile, the Kv7.1/KCNE3 complex forms a leak channel 
in crypt cells of the intestine which is constitutively open at resting potentials (Schroeder 
et al., 2000). 
 
Regarding their pharmacology, Kv7 channel currents are sensitive to the classic potassium 
channel blockers TEA and Ba2+ (Kew and Davies, 2010). XE991 and linopidine are known Kv7 
channel blockers, and are selective over other Kv channel complexes. Chromanol 293B is a 
selective blocker for Kv7.1 subunits, but displays less sensitivity on Kv7.2-7.5 channel 
currents (Seebohm et al., 2001, Schroeder et al., 2000). Retigabine is an anti-epileptic drug 
that has been showed to selectively activate Kv7 channels (Tatulian et al., 2001). However, 
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Stott et al. (2014) has reported that Kv7.1 has lower sensitivity to retigabine-induced 
enhancement compared to Kv7.2-Kv7.5, due to the absence of a critical, conserved 
tryptophan residue in TM6 which forms part of the binding pocket for the drug. 
 
1.4.5.4 Kv 10, 11 and 12 channels 
Kv10, Kv11 and Kv12 channels are encoded by eight different genes, collectively referred to 
as the ether-a-go-go (eag) K+ channel family and designated KCNHx for the human forms. 
These three channel types can be characterised by their different biophysical properties. 
Kv10 channels are identified by very rapid activation and lack of inactivation. Kv12 channels 
are characterized by more slowly activation compared with Kv10 channels, and may 
(Kv12.1) or may not (Kv12.2) exhibit inactivation. Kv11 channels display slowest activation 
properties in these three channel types, but it can be rapidly inactivated (Kew and Davies, 
2010), leading to what appears to be an inwardly rectifying current voltage relationship. 
However, during repolarisation, the channels pass back through the open state to return 
to the closed state, a phenomenon that results in a large repolarising current.  This 
biophysical phenotype is unique and is central to regulation of cardiac cell excitability. Like 
Kv7 channels, mutations to erg channels induce pathologies such as cardiac long QT 
syndrome (LQT2) (Sanguinetti and Tristani-Firouzi, 2006). Epilepsy (Li et al., 2016), along 
with schizophrenia (Calcaterra et al., 2016) and cancer (Asher et al., 2010).  
 
The classic potassium channel blockers such as TEA, quinine, quindine and 4-AP display 
weakly inhibition in Kv10 channels. E-4031 is a cardiac drug that blocks Kv11 channels with 
high-affinity (Zhou et al., 1998) and also blocks Kv10 channels (Gessner and Heinemann, 
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2003) but does not affect Kv12 channels (Shi et al., 1998). Human Kv11 (hERG) channels 
remains a critical pharmacological target for therapeutics used in human disease. hERG is 
universally blocked by many different structurally unrelated chemical compounds ranging 
from anti-histamines to antibiotics to anti-epileptics. The reason for this appears to be 
related to the absence of a pivotal conserved proline residue in TM6 that is present across 
the Kv channel family inducing a widening of the inner cavity of the channel, combined with 
presence of two aromatic residues (per subunit) that point into the internal cavity of the 
hERG channel and create a non-specific binding site for many different types of compounds 
(Mitcheson et al., 2000). Recently several activators have been identified for Kv11 channels, 
such as RPR260243 (Kang et al., 2005b) and NS1643 (Hansen et al., 2006).  
 
1.4.5.5 KCa channels 
Calcium-activated K+ channels (KCa) are gated by either voltage and Ca2+ combined or Ca2+ 
alone and their activity is directly related to the intracellular Ca2+ concentration. The 
subfamily of KCa channels contains 8 members and according to their biophysical and 
pharmacological properties can be subdivided into three groups; small conductance (SK) 
channels, intermediate conductance (IK) channels and big conductance (BK) channels. SK 
and IK subunits have the same structure as voltage-gated K+ channels with 6 
transmembrane domains and 1 pore loop domain, however they are not voltage-activated. 
Instead they possess a calmodulin binding domain located in the C-terminus. This 
calmodulin binding site is utilised for Ca2+ sensing that directly induces activation and 
inactivation of these channels. In contrast, BK channels uniquely have 7 transmembrane 
domains, possessing an extra TM domain (TM0) prior to the voltage sensor domain, and 
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therefore an accompanying extracellular N-terminus. The BK channel can be gated by 
voltage, although weakly compared to other voltage-gated channels, and intracellular 
calcium ions (Gueguinou et al., 2014, Kew and Davies, 2010). Calcium binding serves to 
right-shift the apparent voltage activation threshold/sensitivity of the channel. The BK 
channel can work alone or as a complex with a modulatory β subunit (Figure 1.13). BK 
channels are especially important in smooth muscle cells, where they are maximally 
activated at the peak of the action potential and participate in the repolarization phase 
(Vogalis, 2000). Therefore, BK channels are able to sense in an integrative way the changes 
in both membrane voltage and intracellular Ca2+ levels and to respond by mediating an 
outward hyperpolarizing K+ current. These features award to BK channels remarkable 
functional roles in excitable cells, such as the regulation of neurotransmitter release and 
smooth muscle contractility.  
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Figure 1.13: Characteristics of KCa channels. KCa channels are divided into 3 families that 
include large conductance (BK) channels, intermediate conductance (IK) channels and small 
conductance (SK) channels. The α-subunit associate to form tetramers for SK and IK, with 
β subunit for BK or without known auxiliary subunit for SK and IK channels (Gueguinou et 
al., 2014).  
 
KCa channels are widely distributed throughout the nervous system. SK and BK channels are 
expressed in CNS, while IK channel is mainly expressed in PNS. Both BK and SK channels 
have been identified in intestinal smooth muscle cells, which are essential to the regulation 
of smooth muscle contractility (Tang et al., 2015, Wang et al., 2010). Unlike for SK and BK 
channels, the expression of IK subunits is largely non-neuronal, for example in the salivary 
glands, the placenta and the lungs, and are suggested to play an essential role in 
lymphocyte activation (Gueguinou et al., 2014). Furthermore, KCa channels have been 
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found in various tumour cell lines, including prostate cancer, breast cancer, gliomas, and 
melanoma colon cancer. Here they are thought to play a functional role in regulating cancer 
cell migration and proliferation (Gueguinou et al., 2014, Bulk et al., 2015, Potier et al., 
2006).  
 
Pharmacology of KCa channels has traditionally been centred on various peptide toxin 
blockers or small organic molecules that either inhibit by a pore-blocking mechanism or act 
as positive or inhibitory modifiers of the gating processes. Apamin has been revealed to be 
a selective blocker of SK channels with the affinity in SK2 > SK3 > SK1. IK channels can be 
inhibited by several scorpion toxins such as charybdotoxin, maurotoxin and margatoxin 
(Kew and Davies, 2010). There are two well characterised peptide inhibitors of BK channels, 
iberiotoxin (IbTX) and charybdotoxin (ChTX). A number of non-peptide compounds also 
inhibit BK channels, such as TEA with IC50 ~0.14 mM and paxilline with IC50 ~ 1.9 nM (Kew 
and Davies, 2010). SKA-31 is an activator for SK1, SK2 and IK channels, displaying a higher 
affinity for IK than to SK channels (Sankaranarayanan et al., 2009). Furthermore, a small 
molecules known as NS309 has been shown activate both IK and SK channels but displays 
no activity towards BK channels (Strobaek et al., 2004, Morimura et al., 2006).  
 
1.4.5.6 Gating mechanisms of voltage-gated K+ channels 
As previously stated, signal transduction in excitable cell requires an extremely rapid 
mechanism for opening and closing (gating) the ion channel pore. In voltage-gated 
potassium channels, open/closed transitions are created at the level of the TM6 (S6) 
domain. As shown in Figure 1.14, this gating mechanism involves rotation of the TM6 of 
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each subunit of the channel thereby, like an iris of a camera, shutting the intracellular 
entrance to the channel. This rotation of the TM6 domains occurs in response to movement 
of the voltage sensing apparatus, and is therefore directly coupled to changes in 
transmembrane potential. There are also two further mechanism that control the viability 
of the conduction pathway, through a process known as inactivation. Here the intracellular 
TM6 (S6) gate remains open but the channel is no longer able to conduct ions. Firstly, the 
narrowest portion of the conduction pathway, the selectivity filter, may collapse, pinching 
shut the conduction pathway and is also known as C-type inactivation. This mechanism is 
prominent in A-type channels such as Kv4 channels, where transmembrane voltage changes 
are sensed by the voltage sensing apparatus, causing their subsequent realignment and 
mechanically inducing opening of the TM6 gate, which is swiftly followed by a collapse of 
the selectivity filter. It is argued that the C-type inactivation mechanism is allosterically 
coupled to TM6 gate transitions such that opening of the intracellular gate initiates 
inactivation of the filter gate (Bahring et al., 2012, Yellen, 2002). Finally, there is an 
alternative process of inactivation, called N-type inactivation. Again the intracellular (TM6) 
gate remains open, but here the entrance to the intracellular face of the conduction 
pathway is plugged by the binding of an auto-inhibitory peptide, attached to the N-
terminus of the channel subunit, to the cavity of the channel. This type of inactivation by a 
ball peptide occurs in a voltage-dependent manner in Kv1.4 channels, but can also be 
provided by ball peptides intrinsic to auxiliary β subunits (Yellen, 2002, Zhou et al., 2001a).  
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Figure 1.14: The conformational changes that gate the K+ channel pore. (a) Shows a closed 
K+ channel, on the basis of the KcsA structure. The four TM6 (S6) transmembrane segments 
swing together to produce a secure closure at the bundle crossing. This prevents ion flow 
and can also trap organic channel blockers in the enclosed cavity. Alternatively, the channel 
may be inactivated at the selectivity filter (b), or by binding of an auto-inhibitory peptide 
(c) when a binding site in the pore is revealed by opening of the S6 gate (Yellen, 2002). 
 
1.4.6 4TM-2P channel family 
4TM-2P (two-pore domain or K2P) channel subunits consist of four transmembrane 
domains, and two pore-forming regions between TM1 and TM2, and also between TM3 
and TM4 (Figure 1.15a). Therefore functional channels are a result of subunit dimerisation 
as opposed to the tetramerisation required of Kv and Kir channel subunits. K2P channels lack 
voltage dependency and specific ligand gating requirements and as such contribute to 
background potassium conductance across all voltages. Their outward rectification under 
physiological conditions arises from the asymmetric K+ gradient across the membrane as 
predicted by the Goldman-Hodgkin-Katz (GHK) (Goldstein et al., 2001). These features 
allow K2P channels to play an important role in excitable cells (such as neurons and muscle 
cells) because they not only set and regulate resting membrane potential but also 
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contribute significantly to repolarization in many cell types. (Schewe et al., 2016). 
Historically, the first recognised two pore K+ channel (K2P) was discovered in the baker’s 
yeast Saccharomyces Cerevisiae in 1995 and was called TOK (Ketchum et al., 1995). This 
channel had subunits that possess 8TM and 2P domains and led to the identification of 
related two pore channel subunits  from the fruit fly Drosophila melanogaster (KCNKO) in 
1996 (Goldstein et al., 1996). A  few month later, the first mammalian K2P channel 
homologues, a weak inward rectifying K+ channel (TWIK-1 also known as KCNK1) were 
cloned (Lesage et al., 1996).   
 
 
Figure 1.15: Characterisation of 4TM-2P channels. (a) Membrane topology of a typical 4TM-
2P family. Transmembrane domains are labelled M1-M6, with the pore loop labelled P1 & 
P2. (b) The example current traces based on KCNK0. (c) Current-voltage relationship for K2P 
channels under physiological K+ concentration (blue line) and symmetrical K+ concentration 
(dotted green line). Taken from (Goldstein et al., 2001). 
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1.5 Two-pore-domain K+ channels 
The human genome encodes 15 K2P family subunits, which can be divided into following 6 
subfamilies by their different biophysical and pharmacological properties (Figure 1.18): 
TWIK, TASK, TREK TALK, THIK and TRESK. Although each K2P subunit displays same 
structure, they share rather low sequence similarity outside the pore domains (Sanders & 
Koh, 2006). In addition, K2P channel gating can be modulated by voltage, changes in oxygen 
tension, temperature, pH levels and membrane stretch (Kang et al., 2005a, Lewis et al., 
2001, Maingret et al., 1999), but insensitive to classic K+ blocker TEA and 4-AP (Lotshaw, 
2007, Enyedi and Czirjak, 2010).  
 
 
Figure 1.16: Phylogenetic tree of human K2P channels. The nomenclature according to the 
International Union of Pharmacology (K2P X.X) and the HUGO (KCNKX) are presented, 
together with the chromosomal localization and functional characteristic of each channel 
subfamily (Honore, 2007).  
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1.5.1 Weak Inward rectifier TWIK subfamily 
The TWIK subfamily comprises the first mammalian member of K2P channel family to be 
discovered, KCNK1 (TWIK-1), as well as KCNK6 (TWIK-2) and the silent subunit KCNK7 
(TWIK-3) (Lotshaw, 2007). Both TWIK-1 and TWIK-2 display weak inwardly rectifying 
currents, which are sensitive to cytosolic pH levels, inhibited by intracellular acidification 
(Lesage et al., 1996). Unfortunately, the electrophysiological characterization of TWIK 
subfamily members has been obstructed by their low or absent functional expression in 
heterologous systems, thought to be due to suppression by a small ubiquitin-like 
polypeptide, SUMO. However, either deSUMOylation of expressed channels using a SUMO-
selective protease or mutation of the predicted SUMOylation site K274 to a glutamic acid 
can prevent SUMOylation and increase functional expression (Rajan et al., 2005). 
Interestingly, TWIK-1 is the only member in TWIK subfamily that subject to SUMOylation, 
since TWIK-2 lacks lysine within its C-terminus while the lysine in TWIK-3 does not appear 
to reside within any known variations of the SUMOylation sequence (Lotshaw, 2007). In 
addition, TWIK-1 has been reported to form functional channels upon heteromeric 
assembly with other K2P subunits, such as TASK-1, TASK-3 and TREK-1 (Hwang et al., 2014, 
Berg et al., 2004a, Plant et al., 2012).  
 
Pharmacological characterization of TWIK family is still very limited by virtue of its poor 
functional expression. There are no selective pharmacological modulators available for 
either TWIK-1 or TWIK-2. Both Ba2+ and quinidine have been shown to have an inhibitory 
effect on TWIK-1 channel (Lesage et al., 1996). However, human TWIK-2 was identified to 
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be insensitive to both Ba2+ and quinidine (Chavez et al., 1999) while rat TWIK-2 was 
significantly inhibited by both Ba2+ and quinidine (Patel et al., 2000).  
 
1.5.2 Mechano-gated TREK subfamily 
The TWIK-related K+ channel (TREK) family is comprised of KCNK2 (TREK-1) (Fink et al., 
1996), KCNK10 (TREK-2) (Lesage et al., 2000) and the closely related TWIK-related 
arachidonic acid activated K+ channel KCNK4 (TRAAK) (Fink et al., 1998). The TREK subfamily 
have been demonstrated to contribute to the cellular mechanisms of apoptosis, 
vasodilatation, anesthesia, pain, neuroprotection and depression (Noel et al., 2011). 
Characterisation of TREK-1 identified showed it to be outwardly rectifying (Fink, Lesage et 
al. 1998), with the presence of physiological Mg2+ or Ca2+ saturating the unitary 
conductance observed in symmetrical K+ at negative potentials (Kim et al., 2001a, Patel et 
al., 1998). While the amplitude of TREK-2 and TRAAK channel currents is not influenced 
significantly by the presence of extracellular Mg2+ (Bang et al., 2000, Kim et al., 2001a, 
Lesage et al., 2000). These channels present a low, weakly voltage-dependent open 
probability that can be activated by both chemical and physical stimuli, including mechano- 
stretch (Patel et al., 1998, Lesage et al., 2000, Kim et al., 2001a), polyunsaturated fatty acids 
(PUFA) (Patel et al., 1998, Kim et al., 2001b, Kim et al., 2001a), temperature increasing 
(Maingret et al., 2000a, Kang et al., 2005a) and cytosolic acidification, except TRAAK which 
activated by cytosolic alkalinisation (Lesage et al., 2000, Kim et al., 2001b, Kim et al., 2001a). 
For instance, regarding their mechano-sensitivity, TREK channels are activated by laminar 
and shear stress due to membrane cup formation, whilst they are inhibited by shrinkage of 
the cell which induces membrane crenation (Patel et al., 1998). Furthermore, these 
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mechano-gated TREK channels have been identified to be functionally coupled to G-protein 
signalling pathways and activation of the Gs/cAMP/PKA and the Gq/PLC/DAG/PKC 
signalling pathways indirectly inhibit TREK-1 channels by phosphorylating defined serine 
residues on the C-terminal tail (Enyedi and Czirjak, 2010, Lesage et al., 2000). 
 
TREK-1 subunits were the first members of the TREK subfamily to be identified, (Fink et al., 
1996). TREK-1 shares 63% sequence identity and 78% homology with TREK-2 (Noel et al., 
2011), which was firstly cloned from human brain by Lesage et al (2000). While human 
TRAAK share 38% sequence identity to human TREK-1 and 40% sequence identity to human 
TREK-2 (Fink et al., 1998). The identity falls to 45% and homology to 69% with TRAAK and 
to 50–55% homology with the other K2P subunits (Noel et al., 2011). Previous studies 
reported that mouse TREK-1 is widely expressed in brain, lung, kidney, heart as well as GI 
tract (Fink et al., 1996, Koh et al., 2001, Talley et al., 2001b), while human TREK-1 is 
abundantly expressed in brain and GI tract (Meadows et al., 2000, Medhurst et al., 2001). 
TREK-2 was abundantly expressed in human kidney, pancreas, brain and GI tract, 
overlapping with TREK-1 expression in many brain regions as well as in peripheral organs 
(Lesage et al., 2000, Medhurst et al., 2001), whereas TRAAK is present exclusively in brain, 
spinal cord and retina (Fink et al., 1998) 
 
Regarding their pharmacology profile, TREK-1 and TRAAK can be inhibited by the classical 
pore blocking ion, Ba2+ at high concentration ~1 mM (Ma et al., 2011, Fink et al., 1998). The 
serotonin reuptake inhibitors such as fluoxetine and its active metabolite norfluoxetine 
have been reported as a blocker of TREK-1 (Kennard et al., 2005) and TREK-2 (Dong et al., 
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2015). Recently, an endogenous peptide called Spadin has been reported as a selective 
blocker to TREK-1 with IC50 ~ 100nM (Mazella et al., 2010), but had effect to TREK-2 and 
TRAAK channel currents (Moha Ou Maati et al., 2012). The neuroprotective agent riluzole 
has been reported as an activator of TREK channels at concentration ~100 µM (Duprat et 
al., 2000). Fenamates, non-steroid anti-inflammatory drugs, including BL-1249 and FFA 
(flufenamic acid) have been revealed to directly and reversibly activate all three channels 
(Veale et al., 2014), but BL-1249 displays selectively among the TREK subfamily, activing 
TRAAK around 10 fold less potently than TREK-1 (Pope et al., 2018). Also, the caffeic acid 
derivative and lipoxygenase inhibitor cinnamyl 1-3,4-dihydroxy-alpha-cyanocinnamate 
(CDC) has been revealed to activate TREK-1 (Danthi et al., 2004).  
 
1.5.3 Acid-sensitive TASK subfamily 
The TWIK-related acid-sensitive K+ channel family (TASK) comprises of three channels, 
TASK-1 (KCNK3), TASK-3 (KCNK9) and non-functional TASK-5 (KCNK15) (Duprat et al., 1997). 
The non-functional TASK-5 channels share high sequence similarity with the other two 
members thereby has been classified into TASK subfamily. TASK-1 and TASK-3 are closely 
related with similar biophysical activities as well as overlapping pharmacological 
phenotypes. Both functional channels are strongly inhibited by extracellular acidification 
such that only about 10% of the current remains following a reduction of pH from 7.3 to 
6.3. TASK-1 has a pKa (acid dissociation constant) ~ 7.3 whereas TASK-3 has a pKa ~ 6.8 
(Kang et al., 2004a, Berg et al., 2004b). The activity of these two channels can be influenced 
by several regulatory factors in the same direction, such as G-protein receptors, oxygen 
and partner proteins located in C-terminus (e.g. 14-3-3, β-COP and p11). For instance, 
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stimulation of Gq-coupled receptors leads to an inhibition of TASK-1 and TASK-3 currents. 
The effect is mediated by liberation of Gqα, which binds directly to and inhibits the channels 
(Enyedi and Czirjak, 2010, Feliciangeli et al., 2015). In addition, TASK-1 and TASK-3 can form 
a functional heteromeric channels exhibiting properties distinct from TASK-1 and TASK-3 
alone (Czirjak and Enyedi, 2002, Berg et al., 2004a), however  TASK-5 is unable to form 
functional channels with other  K2P channels (Enyedi and Czirjak, 2010). TASK-1 has been 
reported widely expressed in pancreas, placenta, brain, lung and less so in heart. TASK-3 
abundantly distributed in brain with lower expression levels in a variety of peripheral 
organs (Lotshaw, 2007).  
 
Similarly to TREK subfamily, TASK channels are insensitive to classic K+ blockers, TEA, Ba2+ 
and 4-AP, as well as arachidonic acid (Maingret et al., 2000b, Maingret et al., 2001). The 
endocannabinoid anandamide and its more stable analog, methanandamide, exhibit high 
selectively for TASK-1 and TASK-3, as it does not inhibit other K2P channels (Maingret et al., 
2001). The polyvalent catonic dye ruthenium red is a selective blocker for TASK-3 channel, 
and can be used to distinguish TASK-3 currents from other K2P channel currents (Czirjak and 
Enyedi, 2002, Aller et al., 2005). Volatile anaesthetic agents such as isoflurane and 
halothane, activate TASK-1 and TASK-3 and this requires the proximal cytoplasmic C-
terminal domain (Patel et al., 1999, Sirois et al., 2000). 
 
1.5.4 Alkaline-activated TALK subfamily 
The TWIK-related alkaline pH-activated K+ channel (TALK) subfamily is comprised of three 
members: TASK-2 (KCNK5), TALK-1 (KCNK16) and TALK-2 (KCNK17). All three members are 
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sensitive to extracellular pH levels in the alkaline range and are either completely or almost 
completely inhibited at the physiological pH of 7.4, exhibiting robust currents by 
alkalinisation at a pH range from 7.5 to 10 (Girard et al., 2001, Reyes et al., 1998). TASK-2 
channels are broadly distributed in epithelial tissues in kidney and pancreas and to lesser 
extents in liver, placenta and small intestine, and are also expressed in nervous tissue in 
brain (Reyes et al., 1998). TALK-2 channels are localised to pancreas, liver, heart, lung and 
placenta. In contrast, TALK-1 channels have to date only been shown to be expressed in 
exocrine pancreas (Duprat et al., 2005, Girard et al., 2001).  
 
All TALK channel currents are voltage-independent and sensitive to Ba2+ and volatile 
anesthetics (e.g. halothane), but not to other traditional K+ channel blockers, such as TEA, 
4-AP and Cs+. Quinine has been reported to inhibit the basal activity of TALK-1 channels, 
whereas activate TALK-2 channels (Girard et al., 2001). An interesting pharmacological 
feature of TALK-2 channels is their stimulation by nitric oxide , eliciting robust TALK-2 
channel currents, a mechanism notably absent in TALK-1 channels (Duprat et al., 2005). 
Clofilium know as a blocker of the hERG channel which also inhibits TASK-2 with an IC50 of 
20 µM (Niemeyer et al., 2001).  
 
1.5.5 Halothane-inhibited THIK subfamily 
The halothane-inhibited THIK subfamily comprises three members, THIK-1 (KCNK13) and 
the non-functional THIK-2 (KCNK12), and THIK-1 exhibits leak currents displaying weak 
inward rectification in symmetrical K+ (Rajan et al., 2001). In rat, THIK-1 mRNA was widely 
expressed through the body (e.g. muscle, heart, testis, lung, brain, kidney, liver and 
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stomach) and THIK-2 mRNA was similarly wide distributed except in skeletal muscle, heart 
and testis (Rajan et al., 2001) . Unfortunately, the expression of THIK-1 and THIK-2 have not 
been investigated in human yet. THIK-1 is insensitive to extracellular pH levels, 
temperature and lysophospholipids. However, THIK-1 is activated by arachidonic acid and 
inhibited by halothane, giving the name to this subfamily (Rajan et al., 2001).  
 
1.5.6 Calcium-activated TRESK subfamily 
The calcium-activated TRESK subfamily is the last K2P subfamily to be identified, consisting 
of only one subunit TRESK (KCNK18) (Enyedi and Czirjak, 2010). The predicted topology of 
TRESK followed the generalisations established for all K2P channels presenting 4 
transmembrane domains and 2 pore domains. However, TRESK is differed in possessing an 
exceptionally long (91 amino acids) intracellular TM2-TM3 linker and a short intracellular 
C-terminus (~13 residues) (Kew and Davies, 2010). Interestingly, the human and mouse 
homolog of TRESK exhibited an unexpectedly low (68%) sequence identity, and thus mouse 
homolog of TRESK was reported and presented as TRESK-2 (Kang et al., 2004b). TRESK 
mRNA expression was initially found only in spinal cord (Sano et al., 2003), but has since 
been detected in brain (Liu et al., 2004).  
 
The TRESK channel is regulated by the calcium/calmodulin-dependent protein 
phosphatase, calcineurin, meaning that increasing intracellular Ca2+ levels activate the 
channel. TRESK channels are also sensitive to volatile anesthetics, including isoflurane, 
halothane, sevoflurane, desflurane and chloroform (Czirjak et al., 2004, Enyedi and Czirjak, 
2010) and both human and mouse homologues are sensitive to intracellular pH levels. 
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Human TRESK is weakly sensitive to extracellular pH while the mouse TRESK was strongly 
regulated within the physiological to pathophysiological range of extracellular pH 
(Keshavaprasad et al., 2005, Kang et al., 2004b). Zinc and mercuric ions distinguish TRESK 
from other K2P channels, inducing a significant and potent inhibitory effect (Czirjak and 
Enyedi, 2006). 
 
1.5.7 Heterodimerization between K2P subunit genes 
Heterodimerization of subunits is a widespread mechanism for increasing diversity in K+ 
channel subfamilies. The resulting heterodimers are typically characterized by different 
biophysical and regulatory properties from the homodimers of the parent subunits. Certain 
Kv, Kir or K2P (e.g. Kv8.1, Kir5.1 or K2P1.1) subunits cannot form functional homodimers on 
their own, however, via heterodimerization they can also gain important physiological 
function. There are several heteromeric K2P channels (see Table) have been described in 
recent studies. For example, TASK-1 and TASK-3 can form functional heterodimers 
detecting in several cell type (Berg et al., 2004a, Kang et al., 2004a, Kim et al., 2009), and 
exhibiting properties distinct from TASK-1 and TASK-3 alone, which showed intermediate 
pH sensitivity and ruthenium red insensitivity (Czirjak and Enyedi, 2002). TWIK-1 was also 
reported that can form heterodimeric channels with TASK channel subunits (TASK-1 or 
TASK-3) and TREK-1 channel, and these heterodimeric channels exhibit biophysical and 
pharmacological properties different from their parental channels (Plant et al., 2012, 
Hwang et al., 2014, Choi et al., 2018).  
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Table 1.2: Heterodimers of K2P channels. 
K2P Heterodimers Biophysical/Pharmacological Activity 
TWIK-1/TREK-1 The heterodimer generate passive 
conductance and was reported in 
hippocampal astrocytes (Hwang et al., 
2014). 
TWIK-1/TASK-1 (or TASK-3) The heterodimer exhibit acid-sensitive and 
halothane-sensitive outwardly rectifying 
K+ currents in cerebellar granule neurons 
(Plant et al., 2012, Choi et al., 2018). 
TREK-1/TREK-2 The heterodimer was inhibited by 
extracellular acidification and by spadin 
similarly to TREK-1 (Lengyel et al., 2016). 
TRAAK/TREK-1 (or TREK-2) The heterodimer exhibit different 
electrophysiological, regulatory and 
pharmacological properties different from 
those of homodimeric channels (Blin et al., 
2016).  
TASK-1/TASK-3 The heterodimer mediate the pH and 
isoflurane-sensitive K+ currents (Berg et 
al., 2004a, Czirjak and Enyedi, 2002). 
TASK-1/TALK-2 The heterodimer display unique hybrid to 
extracellular pH sensitivity and halothane 
compared to their parental channel (Suzuki et 
al., 2017). 
THIK-1/THIK-2 THIK1 was able to counteract the 
endoplasmic retention of THIK-2 (Blin et 
al., 2014). 
 
1.6 Aims 
Gastrointestinal tract motility relies on highly coordinated contractions of its longitudinal 
and circular smooth muscles. Disruption to this physiological process can result in long term 
motility disorders such as IBS. Although much is known about the ionic conductances 
responsible for GI smooth muscle contraction, comparably little is known about the 
underlying K+ channels responsible for suppressing smooth muscle contractility and 
promoting GI tract relaxation. The hypothesis underpinning this thesis is that K2P channels 
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have expressed and play a function role in regulating intestinal contractility. The overall 
aims of my PhD are; 1) to characterise the expression profiles of potassium channel 
subtypes along the mouse ileum and colon using quantitative RT-PCR methodology, 2) to 
describe the localisation of various K2P potassium channel subtypes along the mouse ileum 
and colon using immunohistochemical techniques, 3) to determine the functional role of 
potassium channel subtypes in regulating intestinal smooth muscle contractility, and 4) to 
further characterise the biophysical and pharmacological properties of mechano-gated 
TREK channels cloned from mouse.   
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Chapter 2 - Materials and Method 
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2.1 Animals 
Adult (2-4 months old) C57BL/6 mice (Charles River, Margate, UK) of either sex (weighing 
~20-30 g) were used through whole project study. SOX10-lox-GFP-4xPolyA-lox-DTA 
transgenic mice were also used in immunohistochemistry studies, which express the 
enhanced green fluorescent protein (EGFP) under transcriptional control of the SOX10 gene 
(Kessaris et al., 2006). The SOX10-EGFP transgenic line was from Professor Arthur Butt 
(University of Portsmouth, U.K.), and was originally a gift from Professor Bill Richardson 
(University College London, U.K.). All procedures involving l animals were approved by the 
Ethics Committee of the University of Portsmouth and were performed by a personal 
licence holder, in accordance with the regulations issued by the Home Office of the United 
Kingdom under the Animals (Scientific Procedures) Act, 1986. All animals were housed in 
standard plastic cages, on sawdust bedding in an air-conditioned room at 22 ± 1°C under 
lighting controls with 12 hrs light and dark cycles. Standard mouse chow and tap water 
were provided ad libitum.  
 
2.2 Quantitative RT-PCR 
2.2.1 Total RNA Extraction 
Adult C57BL/6 mice (N = 3) were killed by cervical dislocation and approximately 100 mg of 
distal ileum and distal colon were dissected and stored in RNA Later (Qiagen, Manchester, 
UK) with ice. Extraction of total RNA was performed using the RNeasy Midi kit (Qiagen, 
Manchester, UK) following the manufacturer’s instructions. Briefly, tissue was disrupted 
and homogenized using the TissueRuptor with sterile plastic pestle (Fisher) in round 
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bottomed collection tubes containing 2 ml guanidine thiocyanate (GITC) lysis buffer (RLT) 
and then centrifuged at 5000 x g for 10 minutes at 20°C. GITC is a chaotropic salt, i.e. a 
potent protein denaturant which inactivates RNases thus allowing for the RNA to be 
isolated intact. The supernatant was carefully removed and transferred to new collection 
tubes by pipetting before adding 70 % molecular grade ethanol at 1:1 ratio. Samples were 
then transferred onto an RNeasy Midi tube containing a silica-gel membrane upon which 
the RNA would bind during subsequent centrifugation at 5000 x g for 5 minutes. A wash 
with 4 ml of a chaotropic salt containing buffer RW1 were added onto tube and performed 
at 5000 x g for 5 minutes in order to wash away any remaining contaminating impurities 
such as degraded proteins. A further wash with 2.5 ml ethanol RPE buffer was applied at 
5000 x g for 2 minutes, then this step was repeated at 5000 x g for 5 minutes in order to 
wash away any remaining salts. Finally, high quality total RNA was eluted in 150 µl RNA-
free water by centrifugation for 3 minutes at 5000 x g.  
 
The purity and concentration of isolated total RNA was evaluated using a ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) to measure the UV 
absorption of each of the samples. The absorption at 260 nm (A260) was used to identify 
the concentration of single stranded RNA in undiluted samples. The ratio of absorbance at 
260 nm and 280 nm (A260/A280) was used to quantify the purity of samples. A ratio of ~1.8 
indicates an acceptable purity for DNA, and a ratio of ~2.0 for RNA. RNA optimally absorbs 
light at a wavelength of 260 nm due to its high content of nucleotides, while proteins and 
other impurities that might be contaminating the isolated RNA absorb best at 280 nm, thus 
the A260/A280 ratio is the preferred method to evaluate sample purity.  
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mRNA was reverse transcribed into complementary DNA (cDNA) using the RT2 first Strand 
Kit (Qiagen, Manchester, UK), following the manufacturer’s instructions. Briefly, 500 ng 
total RNA was incubated in a two-step process with genomic DNA elimination mix and 
Reverse-transcription enzyme mix. Random hexamers and oligo-dT prime reverse 
transcription in an unbiased manner and generates full length cDNA. 
 
2.2.2 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was used to define the expression profiles of 96 potassium channel gene 
transcripts from ileum and colon tissue sections. Primers were designed to target the 15 
identified mouse Kir genes, 40 Kv genes, 8 Kca genes, 14 K2P genes (mice lack the KCNK17 
gene encoding for TALK-2), 16 β subunit genes and 3 housekeeping genes including GAPDH, 
RPLP0 and HPRT. All qRT-PCR plate arrays were bought from Primerdesign (Southampton, 
UK). 1350 µl of 2x SYBR Green qRT-PCR Mastermix (Qiagen) was mixed with 102 µl cDNA 
and 1248 µl RNA-free water. Then, 25 µl of cDNA mixture was pipetted in each well of the 
96-well-plate, and along with the 5 µl of primer already contained in each well, gave a  total 
reaction volume of 30µl. The reactions were thermo cycled on a Roche Lightcyclcer 96 
instrument (Roche) using the following protocol; pre-incubation, 95°C for 60 seconds (1 
cycle), followed by 2 step amplification, 95°C for 15 seconds and 60°C  for 1 minutes (45 
cycles), finally melting step, 60°C for 15 seconds and 95°C for 1 seconds. Results were 
analyzed in the LightCycler 96 initially, using relative quantitative method in order to 
analyze changes in gene expression in given samples relative to the reference samples. 
Data normalization was performed using the best housekeeping genes for each 
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experiment. Optimal housekeeping gene were chosen using the NormFinder logarithm 
(Andersen et al., 2004) and the standard deviation (SD) method (Mane et al., 2008), which 
is a way to establish which housekeeping gene or combination of genes was the most stable 
and therefore appropriate to use for normalisation. Then, data were analyzed by using ΔCt 
method for studying the expression level of each potassium channel transcript with 
following formula:  
Ct sample – Ct Calibrator (mean of best housekeeping genes) = ΔCt 
Relative quantity = Average (2- ΔCt) 
The Ct (cycle threshold) is defined as the number of cycles required for the fluorescent 
signal to across the threshold (i.e. exceeds background level). Ct levels are inversely 
proportional to the amount of target nucleic acid in the sample.  All graphs were 
constructed using GraphPad Prism7 software (GraphPad Software, San Diego, CA, USA).  
 
2.3 Reverse transcription-polymerase chain reaction (RT-PCR) 
mRNA from mouse ileum, colon and whole brain were extracted (2.2.1) and reverse 
transcribed into complementary DNA (cDNA) using SuperScriptTM First-Strand Synthesis 
System for RT-PCR kit (Invitrogen, California, USA). In some cases plasmid DNA constructs 
expressing mTREK-1, mTREK-2 and mTRAAK genes were used as positive controls and were 
a kind gift from G. Sandoz (Université de Nice Sophia Antipolis, Nice, France). The total PCR 
reaction volume was 50 μl, containing 32.5 μl ddH2O, 1 μl dNTP mix, 1 μl DMSO, 10 μl x5 
reaction buffer, 1 μl cDNA (10 ng), 2 μl Forward Primer (10 μM), 2 μl Reverse Primer (10 
μM), 0.5 μl Iproof Taq (2 units/μl). The primers used in this study (Table 2.1) were designed 
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using the National Center for Biotechnology information (NCBI) Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and synthesised by Sigma-Aldrich 
(Gillingham, UK). The PCR reaction were cycled in C1000 Touch Thermal Cycler (Biorad, 
Hercules, CA) as following protocol: a single step at 98 °C for 2 minutes, followed by 35 
cycles of 98 °C for 10 seconds, 55 °C for 30 seconds and 72 °C for 30 seconds, and a final 
single step at 72 °C for 10 minutes. 25 μl of the RT-PCR reaction products were seperated 
on a 2 % (w/v) agarose gel at 10 V/cm for 30-40 minutes. The agarose gel was made by 
dissolving 1 g of agarose in 50 ml of 1 x TAE buffer (containing 40 mM tris-base, 20 mM 
acetic acid, 1 mM EDTA, pH was adjusted to 8.0) and adding 5 μl of SYBR safe DNA Gel Stain 
(Invitrogen) to allow visualisation of DNA. Gel images were captured under UV light using 
a BioRad Gel Doc EZ System (BioRad).  
 
Table 2.1: Details of RT-PCR primer sequences.  
Mouse 
Gene 
Accession 
number 
Primer sequence RT-PCR 
Product 
length (bp) 
TREK-1 XM_006497121.3 F: GTTTGGCTTTCTACTGGCTG 
R: GACCGTTCAGATAGATGCTC 
676 
TREK-2 NM_001316665.1 F: GGCTAATGTCACTGCTGAGTTCC 
R: ACAAGACAACACATAGTCCAATTCC 
624 
TRAAK NM_008431.3 F: GTGACCCAGCGAACTGGGCC 
R: GCCACGCTCACTCTGCGTGT 
219 
β actin NM_007393.5 F: TGCCGCATCCTCTTCCTC 
R: CGCCTTCACCGTTCCAGT 
647 
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2.4 Immunohistochemistry 
2.4.1 Tissue preparation for immunohistochemistry 
Adult C57BL/6J mice and SOX10 transgenic mice of either sex were anesthetised with 
isoflurane and pentobarbitone (1.25 mg/kg bodyweight, i.p.). Animals were transcardially 
perfused using a fixative containing 1 % paraformaldehyde and 15 % v/v saturated picric 
acid in 0.1 M phosphate buffer (pH 7.4), as previously described (Seifi et al., 2014). After 
perfusion, ileum and colon tissues were surgically removed and post-fixed in the same 
fixative overnight at 4 °C, before washing in 0.1 M phosphate buffer to clear residual 
fixative. Whole-mount preparations of the longitudinal muscle-myenteric plexus and 
circular muscle-submucosal plexus were obtained by removing the mucosa and submucosa 
layer and cut open along its longitudinal axis using a dissecting microscope and fine forceps, 
and stored in 0.1 M phosphate buffer containing 0.05% sodium azide at 4 °C until use.  
 
2.4.2 Smooth muscle cell preparation for immunocytochemistry 
 Adult C57BL/6J mice were killed by cervical dissociation and the ileum/colon was quickly 
removed and placed in a Sylgard-lined dish containing Ca2+-free Hanks’ solution (containing 
125 mM NaCl, 5.36 mM KCl, 15.5 mM NaHCO3, 0.336 mM Na2HPO4, 0.44 mM KH2PO4, 10 
mM glucose, 2.9 mM sucrose, 11 mM HEPES, adjusted pH to 7.4 with tris). The ileum/colon 
was cut open along its longitudinal axis and secured to a Sylgard-lined dish by micropins, 
with the serosal side uppermost. The mucosa and submucosa layer were removed by using 
a dissecting microscope and fine forceps to leave a layer of smooth muscle. The muscle 
layer was then cut into small pieces (~ 0.5 cm) and incubated in Hank’s solution containing 
1.6 mg/ml collagenase type I , 4 mg/ml fatty acid-free bovine serum albumin, 1 mg/ml 
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papain and 1 mM dithiothreitol (all purchased from Sigma-Aldrich, Gillingham, UK) at 37 °C 
for 10-12 minutes. After enzymatic digestion the muscles were washed with Ca2+-free 
Hanks’ solution 5-6 times. Muscle tissues were then gently triturated to create a cell 
suspension, and visualised under a microscope. 1 μl of 100 mM CaCl2 (final concentration 
100 μM) and 0.5 μl of 1M MgCl2 (final concentration 500 μM) were added into 1 ml smooth 
muscle cell suspension, and then stored at 4 °C for 1 hour before use.  
 
2.4.3 Immunohistochemistry 
The native K2P subunits (mechano-gated TREK subfamily, TWIK subfamily and TASK 
subfamily) immunoreactivity patterns within the ENS and smooth muscle cells of the mouse 
ileum and colon were confirmed in at least 3 animals. Nonspecific binding of secondary 
antibodies was blocked by incubating the tissue with 20 % normal horse serum, diluted in 
Tris buffer saline containing 0.3 % Triton X-100 (TBS-Tx) for 2h at room temperature. Tissue 
sections were then incubated with cocktails of primary antibodies (Table 2.2), diluted in 
TBS-Tx and 20 % normal horse serum (Sigma-Aldrich) overnight at 4 °C on a rotating 
platform. Tissues were then washed with TBS-Tx 3 times and incubated in a mixture of 
appropriate secondary antibodies (all acquired from Jackson ImmunoResearch, Ely, UK) 
conjugated with either AlexaFluor 488 (1:1000), indocarbocyanine (Cy3 1:1000) or 
indodicarbocyanine (Cy5 1:500) for 2 h at room temperature. The tissue was then washed 
in TBS-Tx again 3 times and mounted on glass slides in Mowiol mounting medium 
(Polysciences) under a cover slip. Secondary antibody specificity was assessed by omitting 
the primary antibodies in the incubation sequence. To confirm the absence of cross 
reactivity between IgGs in double and triple immunolabeling experiments, some sections 
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were processed using only a single primary antibody with the full complement of secondary 
antibodies. Immunohistochemical labelling was determined by confocal microscopy (see 
2.4.5), based on 3-4 sections for each antibody from n = 3 ileums and colons.  
 
2.4.4 Immunocytochemistry  
Smooth muscle cells were transferred into cover slip by pipette and left for 45 minutes in 
order to settle and adhere to the cover slip.  Cell solution was then removed and fixed with 
4 % paraformaldehyde/PBS (Alfa Aesar, Heysham, UK) for 20 minutes. After washing cells 
3 x 5 minutes in PBS (Sigma-Aldrich), cells were blocked for 45 minutes at room 
temperature using 10 % normal horse serum/PBS containing 0.1 % Triton X-100 in order to 
prevent non-specific binding of both the primary and secondary antibodies to other 
antigens in the cells. Smooth muscle cells were then incubated for 1 h with primary 
antibodies (Table 2.2), diluted in PBS/0.1 % Triton X-100 (PBST) and 10 % normal horse 
serum, then washed 3 x 5 minutes with PBST. The secondary antibody cocktails were made 
in (PBST) and 10 % normal horse serum and added to the cells for 1 hour at room 
temperature. After completion of immune-staining, the cells were once again washed 3 x 
5 minutes with PBST. Finally, cover slips were washed once in milliQ water and then 
mounted on clean slides, using mounting medium (PolySciences, Warrington, PA, USA).  
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Table 2.2: Details of antibodies used for immunohistochemistry and 
immunocytochemistry. 
 
Primary 
antibody 
Host Source Dilution Secondary antibody 
NOS Sheep polyclonal Millipore 
(AB1529) 
1:1000 Donkey anti-sheep Alexa 
488 
 
ChAT 
 
Goat polyclonal Millipore 
(AB144P) 
1:500 Donkey anti-goat Alexa 
488 
 
CR 
 
Goat polyclonal Swant (CG1) 1:500 Donkey anti-goat Alexa 
488 
 
α-actinin 
 
Mouse 
monoclonal 
Sigma-Aldrich 
(A5044) 
1:500 Donkey anti-mouse cy5 
 
TWIK-1 
 
Rabbit polyclonal Alomone 
Labs (APC-
110) 
1:2000 Donkey anti-rabbit cy3 
 
TWIK-2 Rabbit polyclonal Alomone 
Labs (APC-
040) 
1:1000 Donkey anti-rabbit cy3 
 
TASK-1 
 
Rabbit polyclonal Alomone 
Labs (APC-
024) 
1:1000 Donkey anti-rabbit cy3 
 
TASK-2 
 
Rabbit polyclonal Alomone 
Labs (APC-
037) 
1:1000 Donkey anti-rabbit cy3 
 
TASK-3 
 
Rabbit polyclonal Alomone 
Labs (APC-
044) 
1:2000 Donkey anti-rabbit cy3 
 
TREK-1 
 
Rabbit polyclonal Alomone 
Labs (APC-
047) 
1:1000 Donkey anti-rabbit cy3 
 
TREK-2 
 
Rabbit polyclonal Alomone 
Labs (APC-
055) 
1:1000 Donkey anti-rabbit cy3 
 
TRAAK 
 
Rabbit polyclonal Alomone 
Labs (APC-
108) 
1:1000 Donkey anti-rabbit cy3 
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2.4.5 Image capture and analysis 
Sections were examined with a confocal laser-scanning microscope (LSM710; Zeiss) using 
either a Plan Apochromatic 40x DIC oil objective (NA 1.3; pixel size 0.29 μm) or a Plan 
Apochromatic 63x oil objective (NA 1.4; pixel size 0.13 μm). Z-stacks were used for routine 
evaluation of labelling. All images shown represent a single optical section. Images were 
acquired using sequential acquisition of different channels to avoid crossover between 
fluorophores, with the pinholes adjusted to one airy unit for all channels. Identical settings 
were used to image negative controls. Images were processed using Zen2009 Light Edition 
software (Zeiss, Cambridge, UK) and exported into Adobe Photoshop CC 2015.5. Only 
brightness and contrast were adjusted for the whole frame, and no part of a frame was 
enhanced or modified in any way. 
 
2.5 Organ bath 
2.5.1 Equipment setup 
Adult WT C57BL/6 mice of either sex (weighing~20-30 g) were used in this study. Mice were 
euthanised by carbon dioxide asphyxiation and cervical dislocation.  Both distal ileum and 
distal colon were isolated and cut into segments of about 2-3 cm in length. The faecal 
matter was gently removed by flushing with 1 ml Kreb’s solution consisting of (in mM); NaCl 
(118), KH2PO4 (1.2), NaHCO3 (25), D+ glucose (11), MgSO4 (1.2), KCl (4.7) and CaCl2 (2.5), pH 
7.4. Tissues were mounted longitudinally on an aerator and suspended from a force 
transducer (Harvard, UK) in a 10 ml chambered Harvard Apparatus 230 V heated tissue 
organ bath containing Krebs solution at either 32°C (CCh pre-contracted experiments) or 
37°C (spontaneous contraction experiments). Gas containing 95 % oxygen and 5 % carbon 
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dioxide continually aerated the organ bath solution (Figure 2.1). changes in isometric 
tension was monitored and recorded by use of a fore displacement transducer (range 0-
50g) coupled with a bridge amplifier(Harvard, UK) (set to a range of 5 mV) connected to a 
desktop PC running the data acquisition software Lab Chart 7 (AD instrument, Oxford, UK); 
with a further noise filter on the program set to 20 Hz. For calibration of the apparatus, a 
one gram weight was placed on the force transducer to display the changes in amplitude 
recorded by the force transducer in grams, the tissue segment was then subjected to one 
gram of resting tension and then left to equilibrate for at least 30 minutes.  
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Figure 2.1: A schematic diagram of a mouse gut preparation in an organ bath (Yildiz et al., 
2013). 
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2.5.2 Organ bath pharmacology 
Viability of ileum and colon tissues was assessed in parallel by exposure to the 
parasympathomimetic carbachol (CCh) at concentrations ranging from 10−9 to 10−4 M. Each 
concentration was applied for approximately 2 minutes, followed by a rinse cycle (30 
seconds per cycle) repeated 3-4 times with fresh Kreb’s solution before the application of 
the next concentration. Responses to classical potassium channel blockers were performed 
directly into bath when spontaneous contraction was stable, changes in the force were 
measured. Like CCh, blockers were applied for approximately 2 minutes before the wash. 
Responses to potassium channel activators were performed after exposure to submaximal 
concentrations of CCh or 60mM KCl and quantified by assessing maximum changes in 
steady state tension. Drugs were applied for approximately 3-4 minutes, followed by a 
repeated wash cycle (4-8 times) to return tension to baseline. Moreover, 10 μl drugs were 
applied if the vehicle DMSO was used, in order to control the DMSO concentration within 
0.1 %. Furthermore, the inhibition effects of K+ channel blocker in activation of BL-1249 (10 
μM) were also investigated. Ba2+, sapdin or tetrodotoxin (TTX) were individually added to 
the bath for 5 or 10 (TTX) minutes before which the relaxation effects was induced by BL-
1249. 
 
In separate experiments, spontaneous contractile activity was quantified. Tissues were 
prepared as described above. After stable baselines were established, changes in the force 
and frequency induced by K2P modulators were recorded and quantified over 5 minutes 
periods pre- and post-drug application. 
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2.5.3 Data analysis for organ bath 
In CCh or KCl pre-contracted experiments, changes in tension were measured from baseline 
to the highest steady state contraction. The relaxation percentage was determined by 
following formula (Figure 2.2); % relaxation = ((C1 – C2)/ C1) X 100, where C1 represents 
the contraction size before the drug and C2 represents the contraction size after the drug. 
All organ bath experiment results were collected from LabChart 7 reader (ADInstruments, 
Oxford, UK) and analyzed in GraphPad Prism software (GraphPad Software, San Diego, CA, 
USA). All data are presented as the arithmetic mean ± SEM unless stated otherwise. 
Sigmoidal curve fitting for determination of IC50 / EC50 values were performed using the 
non-liner regression normalized response function. Statistical analysis were performed 
using either the Student’s t-test (paired or unpaired where appropriate) or two-way 
ANOVA, and deemed significant at p <0.05.   
 
Figure 2.2: Exemplar trace identifying the measurement of tissue contraction.  
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2.6 LB medium and LB agar plates 
Lysogeny broth (LB) medium were made by adding 10 g Bacto-tryptone, 5 g yeast extract 
and 10 g NaCl (Sigma-Aldrich, UK) to 1 litre of deionised water, and the pH adjusted to 7.5 
using NaOH. LB agar plates (1.5 %) were made by adding 15 g agar into 1 litre LB medium 
to make solid media. Both were autoclaved at 121°C for 20 minutes and allowed to cool to 
50 °C before adding 1 ml of stock ampicillin (100 mg/ml) in case of LB agar media to make 
a final concentration of 100 μg/ml. Plates were poured into petri dishes under a Bunsen 
flame in a designated sterile area washed with virkon (500 mg/ml) and 70 % ethanol prior 
to use. Plates were then left to set under a constant flame before being stored inverted at 
4 °C. Both LB agar plates and LB media stored for up to 3 months with antibiotic present.    
 
2.7 Sub-cloning 
2.7.1 Transformation 
Each TREK gene has been cloned into pEXO vector and shipped dried on filter paper. To 
recover the plasmids, a clean razor blade was used to cut out the marked area containing 
the DNA, which were then place in a micro-centrifuge tube with 10 μl of dH2O. Tubes were 
briefly vortexed and let stand for 10 minutes, following by quick centrifuge using 
microcentrifuge minister (VWR, Lutterworth, UK) to elute DNA samples. To a Falcon 
polypropylene snap top tube 5 μl of the plasmid DNA samples and 50 μl of DH10B 
competent cells (bacteria cell, gift from Dr R. Draheim, University of Portsmouth, UK) were 
added and mixed gently using a pipette before being incubated on ice for 30 minutes. The 
snap top tubes were then transferred to a water bath pre-heated to 42 °C and heat shocked 
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for 45 seconds, then returned to ice for a further 2 minutes. 300 μl of LB medium was added 
to each tube and incubated for 1 hr in a MaxQ 8000 incubator (Thermo Scientific, UK) at 
220 rpm and 37 °C. Under a constant Bunsen flame the contents of the tube was spread 
over an LB agar plate using a sterile spreader and left to dry under the flame. The plates 
were then left inverted in a stationary incubator overnight at 37 °C (16-24 hrs). Selected 
colonies were lifted from the plate using a sterile pipette tip and placed in a tube with 4 ml 
of LB medium containing 100 μg/ml ampicillin before being transferred to a shaking 
incubator to be incubated overnight at 200 rpm and 37°C (maximum 16 hrs).  
 
2.7.2 Plasmid purification 
Plasmid DNA was isolated using the QIAquick Mini Prep Kit (Qiagen, Manchester, UK) as 
per manufacturer’s instructions. Inoculated LB media was pelleted at 5,000 rpm for 3 mins 
at 20 °C in a table top Heraeus Megafuge (Thermo scientific, UK). The supernatant liquid 
media was removed and the pellet re-suspended in 250 μl buffer P1 and pipetted gently 
up and down to mix it until no clumps were visible. The re-suspension was transferred into 
a 1.5 ml micro-centrifuge tube before 250 μl of buffer P2 was added and the tube gently 
inverted 4-6 times before 350 μl of buffer N3 was added and the tube inverted again for 
another 4-6 times. The solution was centrifuged at 13,000 rpm for 10 mins at 20 °C. The 
supernatant was transferred to a supplied spin column and centrifuged for 1 minute at 13, 
000 rpm and the flow-through discarded. The column was then washed with 750 μl of 
buffer PE (containing ethanol) and centrifuged again for 1 minute at 13,000 rpm, the flow-
through discarded and the centrifugation step repeated to remove any residual PE buffer. 
The column was transferred to a clean Eppendorf tube and the DNA eluted with 50 μl of 
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ddH2O for 1 min and then centrifuged for 1 minute at 13,000 rpm. Recombinant plasmid 
purity and concentration was assessed by using ND-1000 Spectrophotometer as previously 
described (section 2.2.1). 
 
2.7.3 Restriction Digests 
Recombinant plasmids were digested in a reaction volume of 30 μl (5 μl Recombinant 
plasmid; 3 μl Cutsmart buffer; 1 μl EcoRI; 1 μl XbaI; 20  μl ddH2O) and incubated for 2 hrs 
at 37 °C using C1000 Touch Thermal Cycler (Biorad, Hercules, CA).  The digested 
recombinant plasmids products were then mixed with 6 μl 6 x DNA loading dye (Thermo 
Scientific, UK) and separated on a 1 % agarose gel as previously described (section 2.3) .  
 
2.7.4 DNA purification from agarose gel 
The agarose gel was visualized under UV light by using UVP Visi-Blue™ Transilluminators 
(Fisher Scientific, UK), and gel slice containing the DNA fragments were excised using clean 
scalpel blade and placed into a 1.5ml microtube. The mass of agarose gel was determined 
by comparing the weight of the tube with that on an empty microtube using a sartorious 
scale. Plasmids were purified from the gel using the QIAquick Gel Extraction Kit (Qiagen, 
Manchester, UK) as per manufacturer’s instructions. The gel section was dissolved in 3 x 
volumes of OG buffer (e.g. 300 μl for 100 mg of gel) and then incubated in heatblock at 50 
°C for 10 minutes until the gel had completely dissolved. 1 volumes of 100 % isopropanol 
was added to the solubilized gel solution, and transferred to a supplied QIAquick spin 
column and centrifuged for a 1 minute at 13,000 rpm and the flow-through discarded. 750 
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μl of buffer PE were applied to the column and centrifuged for a further 1 minute at 13,000 
rpm. The flow-through was discarded and the column centrifuged to remove any residual 
PE buffer. The spin column was then transferred to a clean 1.5 ml micro-centrifuge tube 
and the DNA eluted with 30 μl of ddH2O for 1 min and before centrifugation at 13,000 rpm 
for 1 minute. The concentration of DNA was assessed using a nanodrop ND-1000 
Spectrophotometer, as previously described (section 2.2.1).  
 
2.7.5 Ligation 
Ligation is a process joining of DNA sticky ends using a specialised enzyme, T4 DNA ligase. 
Reactions contained 1 μl ligase buffer, 1 μl T4 ligase enzyme (New England Biosciences), 2 
μl pMAX vector and 6 μl DNA insert. The reaction was incubated at room temperature 
(between 20 and 22 °C) for 1 hour. Ligations were then transformed into bacteria as 
described in section 2.7.1, colonies selected and grown (section 2.7.1.) and plasmid DNA 
extracted (Section 2.7.2). Successful ligations were verified by performing a diagnostic 
digest as described in section 2.7.3. The New England Biosciences (NEB) enzymes EcoRI (5’-
GAATTC-3’) and XhoI (5’-CTCGAG-3’) were identified two single cut restriction sites which 
flanked the gene in the site of pMAX vector.  
 
2.7.6 Sequencing 
Recombinant plasmids were sent for Mix2Seq sequencing by using a pre-paid service 
(Eurofins, Ebersberg, Germany). Plasmids were diluted in 15 μl of deionised water to a 
concentration of 100 ng/μl and mixed with 2 ul of a single primer (10 uM), either a forward 
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primer (T7 short) or a reverse primer (XBG) making the final volume of each tube 17 μl. 
Read lengths were sufficient to enable coverage of the entire gene using plasmid specific, 
gene flanking sequencing primers. DNA sequencing were then compared to the templet 
sequencing by using software DNASTAR (DNASTAR, Inc, Madison, WI, USA). 
 
2.8 Site directed mutagenesis 
Mutagenesis primers were designed using online freeware PrimerX 
(http://www.bioinformatics.org/primerx/index.htm). Primer parameters were set for a 
primer melt temperature between 75 – 85°C, GC content between 40 % - 60 %, and a length 
between 25 – 45 base pairs, and primers were also designed to terminate with a G or C, 
and have the mutation site at the centre of the primer were possible. All primers were 
synthesised by Sigma-Aldrich oligo (details see Table 2.3). Primers were reconstituted to 
100 μM stock concentrations with deionised water according to manufactures guidelines 
and diluted to give 10 μM working solutions.  
 
Table 2.3: Details of mutagenesis primer sequences 
Mutagenesis gene Primer sequence 
mTREK-2-V188A  F: CTTTTGTATTTTATATGCCATCTTTGGGATCCCGC 
R: GCGGGATCCCAAAGATGGCATATAAAATACAAAAG 
mTRAAK-K38Q  F: GCAGGCTCAGAAGCAAATGGATCATGGC 
R: GCCATGATCCATTTGCTTCTGAGCCTGC 
mTRAAK-K330Q  F: GCACCCGCAGAGCAGGTTGAGACTC 
R: GAGTCTCAACCTGCTCTGCGGGTGC 
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50 μl PCR reaction samples were prepared as above (section 2.3). Samples were cycled in 
C1000 Touch Thermal Cycler (Biorad, Hercules, CA) as following protocol; 98 °C for 2 
minutes (1 cycle), followed by 18 cycles of 98 °C for 10 seconds, 56 °C for 30 seconds and 
72 °C for 2 minutes 30 seconds, and a final single elongation step of 72 °C for 10 minutes.  
After cycling had completed, 1 μl DpnI (20,000 units/ml) (New England Biosciences, Hitchin, 
UK) enzyme was added into PCR sample and incubated for a further 1 hr at 37 °C in order 
to digest the parental/template DNA. PCR products were separated by 1% agarose gel 
electrophoresis and visualised to verify successful amplification (section 2.3). 10 μl of 
successful amplifications were transformed (section 2.7.1), colonies selected, cultured 
(section 2.7.1) and plasmid DNA purified by miniprep (section 2.7.2). To remove the 
influence of any spurious mutations generated during the process, mutated genes were 
subcloned into fresh wild type backbone pMAX plasmid following previously described 
protocols (digestion with restriction enzymes (section 2.7.3), separation on agarose gel and 
subsequent extraction(section 2.7.4), ligation into fresh pMAX vector (section 2.7.5), 
transformation of new construct (section 2.7.1), purification by mini prep (section 2.7.2), 
diagnostic digest (section 2.7.5) and sequencing to check for the correct mutation and 
position (section 2.7.6).  
 
2.9 Chimera constructs 
Chimera of mTREK-2 channel were C-terminus was replaced with the C-terminus of mTREK-
1 were constructed using PCR methodology using a two-step process. TREK-1 C-terminus 
cloned by PCR using forward primers (5’-GTGTGGTTCTGGATCCTCGTTGG-3’) and reverse 
primer (5’-GGGTGTTCTTGAGGCTGGTTTAGTGG-3’) and TREK-1 as template using protocol 
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in section 2.3. The cloning product was a 434 bp amplicon. Then the processes it goes 
though 1 % agarose gel running (section 2.3) and subsequent extraction (section 2.7.4) and 
is then PCR amplicon used as a reverse primer in PCR reaction containing TREK-2 as 
template and forward primer (5’-TAATACGACTCACTATAGGG-3’). The final amplified 
product was a 1336 bp amplicon. Again PCR amplicons treated as before (section 2.3) and 
purified (section 2.7.4). Since the clone contains ORF and 5’ and 3’ MCS digest performed 
to allow subcloning into prepared pMAX wild type backbone, following noted procedures 
digestion with restriction enzymes (section 2.7.3), separation on agarose gel and 
subsequent extraction(section 2.7.4), ligation into fresh pMAX vector (section 2.7.5), 
transformation of new construct (section 2.7.1), purification by mini prep (section 2.7.2), 
diagnostic digest (section 2.7.5) and sequencing to check for the correct mutation and 
position (section 2.7.6).  
 
2.10 cRNA generation 
2.10.1 Linearisation 
Successful recombinant plasmids were linearised by cutting the plasmid construct 3’ 
downstream of the gene and poly A tail so that subsequent in virto transcription only 
transcribes the gene and not the whole plasmid. 30 μl reaction sample was prepared 
(containing 10 μg Recombinant plasmid; 4 μl Cutsmart buffer; 1 μl PacI; made to volume 
with ddH2O) and incubated for 2 hrs at 37°C (section 2.7.3). Successful linearisation was 
assessed on a 1% agarose gel (section 2.3). Reactions were PCR purified using the QIAquick 
Gel Purification Kit (Qiagen, Manchester, UK) as per manufacturer’s instructions. The total 
reaction volume (29 μl) is mixed with 5 volumes of PB (1 volume = 29 μl) for a total of 
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volume of 174 μl. The total reaction is placed onto a spin column and centrifuged at 20 °C 
at 13,000 rpm for 1 min and the flow-through discarded. The spin column is then loaded 
with 750 μl of wash buffer PE and spun again at 20 °C for 1 min and the flow-through 
discarded. The spin column is then spun a subsequent time at 20 °C for 1 min to remove 
any excess wash solution. The spin column is then placed into a fresh Eppendorf tube and 
30 μl ddH2O added directly onto the column membrane, the column is then left for 1 min 
before being spun at 20 °C for 1 min to collect and the flow-through is collected at the end 
ready to check purity and concentration using a ND-1000 spectrophotometer (section 
2.1.2).  
 
2.10.2 In-vitro transcription 
cRNA was prepared from linearised constructs using the T7 m-Message Machine Kit 
(Ambion, Austin, TX). The cRNA reaction volume was 20 μl (10 μl 2 x NTP/CAP; 2 μl 10 x 
Reaction Buffer; linearised TREK-1 pMAX construct (1 μg); ddH2O; 2 μl enzyme mix). 
Reactions were gently vortexed before being incubated for 2 hrs at 37°C using a C1000 
Touch Thermal Cycler (Biorad, Hercules, CA. USA). The reaction was then transferred into 
1.5 ml Eppendorf containing 30 μl lithium chloride (7.5 M) and 30 μl ddH2O, mixed and 
then incubated at -20°C for overnight to allow cRNA precipitation. The precipitate was then 
pelleted at 13,000 rpm 15 min at 4°C and the supernatant removed using a pipette. The 
pellet was then washed with 1 ml of ice cold (- 20°C) 70 % ethanol and re-centrifuged at 
13,000 rpm for 15 mins at 4°C. The ethanol was then removed using a pipette, and the 
pellet was left to air dry for no more than 5 mins. The pellet was reconstituted in RNase 
and DNase free molecular grade water to a volume of 20 μl. cRNA was qualitatively 
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assessed by separation by electrophoresis on a 1 % agarose gel (section 2.3) and quantified 
spectrophotometrically using a ND-1000 spectrophotometer (section 2.2.1.). All cRNA 
samples were stored at -80°C. 
 
2.11 Electrophysiology 
2.11.1 Preparation of oocytes  
Xenopus laevis ovaries were provided by European Xenopus Resource Centre (University of 
Portsmouth, Portsmouth, UK) and oocytes subsequently prepared and isolated as detailed. 
In brief, frogs were anesthetized and sacrificed using a Schedule 1 method (MS222) 
followed by pithing and ovariectomy, in accordance with the Animals (Scientific 
Procedures) Act 1986 (UK) by a licence holder. Ovaries were stored in 50 ml falcon tubes 
containing Ca2+-free OR-2 solution (in mM): NaCl (82.5), KCl (2.5), MgCl2 (1), HEPES (10), pH 
7.4 tris-base.  Oocytes were manually separated using forceps into clumps of 10-15 oocytes 
and rinsed 3-4 times with OR-2 solution. Oocytes were suspended in 40 ml of OR-2 solutions 
containing 80 mg (2 mg/ml) of type II collagenase (Worthington, US) for 1 hour – 1 hour 30 
minutes at room temperature on tube rotator (Stuart, UK) with speed 10 rpm. Oocytes 
were spot checked under a binocular compound microscope to visually assess the loss of 
the follicular layer, classified by the absence of the vascular network covering the oocytes 
(Figure 2.3). The enzymatic reaction was halted and collagenase removed by rinsing 
oocytes3-4 times in calcium containing ND-96 solution (in mM): NaCl (96), KCl (2), MgCl2 
(1), CaCl2 (1.8), HEPES (10), pH 7.6 tris-base, containing 50 µg/ml gentamycin and 1% 
penicillin/streptomycin remove. Suspended oocytes were then transferred to a petri dish. 
Stage IV-V oocytes were selected using a pasture pipette, modified to possess an enlarged 
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polished outlet to provide safe transports of oocytes, and distributed into small petri-dishes 
containing fresh ND-96 solution and incubated at 16°C.  
 
Figure 2.3: Schematic demonstrating the removal of the follicular cell layer and connective 
tissue via the use of collagenase enzymes. Post-treatment the oocyte only has the inner 
plasma membrane and its vitelline membrane intact, ready for injection. 
 
2.11.2 Pipette fabrication 
Glass micropipettes were fabricated via a two-stage process using a Narishige PP-83 pipette 
puller (Narishige Scientific Instrument Laboratory, Japan). For TEVC pipette fabrication, the 
glass used for injection and recording electrodes were manufactured from microinjection 
capillaries borosilicate glass with 3.5 inch length bores for Drummond Nanoject 
(alphalavoratores, Eastleigh, UK), and thin-walled borosilicate glass capillaries with 1.0mm 
OD, 0.78mm ID, 75 mm L (Harvard Apparatus, UK), respectively.  
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2.11.3 Oocyte injection 
Glass pipettes were back filled with mineral oil (Sigma-Aldrich) and inserted onto the 
Nanoinject Microinjector. Pipettes were then broken under microscope by carefully 
crushing the tip against the petri dish until a break was made which resembled the end of 
a hyper dermic needle (an opening between 2-3 μm in diameter). Injections were 
performed in a sterile injection-chamber constructed to provide a wall to serve as 
mechanical resistance to the oocytes during insertion of the microinjection pipette (Fig 
2.4). The chamber was filled with ND96 throughout the procedure to ensure oocytes were 
covered in solution at all times. 
 
Figure 2.4: Schematic of the injection procedure. Oocytes are placed into a dish filled with 
a raised wall. Oocytes are placed alongside this wall, which serves as mechanical resistance 
during injection. The dish is filled with ND-96 storage buffer throughout the procedure. 
 
All cRNA samples were diluted to a final concentration of 10 ng/ 23 nl which equates to 
43.47 ng/nl, except mTRAAK, which diluted to a final concentration of 20 ng/ 23 nl. For 
example, concentration of RNA for mTREK-1 500 ng/μl, so 500/43.47 = factor of 11.5, which 
give us concentration 11.5 ng / 23 nl. Hence using equation C1V1 = C2V2 to calculate that 
dilute 8.3 μl of RNA with 1.7 μl of RNase-free water to get a concentration of 10 ng/ 23 nl. 
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So when 23 nl is injected it will in fact be 10 ng of mTREK-1 RNA. Selected oocytes were 
injected one-by-one with cRNA (2-10 ng per oocyte; 23 nl injection volume) and transferred 
to fresh ND-96 daily and infected, damaged oocytes removed to prevent cross 
contamination, and stored at 16 °C.  
 
2.11.4 Two-electrode voltage clamp (TEVC) 
Whole-cell currents of injected oocytes were assessed using TEVC, a technique was used to 
measure ionic currents in response to precisely controlled changes in the transmembrane 
potential of an isolated cell. TEVC Oocyte currents were recorded using an OC-725C oocyte 
clamp amplifier (Warner Instruments, Harvard Apparatus, UK) and Axon Digidata 1440A 
(Molecular Devices, UK) and visualised using pCLAMP 10.4 software (Molecular Devices, 
LLC, Sunnyvale, CA) installed on a computer with a Windows 7 operating system. All 
experiments were performed at room temperature (between 20 – 22°C) with constant, 
gravity fed solution flow at 1-2 ml/min with a bathing solution containing (in mM): 96 NaCl, 
4 KCl, 1 MgCl2, 0.3 CaCl2, 10 HEPES (pH 7.6, tris-base). Two microelectrodes were backfilled 
half way with 3 M KCl using a MicroFil syringe needle (VWR, Lutterworth, UK) and one 
electrode secured into each of the two electrode holders, making sure that Ag/AgCl wire 
makes contact and therefore electrical connection with KCl solution in the pipette. Pipette 
tip resistances were measured by placing the electrodes into the bath solution and 
adjusting the offset. A resistance of 0.2 - 1 M  is desirable. Electrodes were advanced into 
the oocyte one at a time using manually controlled micromanipulators attached to the base 
of the TEVC platform. Electrodes touching the oocytes form a slight indent on the oocyte 
membrane, at this point the electrodes were advanced further and successful penetration 
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is seen when the LCD display for each electrode on the amplifier reads the membrane 
potential of the cell (Fig. 2.5A). The clamp was adjusted to fast and the gain turned to 
maximum before the voltage protocol was applied. Oocyte membrane potential was held 
at -80 mV and step depolarised to potentials ranging from -120 mV to +60 mV in 10 mV 
steps for a duration of 1 s (Figure 2.5B). Recorded currents were not adjusted for leak or 
capacitance. 
 
Figure 2.5: Schematic summarising the oocyte set-up in as part of a TEVC recording. A) The 
oocyte is impaled by two glass microelectrodes, one for voltage sensing and one for current 
injection. The transmembrane potential is measured by the voltage-sensing electrode (V1) 
connected to a high input impedance amplifier (Amp 1). This signal is compared to a 
command voltage generated by a computer at the input of Amp 2. The output of the high 
gain feedback Amp 2 is a current delivered to the cell interior by the second micropipette. 
This current is sufficient to force the transmembrane potential to equal the command 
voltage. The current delivered by micropipette 2 is monitored as “I2” via a current-to-
voltage converter. B) Diagram of a typical voltage protocol for recording voltage families. -
80 mV denotes the command potential, -120 to -60 mV are the highest and lowest voltages 
of the step protocol. 
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2.11.5 Potassium selectivity experiments 
For selectivity measurements, oocytes were exposed to different levels of extracellular K+; 
[K+]o of 4, 20, 100 and 140 mM (Table 2.4). Briefly, ionic currents were initially recorded 
using the voltage family protocol in bath solution containing 4 mM K+. The solution was 
then be switched to one containing 20 mM K+ and allowed to equilibrate for 1-2 minutes 
before applying the voltage protocol again. This procedure was repeated after exchange of 
the bath solution again to one containing 100 mM K+ and 140 mM K+. Current-voltage (IV) 
curves were plotted using Clampfit 10.7 software (Axon Instruments, Inc.), and the data 
transferred into an excel spreadsheet to calculate the mean IV relationship for all cells in 
that experiment. Traces were modified with the x-axis cut off at 1200ms with the y-axis 
value dependent on maximum current amplitude of that experiment. Channel reversal 
potential was calculated from IVs (between -120 to 60 mV) taken from whole cell 
recordings. IVs were analysed for the point at which the line of the graph crossed the x-
axis. In the case of K+ selectivity experiments the average reversal potential was plotted 
against the [K+]o to produce a Nernstian slope. This slope could be directly compared to the 
theoretical slope of a perfectly selective channel derived using the Nernst equation in 
differing potassium conditions;  
 
Where R is the universal gas constant (8.3145 J mol-1 K-1), T is the temperature in kelvin, F 
is the Faraday constant (9.6485 × 104 C mol−1), z is the valance and [K]i / [K]o are the 
concentrations of K+ ions inside and outside the cell respectively. The Nerstian slope of a 
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channel which only passes potassium is theorised to have a Nerstian slope of 58.2 mV, such 
that a 10 fold increase in extracellular K+ ion concentration should shift reversal potential 
58.2 mV positive. 
 
Table 2.4: The composition of different concentration of K+ solution.  
Compound 4 mM K+ 20 mM K+ 100 mM K+ 140 mM K+ 
NaCl 96 mM 80 mM X X 
KCl 4 mM 20 mM 100 mM 140 mM 
MgCl2 1 mM 1 mM 1 mM 1 mM 
CaCl2 0.3 mM 0.3 mM 0.3 mM 0.3 mM 
HEPES, pH 7.6 (Tris) 5 mM 5 mM 5 mM 5 mM 
 
 
2.11.6 Application of drugs 
TREK family channel pharmacology were conducted by diluting the stock concentration of 
the compound of interest in 30 ml of 4 mM K+ solution to the desired working 
concentration. Pharmacological compounds were applied by gravity perfusion at a rate of 
1 ml per minute. Oocytes expressing mTREK-1, hTREK-1, mTREK-2 and mTRAAK channels 
were recorded in 4 mM K+ solution as a control to establish baseline current levels, using 
protocol showing Figure 2.5B. To ascertain the successful exchange of bath solutions 
between 4 mM K+ and drugs, a single-pulse protocol was used where oocytes were clamped 
at -80 mV and subjected to a 1 s pulse of 50 mV at 0.1Hz until equilibrium had been reached, 
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and then the relevant protocol applied. After the experiment had been conducted the same 
protocol was applied to observe the wash out of the compound, with equilibrium once 
again dictating when this was successfully achieved. 
 
2.11.7 Data Analysis for TEVC 
All TEVC data were analysed using Clampfit 10.7 (Axon Instruments, Inc.), and tabulated in 
Excel (Microsoft Office 2013). Current-voltage (I-V) relationships were generated from 
steady-state currents at potentials between -120 mV and +60 mV. Statistical analyses and 
graphical evaluations were performed with GraphPad Prism 7.0 (GraphPad Software, San 
Diego, CA, USA). For all analysis, n values represent the number of oocytes. All data are 
presented as the arithmetic mean ± SEM unless stated otherwise. Statistical comparisons 
were made using either Student’s paired t-test or two-way ANOVA. A p < 0.05 was 
considered statistically significant. 
 
2.12 Drugs 
All pharmacological compounds were reconstituted/diluted where applicable and in 
accordance with manufacturer’s instructions (Table 2.5).  
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Table 2.5: Details of drugs used in organ bath (OB) and TEVC studies. 
Drug Company Stock conc. 
(mM) 
Dissolved in Used for 
CCh Sigma-Aldrich 10 Kreb’s solution OB 
KCl Sigma-Aldrich 30 ddH2O OB 
Ba2+ Sigma-Aldrich 1000 ddH2O OB & TEVC 
TEA Sigma-Aldrich 1000 ddH2O OB 
4-AP Tocris Bioscience 1000 ddH2O OB 
XE-991 Tocris Bioscience 100 DMSO OB 
Chromanol 293B Tocris Bioscience 100 DMSO OB 
Riluzole Sigma-Aldrich 100 DMSO OB 
Retigabine Tocris Bioscience 100 DMSO OB 
Arachidonic acid Sigma-Aldrich 100 DMSO OB & TEVC 
Flufenamic acid Sigma-Aldrich 100 DMSO OB 
BL-1249 Sigma-Aldrich 30 DMSO OB & TEVC 
CDC Sigma-Aldrich 100 DMSO OB & TEVC 
ML-365 Tocris Bioscience 10 DMSO OB 
melittin Tocris Bioscience 100 ddH2O OB 
zileuton Tocris Bioscience 100 DMSO OB 
aspirin Sigma-Aldrich 100 DMSO OB 
diazoxide Tocris Bioscience 100 DMSO OB 
cromakalim Tocris Bioscience 20 DMSO OB 
NS5806 Tocris Bioscience 50 DMSO OB 
NS19504 Tocris Bioscience 100 DMSO OB 
NS11021 Tocris Bioscience 100 DMSO OB 
NS309 Tocris Bioscience 100 DMSO OB 
SKA-31 Tocris Bioscience 100 DMSO OB 
TTX Tocris Bioscience 0.1 ddH2O OB 
DHA Sigma-Aldrich 100 DMSO TEVC 
spadin Tocris Bioscience 1 ddH2O OB & TEVC 
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3.1 Introduction and Aims 
Potassium channels form the largest family of ion channel proteins, and can be structurally 
and functionally divided into three distinct sub families: voltage-gated (Kv), inward-rectifier 
(Kir) and leak (K2P). Opening of potassium channels allows K+ ion efflux down its 
electrochemical gradient resulting in membrane potential repolarization, and therefore is 
central to controlling cellular excitability and signal transduction. Given this key 
physiological role, potassium channels are important therapeutic targets for a multitude of 
pathologies in neuronal, cardiovascular and muscular tissues. Recently, potassium channels 
encoded by KCNQ genes (Kv7) have been identified in smooth muscle and revealed as 
important regulators of vascular contractility (Greenwood and Ohya, 2009). However, little 
is currently known about the expression profiles of KCNQ/Kv7 channels in other smooth 
muscle tissues, including that of the GI tract. Similarly, K2P channels are a large subfamily of 
potassium channels whose functional characteristics make them ideal for setting and 
regulating membrane potential. However, very little is currently known about the 
expression, distribution or functional contribution of K2P channels to GI smooth muscle 
contractility. Thus, the initial goal of this study was to establish the expression profile of 
potassium channel transcripts in GI tract, with a view to identifying specific potassium 
channels that could be functionally targeted to modulate GI motility. This was achieved 
utilising quantitative RT-PCR analysis of mRNA transcripts of potassium channel genes in 
mouse ileum and colon whole tissue preparations. To determine relative transcript 
expression levels of the 93 known potassium channels in the mouse, mRNA was quantified 
by real-time PCR (qPCR) analysis from 3 animals, and normalised against the combined 
housekeeping genes GAPDH + HPRT by the comparative 2-∆Ct method. This was followed by 
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qualitative RT-PCR to specifically highlight mRNA expression of the mechano-gated K2P 
channels TREK-1, TREK-2 and TRAAK in GI tissue. 
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3.2 Results  
3.2.1 Determination of most stable reference genes 
The Mouse Intestinal Ion Channels RT2 ProfilerTM qPCR Array contained multiple reference 
genes, and the NormFinder algorithm (Andersen et al., 2004) was used to establish which 
single gene or combination of genes was the most stable and therefore appropriate to use 
for normalisation. The three reference gene options GAPDH, RPLP0 and HPRT are 
presented in Figure 3.1 and with a stability value of 0.04, 0.143 and 0.036 respectively in 
ileum, and 0.60, 1.74 and 0.14 respectively in colon. GAPDH and HPRT presented the lowest 
stability value in both ileum and colon, and therefore were determined to be the best 
combination references for normalisation.  
 
 
Figure 3.1: Estimation of stability of candidate reference genes using NormFinder. Genes 
are ranked according to their expression stability across all samples in ileum (A) and colon 
(B).   
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Mane et al, (2008) suggested that ideal reference genes should have a normal distribution 
across samples and a low standard deviation. In the customised plate for potassium 
channels, statistical analysis was performed to identify reference genes with the lowest 
standard deviation of the Ct values across all ileum and colon samples, and confirmed 
GAPDH to be a suitable stable gene for normalisation in the customised array (Figure 3.2).  
 
 
Figure 3.2: Calculation of stability of candidate reference genes based on Ct stability. Genes 
are ranked according to their expression stability across all samples in ileum (A) and colon 
(B). Data are expressed as Ct values of housekeeping gene GAPDH and HPRT 
(mean ± SD, n = 3).  
 
3.2.2 Voltage-gated K+ channels (Kv) 
The Kv family consist of 40 α subunits in 12 subfamilies. These channels include three major 
groups of the following proteins: 1) members of Kv1-Kv6 subfamilies and Kv8-Kv9 
subfamilies; 2) proteins of Kv7 subfamily (often called KCNQ family); 3) the Kv10-Kv12 
subfamilies (Kew and Davies, 2010).  Table 3.1 lists both the gene and protein names of all 
Kv channels studied. 
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Table 3.1: Voltage-gated K+ channel alpha subunits, providing both the gene and protein 
names and details of their accessory subunits.  
Classification Family Gene Name (Protein Name) Main 
accessory 
subunits 
Kv1.x Shaker KCNA1 (Kv1.1), KCNA2 (Kv1.2), KCNA3 (Kv1.3), 
KCNA4 (Kv1.4), KCNA5 (Kv1.5), KCNA6 (Kv1.6), 
KCNA7 (Kv1.7), KCNA8 (Kv1.8) 
Kv β1- β2 
Kv2.x Shab KCNB1 (Kv2.1), KCNB2 (Kv2.2)  
Kv3.x Shaw KCNC1 (Kv3.1), KCNC2 (Kv3.2), KCNC3 (Kv3.3), 
KCNC4 (Kv3.4) 
KCNE3 (Kv 
3.4) 
Kv4.x Shal KCND1 (Kv4.a), KCND2 (Kv4.2), KCND3 (Kv4.3) KCNIP1-4 
Kv5.1 Modifier KCNF1 (Kv5.1) - 
Kv6.x Modifiers KCNG1 (Kv6.1), KCNG2 (Kv6.2), KCNG3 (Kv6.3), 
KCNG4 (Kv6.4) 
- 
Kv7.x - KCNQ1 (Kv7.1), KCNQ2 (Kv7.2), KCNQ3 (Kv7.3), 
KCNQ4 (Kv7.4), KCNQ5 (Kv7.5) 
KCNE1-4 
Kv8.x Modifiers KCNV1 (Kv8.1), KCNV2 (Kv8.2) - 
Kv9.x Modifiers KCNS1 (Kv9.1), KCNS2 (Kv9.2), KCNS3 (Kv9.3) - 
Kv10.x EAG KCNH1 (Kv10.1), KCNH5 (Kv10.2) - 
Kv11.x ERG KCNH2 (Kv11.1), KCNH6 (Kv11.2), KCNH7 (Kv11.3) KCNE1 
Kv12.x ELK KCNH8 (Kv12.1), KCNH3 (Kv12.2), KCNH4 (Kv12.3) KCNE1 
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Figure 3.3 displays the mRNA transcript levels of Kv channels investigated in the mouse 
ileum and colon. Results from qRT-PCR array signified that the most abundant Kv channel 
subunit mRNA in the mouse ileum was Kv7.1, almost 13-times greater than the next most 
abundant gene encoding Kv1.3 (n = 3, p < 0.0001, Student’s paired t-test) (Figure 3.3A). 
Next, in rank order in ileum were the transcript levels for genes encoding Kv4.3, Kv2.1 and 
Kv5.1, followed by Kv1.2, Kv1.1, Kv11.1, Kv6.3, Kv6.4, Kv12.2, Kv1.5, Kv3.3 and Kv1.6. Several 
genes were also detected in ileum but at very low levels; Kv2.2, Kv2.1, Kv3.4, Kv4.1, Kv4.2, 
Kv6.1, Kv6.2, Kv7.2, Kv7.3, Kv7.4, Kv7.5, Kv8.2, Kv9.3, Kv10.1, Kv11.2 and Kv12.1. The rest, 
including Kv1.4, Kv1.7, Kv1.8, Kv3.2, Kv8.1, Kv9.1, Kv9.2, Kv10.2, Kv11.3 and Kv12.3 were not 
or barely detectable in ileum. In colon (Figure 3.3B), the Kv7.1 gene also presented the 
highest relative expression level of the 40 subunits, 7-times greater than the next two 
abundant transcripts for subunits Kv5.1 and Kv4.3. This was followed in rank order in colon 
by Kv1.1 > Kv2.1 > Kv6.4 > Kv1.3 > Kv11.1 > Kv1.2 > Kv12.2 > Kv9.3 > Kv1.6. In addition, Kv3.3, 
Kv4.1, Kv6.2, Kv6.3, Kv7.2, Kv7.4, and Kv12.1 were also above the detectable level. Gene 
transcripts encoding for Kv2.2, Kv3.1, Kv3.4, Kv4.2, Kv6.1, Kv7.3, Kv7.5, Kv10.1, and Kv11.2 
were barely detectable when normalized to housekeeping gene, whereas transcripts 
encoding for Kv1.4, Kv1.7, Kv1.8, Kv3.2, Kv8.1, Kv8.2, Kv9.1, Kv9.2, Kv10.2, Kv11.3 and Kv12.3 
were not detected in mouse colon at all as concluded from a lack of measureable Ct value 
after 40 cycles of PCR. 
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Figure 3.3: Differential expression of Kv subtype transcripts in the mouse ileum and colon.   
Quantitative, real-time PCR performed on lysates of acutely isolated ileum (A) and colon 
(B) from wild type mice. Data are expressed as relative mRNA levels (2-ΔCt) compared to 
the housekeeping gene GAPDH (mean ± SEM, n = 3). Kv7.1 (KCNQ1) displayed the highest 
relative expression levels in both ileum and colon and is shown in the inset for clarity. 
Channel protein names have been used instead of the gene names for simplicity as the 
protein names are more commonly known.  
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3.2.3 Calcium-activated K+ channels (KCa) 
KCa channels contains 8 members and classified into five classes: small conductance (SK) 
channels, intermediate conductance (IK) channels, big conductance (BK) channels, KCa4 
subfamilies and KCa5 channels as shown in Table 3.2. 
Table 3.2: Calcium-activated K+ channel subunits, providing both the gene and protein 
names and details of their accessory subunits.  
Classification Family Gene Name (Protein Name) Main 
accessory 
subunits 
KCa1.1 BK KCNMA1(KCa1.1) β1- β4 
KCa2.x SK KCNN1 (KCa2.1), KCNN2 (KCa2.2), KCNN3 (KCa2.3) - 
KCa3.1 IK KCNN4 (KCa3.1) - 
KCa4.x - KCNT1 (KCa4.1), KCNT2 (KCa4.2) - 
KCa5.1 - KCNU1 (KCa5.1) - 
 
All Kca channel gene transcripts showed lower expression levels in both ileum and colon 
compared with other types of potassium channel genes. KCNN4, encoding the IK channel 
was the most abundantly expressed transcript throughout the ileum and colon. KCNMB, 
encoding the BK channel alpha subunit was the second greatest expressed channel 
transcript, the relative expression level was almost 4-times greater in colon than in ileum. 
The SK3 (KCa2.3) channel gene was the highest expressed channel gene from SK family in 
both ileum and colon.  Transcripts for KCa4.2 and SK1 were detected in both ileum and colon 
but at low levels, whilst transcripts for KCa4.1, KCa5.1 and SK2 were barely detectable (Figure 
3.4).  
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Figure 3.4: Differential expression of KCa subtype transcripts in the mouse ileum and colon.   
Quantitative, real-time PCR performed on lysates of acutely isolated ileum (A) and colon 
(B) from wild type mice. Data are expressed as relative mRNA levels (2-ΔCt) compared to 
the housekeeping gene GAPDH (mean ± SEM, n = 3). IK (KCNN4) displayed the highest 
relative expression levels in both ileum and colon and is shown in the inset for clarity. 
Channel protein names have been used instead of the gene names for simplicity as the 
protein names are more commonly known. 
 
3.2.4 Voltage-gated K+ channel accessory subunits 
Kv channels are comprised of α and β subunits, the Kv α subunits form the channel 
conducting pore and β subunits are modulatory subunits. These Kv modulatory subunits 
(e.g. Kvβ, KCNE, KCNIP) are auxiliary proteins that do not have the ability to form functional 
channels in their own right, but associate with α subunits to modulate channel function 
(Pongs and Schwarz, 2010).  
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Table 3.3: β accessory K+ channel subunits, displaying the details of accessory β subunits, 
providing both the gene and protein names and details of their associated α subunits 
Classification Gene Name (Protein Name) Associated α 
subunits 
β subunits KCNMB1(β1), KCNMB2(β2), KCNMB3(β3), KCNMB4(β4) BK channel 
KCNE KCNE1, KCNE2, KCNE3, KCNE4, KCNE1L (KCNE5) Kv7 channels 
KCNIP KCNIP1 (KChIP1), KCNIP2 (KChIP2), KCNIP3 (KChIP3), 
KCNIP4 (KChIP4) 
Kv4 channels 
Kvβ subunits KCNAB1 (Kvβ1), KCNAB2 (Kvβ2),  Kv1 channels 
 
KCNE3 gene transcripts, encoding the MiRP2 protein, were the most abundantly expressed 
of all transcripts tested relative to housekeeping genes, and had almost 4-times higher 
expression in colon than in ileum. KCNAB2 (encoding Kvβ2 subunits) was the second highest 
accessory subunit transcript in ileum, followed by KCNMB1 and KCNIP2. KCNMB4, KCNE4, 
KCNAB1 & 3, KCNIP1 & 3 were detected at very low levels in ileum. KCNMB2 & 3, KCNE1, 2 
& 4 and KCNIP4 were negative (not detected) or barely detectable in mouse ileum. In colon, 
KCNMB1 was showed the second highest relative expression level, and the only accessory 
subunit gene detected in the KCaβ subunits group. Moreover, KCNMB1 subunit gene levels 
were 2-times greater in colon than in ileum. Next in rank order were the transcript levels 
of the KCNAB2, KCNIP4, KCNIP1, KCNE4 and KCNAB1. KCNE2, KCNAB3, KCNIP2 and KCNIP3 
were detected at very low levels, and KCNMB2-4, KCNE1 & 5 were negative or barely 
overserved in mouse colon (Figure 3.5).  
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Figure 3.5: Differential expression of accessory subunits subtype transcripts in the mouse 
ileum and colon. Quantitative, real-time PCR performed on lysates of acutely isolated ileum 
(A) and colon (B) from wild type mice. Data are expressed as relative mRNA levels (2-ΔCt) 
compared to the housekeeping gene GAPDH (mean ± SEM, n = 3). Regulatory subunits 
KCNE3 displayed the highest relative expression levels in both ileum and colon and were 
shown as insets for clarity. Channel protein names have been used instead of the gene 
names for simplicity as the protein names are more commonly known. 
 
 
126 
 
3.2.5 Inwardly rectifying K+ channels (Kir)  
Kir family consist of 15 subunit genes, which can be classified into four following 
subfamilies: 1) classical Kir channels (Kir2.x), 2) G-protein gated subfamilies (Kir3.x), 3) K+-
transport channels (Kir1.x, Kir4.x, Kir5.x, and Kir7.x), 4) ATP-sensitive K+ channels (Kir6.x) as 
shown in Table 3.4.  
Table 3.4: Inwardly Rectifying K+ channels (Kir), providing both the gene and protein names.  
Family Classification Gene Name (Protein Name) 
Classical Kir Kir2.x KCNJ2(Kir2.1), KCNJ12(Kir2.2), KCNJ4(Kir2.3), 
KCNJ14(Kir2.4) 
G-Protein 
Coupled Kir 
Kir3.x KCNJ3(Kir3.1), KCNJ6(Kir3.2), KCNJ9(Kir3.3), KCNJ5(Kir3.4) 
KATP channels Kir6.x KCNJ8(Kir6.1), KCNJ11(Kir6.2) 
K+ Transport Kir Kir1.1 KCNJ1 (Kir1.1) 
Kir4.x KCNJ10 (Kir4.1), KCNJ15 (Kir4.2) 
Kir5.1 KCNJ16 (Kir5.1) 
Kir7.1 KCNJ13 (Kir7.1) 
 
Kir6.1 transcript was the highest expressed subunits with similar expression level in both 
ileum and colon, with the following rank order; Kir6.1 > Kir7.1 > Kir4.1 > Kir2.1 > Kir3.1 in 
ileum (Figure 3.6A) and Kir6.1 > Kir2.1 > Kir7.1 > Kir4.1 > Kir2.2 in colon (Figure 3.6B). Kir2.1 
showed nearly 3-times higher relative expression in colon than in ileum, whereas Kir7.1 
showed similar expression levels across both tissues. Other members of the Kir subfamily 
displayed low or no detectable transcript levels (Figure 3.6).  
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Figure 3.6: Differential expression of Kir subtype transcripts in the mouse ileum and colon.   
Quantitative, real-time PCR performed on lysates of acutely isolated ileum (A) and colon 
(B) from wild type mice. Data are expressed as relative mRNA levels (2-ΔCt) compared to 
the housekeeping gene GAPDH (mean ± SEM, n = 3). Kir6.1 (KCNJ8) displayed the highest 
relative expression levels in both ileum and colon and is shown in an inset for clarity. 
Channel protein names have been used instead of the gene names for simplicity as the 
protein names are more commonly known. 
 
3.2.6 Two-Pore K+ channels (K2P)  
The sub-family of K2P channels includes 14 members in the mouse genome, which can be 
divided into 6 functional subfamilies (TWIK, TASK, TREK, THIK, TALK and TRESK) on the basis 
of sequence and function similarities, as shown in Table 3.5.   
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Table 3.5: Two-Pore K+ channels (K2P), providing both the gene and protein names.  
Classification Gene Name (Protein Name) 
TWIK KCNK1 (K2P1.1; TWIK-1), KCNK6 (K2P6.1; TWIK-2), KCNK7 (K2P 7.1) 
TASK KCNK3 (K2P3.1; TASK-1), KCNK9 (K2P9.1; TASK-3), KCNK15 (K2P15.1; 
TASK-5) 
TREK KCNK2 (K2P2.1; TREK-1), KCNK4 (K2P4.1; TRAAK), KCNK10 (K2P10.1; 
TREK-2) 
THIK KCNK13 (K2P13.1; THIK-1), KCNK12 (K2P12.1; THIK-2) 
TALK KCNK16 (K2P16.1; TALK-1), KCNK17 (K2P17.1; TALK-2), KCNK5 
(K2P5.1; TASK-2) 
TRESK KCNK18 (K2P18.1; TRESK) 
 
The most abundant K2P channel transcripts through mouse gut was KCNK1 (encoding TWIK-
1, K2P1.1), and showed twice the relative expression levels in colon than in ileum. KCNK5, 
encoding TASK-2 channels, was ranked second highest but showed similar expression levels 
across ileum and colon. The rank order was as follows; TWIK-1 > TASK-2 > TREK-1 > TASK-
1> TWIK-2 > THIK-1 > K2P 7.1 in ileum and TWIK-1 > TASK-2 > TWIK-2 > TASK-1 > TREK-1 > 
THIK-1 > K2P 7.1 in colon (Figure 3.7). In both tissues, genes encoding TRAAK, TASK-3, TREK-
2, THIK-2, TASK-5, TALK-1 appeared barely detectable when normalised to housekeeping 
gene GAPDH, whereas transcript encoding for TRESK was not detected in either ileum or 
colon.  
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Figure 3.7: Differential expression of K2P subtype transcripts in the mouse ileum and colon.  
Quantitative, real-time PCR performed on lysates of acutely isolated ileum (A) and colon 
(B) from wild type mice. Data are expressed as relative mRNA levels (2-ΔCt) compared to 
the housekeeping gene GAPDH (mean ± SEM, n = 3). TWIK-1 (KCNK1) and TASK-2 (KCNK5) 
displayed the highest relative expression levels in both ileum and colon and are shown in 
insets for clarity. Channel protein names have been used instead of the gene names for 
simplicity as the protein names are more commonly known. 
 
3.2.7 TREK family subunits mRNA expression in the mouse ileum and colon  
Evidence of an important stretch-dependent potassium (SDK) channel has been cited in 
mouse colonic smooth muscle cells(Koh and Sanders, 2001). The molecular identity of the 
channel is unknown, but has the biophysical hallmarks of a mechano-gated TREK-like 
channel. Given that all three TREK subfamily channels were shown to be expressed in ileum 
and colon, albeit at different levels I performed complimentary expression profiling of the 
three TREK subfamily genes to conclusively determine their expression in ileum and colon. 
Non-quantitative RT-PCR revealed mRNA expression for genes encoding TREK-1, TREK-2 
and TRAAK (n = 3) (Figure 3.8). Plasmids containing the three genes served as a positive 
control for the primers, and β actin was also served as positive control transcript for the 
PCR reaction in ileum and colon. The negative control consisted of a no-template reaction, 
where nuclease-free water replaced cDNA, and served to indicate the presence of 
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unwanted contaminating DNA. The results demonstrate all three mechano-gated TREK 
channel genes were expressed in both ileum and colon with band sizes equating to those 
amplicons derived from the positive control reactions, and no band was detected in the 
absence of cDNA in the negative control (Figure 3.8).  
 
Figure 3.8: Qualitative mRNA expression of TREK family channel genes in the mouse ileum 
and colon. Representative gel electrophoresis images of cDNA amplicons for all three TREK 
family subunits using RT-PCR from homogenates from whole mouse ileum (I) and colon (C) 
(n = 3). Plasmids containing mouse homologues of TREK-1, TREK-2 and TRAAK were used 
as a positive control (M). A negative control (-ve), containing is shown. The expected 
amplicon sizes were 676 bp (TREK-1), 624 bp (TREK-2), 219 bp (TRAAK), 647 bp (β actin).  
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3.3 Discussion  
Gastrointestinal motility disorders, such as irritable bowel syndrome (IBS), can occur when 
coordinated smooth muscle contractility is disrupted. Muscle contraction is a calcium 
dependent process and in smooth muscle requires transmembrane influx of calcium ions 
through voltage-gated calcium channels (VGCC). Aside from the calcium channels, 
potassium ion channels also play an important role in regulating the intracellular 
concentration of Ca2+ by controlling membrane potential, and thus the open probability of 
VGCC, and so in turn regulate GI smooth muscle tone(Vogalis, 2000). However, our 
understanding of the expression profiles and functional roles of K+ channels, particularly in 
smooth muscle tissue of the GI tract, is rather limited. The results within this chapter 
revealed the transcript profiles of the whole family of K+ channels (93 transcripts) in the 
two main anatomical sections of GI tract concerned with GI motility disorders, namely the 
distal section of the small intestine (ileum) and the large intestine (colon). My data showed 
robust transcript expression for many different types of K+ channels in both ileum and 
colon. Regarding Kv family genes, more than 50 % of the genes displayed detectable 
expression in the mouse GI tract. In particular, Kv7.1 and its modulatory subunit MiRP2 
(KCNE3) were the most highly expressed transcripts across the whole K+ channel family. 
From the Kir subfamily, Kir6.1 showed the highest relative expression in the mouse GI tract, 
echoing a previous RT-PCR study in colonic muscle tissue (Jin et al., 2004). However, the 
most novel findings came from the profiling of K2P channel transcripts across small and large 
intestine, as there is a distinct lack of research knowledge regarding these channels in the 
GI system. Therefore the finding of high relative levels of mRNA expression for TWIK-1 and 
TASK-2 revealed these channels may have important functions roles in the GI system, which 
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have not previously been noted. Together these data characterising the expression levels 
of K+ channel subtype genes along the mouse ileum and colon, forms the foundation for 
further investigations in this study.  
 
3.3.1 Limitations of the qRT-PCR analysis 
Before I critically discuss the outcomes of the transcript profiling using quantitative PCR 
technology, there needs to be a clear discussion of the limitations of the conducted 
experiments to contextualise the resulting data. qRT-PCR is a powerful and sensitive 
technology for the quantification and validation of gene expression. Despite the power of 
qRT-PCR, however, a number of key considerations need to be addressed in order to get 
the quantification of mRNA right, from sample preparation through data analysis.  
 
Firstly, my qPCR experiments utilised mRNA extracted from whole tissue sections. Hence, 
it was not possible to unequivocally differentiate the expression profiles of the channel 
genes across different types of cells. Ideally, the expression of channel genes in smooth 
muscle tissue alone versus other cell types, including epithelia, neuronal and glia, would 
have been desirable. However, a qPCR study on purified smooth muscle tissues was not 
feasible in the ileum and colon, due to the difficulty of accurate tissue dissection. This could 
have been overcome through the profiling of cell specific gene markers to help compare 
relative gene expression of channel genes versus cell specific genes, however I was limited 
by the number of genes I could assess on my array, and was unable to include cell specific 
genes to assess proportions of different cell types in the whole sample. Together, this 
means that low level expression levels of some K+ channels transcripts (e.g. Kv7.4, TREK-2, 
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and TRAAK etc.) could likely represent either general low expression across the whole 
tissue or perhaps high expression levels in discrete, specific populations of cells that were 
ultimately diluted across the whole tissue.  Future studies should include cell specific genes 
to help quantify gene expression profiles in specific cell populations. 
 
A further limitation is that some channel transcripts were actually expressed in tissue, but 
could not be determined in my data after analysis. The relative quantification analysis of 2-
ΔCt method used here are the simplest and most commonly used method for accurately 
determining relative expression levels and changes in expression transcripts. This analysis 
method assumes almost 100% efficient target and standard gene PCR reactions given that 
results conform to certain criteria (Livak and Schmittgen, 2001), and this was confirmed in 
my experiments using three positive reference genes in each running. Since PCR efficiencies 
may change between runs or between target and standard genes, other numerous 
methods called “DART method” have emerged that calculate template concentrations 
using amplification simulations or PCR efficiencies derived from CT values or fluorescence 
data (Pfaffl, 2001, Peirson et al., 2003). However, a lack of consensus existed on how to 
best perform and evaluate qPCR experiments. In addition, previous studies analysed results 
from a salmon lice starvation experiment by using both 2-ΔCt method and the DART method 
adjusting for PCR efficiency differences, they found these 2 methods showed different 
results (Skern et al., 2005). Moreover, they would not have more confidence in one method 
than the other unless they had data from their microarray experiments. Therefore, despite 
the fact that both methods are theoretically sound given a number of assumptions, we may 
be misled when these assumptions are not fulfilled. Indeed, in my qRT-PCR experiment, I 
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clearly show several gene transcripts show high expression level, but my RT-PCR findings 
also confirms those low expression levels or absent expression of some K+ transcripts (e.g. 
TREK-2 and TRAAK) were actually expressed in the tissue and also display strong mRNA 
signal band compared TREK-1 channel. Moreover, previous studies confirmed the high 
expression level of BK (Zhu and Huizinga, 2008) or Kv7.4/7.5 channels (Jepps et al., 2009) in 
mouse intestine, but both genes display low expression level in my studies. All analysis 
methods of qRT-PCR data are based on a number of assumptions, and due to experimental 
errors none or few of these assumptions will be completed entirely. Unfortunately, it is not 
always obvious when assumptions are broken to a degree that invalidates the conclusions. 
Since the sources of potential problems are diverse, there is no simple solution, universal 
analytical approach and direct guidelines available for qRT-PCR analysis, and ensure a 
correct conclusion. Therefore, we should urge caution when analysing results, and further 
experiments should be performed with qRT-PCR experiment together, such as RT-PCR and 
microarray, in order to confirm and support your conclusions.  
 
3.3.2 Voltage-gated potassium channels (Kv) 
Evidence for the expression of Kv channels in the GI system is poor, with transcript profiles 
restricted to the Kv4 and Kv7 subfamilies. In this study, we performed the first, whole family 
profiling of Kv channel mRNA in the mouse GI tract. Our data showed robust transcript 
expression for multiple Kv channels including Kv4.3, Kv7.1, Kv5.1 and Kv2.1.  
 
Kv channels can be classified as delayed rectifiers or inactivating A-type channels (Vogalis, 
2000). Inhibition of A-type currents has been reported to increase smooth muscle 
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excitability and contractility in different region of GI tract (e.g. fundus, antrum, jejunum 
and colon). A-type currents have been suggested to be formed through association of Kv4 
channels, which can be assembled as homo- or heterotetramers of Kv4.1, Kv4.2 and Kv4.3 
subunits (Amberg et al., 2003), and through association with KChIP auxiliary subunits. 
Previous studies revealed all three Kv4 channel transcripts were expressed in murine 
proximal colon circular smooth muscle cells, and dampen excitability and may participate 
in maintaining the phasic pattern of electrical activity (Koh et al., 1999). My data showed 
that transcripts encoding Kv4.3 exhibited highest expression level among Kv4 subfamily 
genes in the whole tissue of both ileum and colon, which echoed previous qPCR studies in 
colonic and jejunal smooth muscle (Amberg et al., 2002). Furthermore, protein for all three 
Kv4 subfamily subunits has been confirmed in murine muscular antrum by 
immunohistochemistry (Amberg et al., 2002). The authors also confirmed the contribution 
of Kv4 channels to colonic A-type currents by using flecainide, which is a blocker displaying 
higher sensitivity to Kv4 channels (IC50 ≤ 20 µM) than Kv1 channels (IC50 ≥ 50 µM) (Amberg 
et al., 2002). Moreover, Kv4.3 protein expression recently was detected in the smooth 
muscle regions of small intestine, but the immunoreactivities in mucosa layer was not 
found (Liu et al., 2014). KChIPs, which belongs to the neuronal calcium sensor (NCS) family 
of proteins, binds to the N-terminal region and the T1 domain of Kv4 proteins (An et al., 
2000, Rosati et al., 2001). This protein act as positive modulators improving Kv4 current 
density by increasing expression of the channels in the plasma membrane (Bahring et al., 
2001, An et al., 2000), and also modify the kinetic behaviour of Kv4 channels  (Beck et al., 
2002). There are four known KChIP genes (KChIP1-KChIP4), which all exert similar effects 
on Kv4 channels (Kew and Davies, 2010). Amberg et al, (2002) identified KCNIP1, encoding 
the KChIP1 accessory protein, as the highest expressed KChIP subunit in isolated colonic 
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smooth muscle cells. My data shows the KChIP2 transcript as the highest expressed KChIP 
transcript in ileum and KChIP4 transcript in colon. A-type current in ventricular myocytes 
were underlied by Kv4 channels (Xu et al., 1999, Nerbonne, 2000), and the transcript 
expression of KChIP2 has been shown to account the transmural gradient of A-type 
currents in canine and human ventricles (Rosati et al., 2001). The KChIP2 knock-out mice 
exhibited normal cardiac structure and function, but ventricular A-type currents were 
reduced by approximately half compared to wild-type myocytes. Moreover, KChIP2 knock-
out mice did not express functional A-type currents, and a marked increase in action 
potential duration (Kuo et al., 2001), thereby similar regulation of functional Kv4 channels 
by KChIP2 may occur in GI smooth muscles as cardiac myocytes. Interestingly, the KCNE3 
β-subunit gene, encoding the MiRP2 protein has been reported as a strong inhibitory effect 
on current conducted by heterologously expressed Kv4.3 channels, and this inhibitory 
effect to be specific for Kv4.3 within the Kv4 channel family. MiRP2 reduces the Kv4.3 current 
amplitude, and it slows down the channel activation and inactivation as well as the recovery 
from inactivation. MiRP2 also inhibits A-type currents generated by Kv4.3 in complex with 
the KChIP2 accessory subunit (Lundby and Olesen, 2006). Given the different 
methodologies between the previous studies and the one here, it is difficult to compare 
the results directly. However, high relative expression of Kv4.3 channel genes and their 
accessory subunits KChIP2 and MiRP2 indicate a possible important role for these channels 
in GI tract physiology. 
 
The Kv7 subfamily, encoded by the KCNQ genes, are slow delayed rectifier channels and 
have been identified to play an important role in regulating smooth muscle contractility in 
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different body systems, including the vasculature, bladder, GI tract and airway (Jepps et al., 
2009, Brueggemann et al., 2012, Anderson et al., 2013, Jepps et al., 2013, Greenwood and 
Ohya, 2009). KCNQ4 and 5 have been showed as the most abundantly expressed KCNQ 
transcripts in isolated smooth muscle of murine GI tract (Jepps et al., 2009). Conversely, 
our qPCR analysis revealed the prominent expression of the KCNQ1 gene (encoding Kv7.1) 
among KCNQ genes in the whole tissue of both ileum and colon, which indicate KCNQ1 may 
be expressed in other cell types, such as neurons and epithelial. Moreover we showed that 
the accessory β-subunit gene KCNE3, encoding the MiRP2 protein, displays the highest 
relative expression level among all K+ channels genes. KCNE genes have single 
transmembrane domain and can significantly affect the activation of threshold KCNQ 
channels (Dedek and Waldegger, 2001).  For example, the interaction between Kv7.1 and 
MinK (encoded by the KCNE1 gene) was the first characterised of any Kv7/KCNE complex, 
and underlies the slowly activating K+ (Iks) current in the heart (Ramakers et al., 2003). The 
protein expression of KCNQ1 and KCNE1 have been shown in epithelial cells of gut and 
exocrine pancreas (Warth et al., 2002). However, we were unable to detect significant 
transcript levels of the KCNE1 in either ileum or colon. Importantly, MiRP2 (KCNE3) also 
forms functional complexes with Kv7.1. Co-assembly forms a voltage-independent leak 
channel which is constitutively open at resting potentials (Schroeder et al., 2000). 
Moreover, this channel complex has been shown to be important in K+ transport in a 
number of epithelial tissues including pancreas, airways and intestine (Bleich and Warth, 
2000, Preston et al., 2010, Abbott, 2016, Al-Hazza et al., 2016). For instance, KCNE3 co-
complexes with KCNQ1 has been shown to be a pivotal conductance in intestinal and 
tracheal chloride transport as demonstrated through KCNE3 disruption (Preston et al., 
2010). In addition, KCNQ1 and KCNE3 proteins have been demonstrated to be located to 
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the basolateral membranes of crypt cells of the colon and small intestinal (Dedek and 
Waldegger, 2001). In the GI tract, basolateral potassium channels play an important part in 
the process of transcellular cAMP-stimulated chloride secretion (Schroeder et al., 2000). 
Taken together, the absence of KCNQ1 transcripts in isolated intestinal smooth muscle cells 
(Jepps et al., 2009), and my study showing high levels of KCNQ1 and KCNE3 in whole gut 
tissue, suggests that KCNQ1 and KCNE3 may both be significantly expressed in epithelial 
layers of the GI tract, and form the basolateral potassium conductance to regulate the 
cAMP-mediated Cl- secretion. However, further functional studies are required. 
 
Kv5, Kv6, Kv8 and Kv9 were collectively identified as electrically silent K+ channels, and do 
not form functional homotetrameric channels when expressed alone, but are able to co-
assemble with Kv2 family to form heterotetrameric complexes and increasing Kv channel 
functional diversity (Bocksteins, 2016). Both KCNB1 (Kv2.1) and KCNF1 (Kv5.1) had the 
highest expression levels of the KCNB and silent subunit gene families in our qPCR analysis. 
Kv2.1 is a prominent neuronal potassium channel, and is widely expressed across brain 
tissue, but has also been shown to play roles in non-neuronal tissues including vascular 
smooth muscle where its modulation is associated with hypertension (Joseph et al., 2013, 
Kew and Davies, 2010). Kv2.1 has also been recently reported in guinea pig detrusor smooth 
muscle, and through its association with silent Kv channel subunits has been proposed to 
control smooth muscle excitability and contractility (Hristov et al., 2012). Given the 
prominent expression of KCNB1 and KCNF1 transcripts across ileum and colon shown here, 
it is possible that Kv2.1 may have a similar functional role in GI smooth muscle tissues, either 
alone or in complex with silent subunits including Kv5.1. However, direct protein 
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localisation in smooth muscle and neuronal tissue and conclusive pharmacological 
evidence is currently lacking.  
 
With regards to other voltage-gated delayed rectifier channels, members of the Kv1 family, 
particularly Kv1.1-1.3, encoded by KCNA1-3 genes showed relatively high levels of mRNA 
expression in the ileum and colon, and along with expression of KCNAB2, encoding the 
associated β subunit Kvβ2 which was the second most abundant accessory subunit in ileum 
and colon, suggests a role for these channel complexes in GI tissues. Like Kv2 family 
channels, Kv1 channels are prominently expressed in neuronal tissues of the central and 
peripheral nervous systems, and they regulate action potential firing and neurochemical 
signalling (Kew and Davies, 2010). However, the expression of KCNA2 (Kv1.2) transcripts 
has been previously reported in canine GI smooth muscle cells, but KCNA1 (KV1.1) and 
KCNA3 (KV1.3) transcripts were not detected (Epperson et al., 1999), while KCNA1 (Kv1.1) 
transcripts have also been reported in interstitial cells of Cajal (ICC) (Hatton et al., 2001). 
Although it is not clear which cell types Kv1 channels are expressed in, their prominent 
expression is suggestive of a functional role. It is likely that these channels are expressed in 
the enteric nervous system, although further experimental evidence is required.  However, 
what is clear is a role for Kv1.3 channels in gut lymphocytes and the gut mucosal immune 
system, linked to inflammatory bowel diseases including IBD and Crohn’s (Kazama, 2015). 
Therefore, the notable expression of Kv1.3 transcripts in both ileum and colon shown by 
our study likely represent specific immune cell expression patterns in the GI system. 
Furthermore, Kv6.3 and Kv10.1 have been previous reported expressed in both human small 
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intestine and colon tissue (Ottschytsch et al., 2002). Our results were consistent with the 
literature that Kv6.3 and Kv10.1 also expressed in mouse ileum and colon. 
 
3.3.3 Calcium-gated potassium channels (KCa) 
The KCa3.1 channel (IK) gene, KCNN4, was strongly expressed in both ileum and colon, 
together with the BK (KCa1.1) gene, KCNMA1, and their β1 subunit gene, KCNMB1. 
Interestingly, both the BK channel and β1 subunit genes displayed higher expression levels 
in the colon than in ileum, and the β1 subunit gene was the only expressed subunit gene 
from the KCa accessary β subunit subfamily. This suggests that any intestinal BK channel 
complexes are likely formed through association with the β1 subunit. The BK channel has 
been well-studied in GI tract, with previous studies reporting both mRNA and protein 
expression of BK channel in colonic myocytes and involved in stretch activation of the tissue 
and mechanoelectric transduction (Wang et al., 2010), and their protein expression has 
been also shown in ICCs in mouse jejunum (Zhu and Huizinga, 2008). Patch clamp recording 
in either longitudinal or circular of canine proximal colon muscle strips did not implicate BK 
channels in regulating resting membrane potential, but their blockade by inhibitors such as 
TEA and charybdotxin (ChTX) were able to induce depolarization and subsequent 
contraction of colonic longitudinal smooth muscle cells (Carl et al., 1995). In addition, 
inhibitors (TTX) of BK channels have been shown to increase spontaneous contractile 
activity of ileum longitudinal muscle (Hong et al., 1997) with activators (LDD175) reduce 
the spontaneous contractions (Dela Pena et al., 2009). Thus, the expression and functional 
contribution of BK channels to GI tract smooth muscle contractility suggests that 
modulators of BK channels could provide potential treatments of GI motility disorders. A 
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further identified role for BK channels is in colonic K+ excretion in crypt cells. BK channels 
serve as the luminal (apical) exit pathway according to the pump-leak model of K+ secretion. 
KCaβ2 subunits have been shown to be co-expressed in crypt cells but molecular ablation 
leaves BK channel activity intact (Sorensen et al., 2008, Larsen et al., 2017). KCa channel β1 
subunit has been reported in airway (Semenov et al., 2011) and bladder smooth muscle 
(Petkov et al., 2001) and it is known to interact with BK α subunit in order to regulating 
smooth muscle contraction (Li et al., 2013). We revealed that transcript for the KCaβ1 
subunits was the highest expressed KCaβ subunit in mouse GI tract, and therefore may 
associate with BK to form a physiologically important channel complex. Given the 
important role in determining aspects of BK channel pharmacology, for example 
modulation by alcohol (Kuntamallappanavar and Dopico, 2016), it will be important to 
establish subunit composition profiles of BK channel complexes when designing drugs 
targeting BK channels in GI smooth muscle tissues.     
 
All KCa2 (SK) subfamily subunit genes were detected in the ileum and colon, with a rank 
order of SK3 > SK1 > SK2. Both SK1 and SK3 positive immunolabelling have been established 
in the human colon muscular layers (Chen et al., 2004). The SK1 channel has also been 
localised in enteric neurons (Chen et al., 2004), whereas SK3 channel is mainly found in ICCs 
(Fujita et al., 2001). In previous functional studies, blockers of SK channels depolarize the 
resting membrane potential of circular muscle cells in the ileum (Niel et al., 1983) and 
contracts colonic smooth muscle (Okuno et al., 2011). Activators also induce concentration-
dependent relaxation effects of the pre-contracted proximal stomach (Curro, 2016), 
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indicating that SK channels, like BK channels, may play important roles in the regulation of 
GI smooth muscle contractility.  
 
The strong expression of the KCa3.1 (IK) channel subunit gene in our qPCR analysis agreed 
with previous reports indicating a widespread expression in GI tract, including enteric 
neurons, where they mediate the slow afterhyperpolarization potential (Chen et al., 2004, 
Neylon et al., 2004), smooth muscle cells of canine colon (Koh et al., 1996) and epithelial 
cells of murine colon (Thompson-Vest et al., 2006). 
 
3.3.4 Inward rectifying potassium channels (Kir) 
High mRNA levels for the ATP-sensitive K+ channel (KATP) Kir6.1 gene (KCNJ8) were detected 
in both ileum and colon, which agrees with findings from a previous RT-PCR study revealing 
expression in colonic smooth muscle cells (Jin et al., 2004). KATP channels consist of a 
hetero-octameric complex of pore forming subunits, Kir6.1, Kir6.2, and sulfonylurea 
receptor subunits (SUR1 and SUR2) (Koh et al., 2012). They couple the metabolic state of a 
cell to its electrical activity. Although Kir6.2 and SUR2B gene expression has been previous 
detected in colonic smooth muscle cells (Koh et al., 1998, Jin et al., 2004), qPCR in mouse 
GI tissues indicates a very low expression level of the Kir6.2 gene in our analysis. Moreover, 
both Kir6.2 and SUR1 positive immunolabelling were detected on cholinergic neurons in the 
guinea pig ileum, many of which were identified as sensory by their co-storage of substance 
P and/or calbindin (Liu et al., 1999). Recently, cultured ICC have also been reported to 
express KATP channels that are encoded by Kir6.1 and SUR2B genes in colon cells and Kir6.2 
and SUR2B genes in small intestine cells (Na et al., 2017). Also, both gene and protein 
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expression of Kir6.1 and Kir6.2, and two regulatory subunits (SUR1 and SUR2B) were 
identified by RT-PCR and immunohistochemistry which found they are present in the 
basolateral membrane of the colonic epithelium (Pouokam et al., 2013). Therefore, there 
are different cell types expressing KATP channel transcripts in gut which likely explains their 
prominent expression profile in my qPCR analysis of whole tissue. 
 
qPCR indicated strong expression of the Kir2.1 gene (KCNJ2) mRNA, being the second most 
abundant Kir gene in the colon, and displaying twice the level of expression than in ileum.  
Kir2.1 transcript have previously been reported in circular muscle layer of canine ileum and 
colon, and it also be expressed in ICC which contribute to the generation and maintenance 
of negative membrane potentials between slow waves (Flynn et al., 1999).  
 
A novel finding of the qPCR study was the high relative expression levels of the Kir7.1 gene 
(KCNJ13) and Kir4.1 gene (KCNJ10) in mouse ileum and colon, which have not previously 
been reported in GI tract. Kir7.1 expression has been demonstrated in uterine myocytes, 
and a functional role in regulating the transition from quiescence to contractions in the 
pregnant uterus (McCloskey et al., 2014). It is also known that Kir7.1 channels play a 
significant role in K+ transport in the retinal pigment epithelium (Yang et al., 2008). Given 
its notable expression in ileum and colon, it is likely the channel may have roles in both 
epithelia and smooth muscle tissues. Kir4.1 channels on the other hand are known for their 
prominent expression in glial cells supporting neuronal tissue in the central nervous system 
and are critical in setting the glial resting membrane potential and in K+ spatial buffering 
(Butt and Kalsi, 2006). Glial cells are present in GI tract tissue, supporting cells of the enteric 
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nervous system and are notably required for regulation of intestinal motility (Rao et al., 
2017). Kir4.1 channels have not been shown in GI tract smooth muscle cells specifically, and 
it is likely that their expression is highest in the supporting glia cells. Therefore high 
expression of Kir4.1 transcript in the GI tract may reflect a high expression levels and/or 
high numbers of glia cells in the GI system.  
 
3.3.5 Two-pore domain potassium channels (K2P) 
Our understanding of the expression profiles and functional roles of K2P channels, 
particularly in smooth muscle tissue of the GI tract, is poor, with transcript profiles 
restricted to the TASK and TREK subfamilies. However, of the K2P channels described to 
date, the mechano-gated TREK subfamily of K2P channels are appearing as potential 
regulators of smooth muscle contractility (Parelkar et al., 2010, Lembrechts et al., 2011, 
Monaghan et al., 2011, Lei et al., 2014). 
 
In this study we performed the first, whole family profiling of K2P channel mRNA in the GI 
tract. Our data showed robust transcript expression for multiple K2P channel genes 
including those encoding TWIK-1 (KCNK1), TASK-2 (KCNK5), TASK-1 (KCNK3) and TREK-1 
(KCNK2), and TWIK-2 (KCNK6) The profiles of K2P channel mRNA was comparable across 
ileum and colon, at least at the whole tissue level. The caveat to our transcript profiling, 
that mRNA levels were assessed in whole tissues and could not differentiate between the 
proportions within different cell types present in the GI tract (smooth muscle, neuron, glia, 
epithelia), meant the low level expression of some K2P channel transcripts including TREK-
2 (KCNK10) and TRAAK (KCNK4) may represent discrete, cell specific expression profiles. 
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Given the potential that TREK subfamily channels could be involved in GI smooth muscle 
cells as stretch-activated channels, we conducted further qualitative RT-PCR profiling of the 
three family members, confirming TREK-1, TREK-2 and TRAAK positive expression in ileum 
and colon. A novel finding from our qPCR was the high expression of TWIK-1 and TASK-2 
mRNA in both ileum and colon, indicating these two channels may play a prominent role in 
GI tract physiology. Indeed Cho et al., (2005) previously highlighted TASK-2 expression in 
murine colon and a TASK-2-like conductance as a potential contributor to resting 
membrane potential, although the pharmacological tools used to assess this (lidocaine) 
were used at concentrations too high to be TASK-2 specific. Interestingly, TWIK-1 has been 
recently reported that form functional heterodimers with TREK-1 channel (Hwang et al., 
2014). Since both TWIK-1 and TREK-1 display high expression level in our qPCR analysis, this 
may indicate that the two channel subunits may form the heterodimers in the GI tract. 
However, along with a current lack of pharmacological tools for TWIK-1, the physiological 
importance of TASK-2 and TWIK-1 channels in the GI system remains to be conclusively 
determined. 
 
The detection of TREK-1, TASK-1, TASK-2 and TASK-3 genes also agrees with finding from 
past RT-PCR studies in colonic muscle tissue (Koh et al., 2001, Cho et al., 2005, Kubota et 
al., 2015). However, beyond the transcript profiling, specific localisation and functional 
contributions of K2P channels to GI physiology is severely lacking.  
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3.4 Summary and Conclusions 
The overall aim of this chapter was to provide an insight into the mRNA expression profiles 
of the family of K+ channel genes across mouse ileum and colon, using qPCR and RT-PCR 
analysis. It is evident from the results that K+ channels are abundantly and widely expressed 
in mouse GI tract. Key novel findings are the demonstration of high expression of mRNA 
encoding for Kv7.1 and its accessory KCNE3 subunit gene, and Kir7.1, Kir4.1, TWIK-1 and 
TASK-2 channel genes in ileum and colon. However, it is likely that the expression level of 
some K+ channel transcripts is a product of cell-specific expression patterns. Therefore, 
direct protein localisation studies were required to characterize the distribution of specific 
K+ channel subtypes in muscle and nervous tissue of the mouse GI tract. Given the 
prominent roles of K2P channels in neuronal and cardiac physiology and the opposing 
underwhelming knowledge of K2P channels in GI physiology, I decided to focus my future 
studies on the specific localisation and functional roles of K2P channels in the GI system.  
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Chapter 4 – Localisation of K2P 
channels in the mouse ileum and 
colon 
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4.1 Introduction and Aims 
K+ channels are formed from multimers of subunits containing either a single (K1P) or 
tandem (K2P) pore domain structure. A multitude of voltage-dependent and voltage-
independent K1P channels have been shown to be expressed in smooth muscles of the GI 
tract (for review see Koh et al., 2012). In contrast, our understanding of the expression of 
the voltage-independent K2P channel subfamily in GI tissues is limited. An assessment of 
K2P transcript expression by qRT-PCR as detailed in Chapter 3 provided an insight into the 
gene expression profile of the entire family of K2P channels in both mouse ileum and colon, 
and in particular the high expression of TWIK-1 and TASK-2 channel genes. Previous studies 
have indicated that TREK-like channels may underlie a stretch-dependant conductance in 
colonic smooth muscle cells, based on its biophysical phenotype and similarity to cloned 
murine TREK-1 channels including mechano-sensitivity, insensitivity to classical potassium 
channel blockers, and regulation by nitrenergic stimulation (Koh and Sanders, 2001, Koh et 
al., 2001, Park et al., 2005). However, the specific localisation of K2P channel proteins in 
mouse ileum and colon is still unclear. In this chapter, I will examine the precise cellular 
locations of different K2P channel subtypes including members of the mechano-gated TREK 
subfamily and those channels that displayed high relative expression levels (TWIK-1 and 
TASK-2).  I am particularly interested in profiling their expression in neurons and smooth 
muscle cells, and will utilise immunolabelling in whole mouse gut tissue sections of the 
ileum and colon and more specifically in isolated single smooth muscle cells. 
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4.2 Results 
4.2.1 TWIK-1 and TASK-2 expression in ileum and colon 
Our qPCR data indicated that the genes encoding TWIK-1 and TASK-2 were the two most 
abundantly expressed transcripts within the mouse intestine. Immunohistochemical 
studies were therefore performed with channel specific and cell-type specific antibodies to 
identify the precise cellular location of TWIK-1 and TASK-2 proteins in different tissue layers 
of mouse ileum and colon. Expression of TWIK-1 protein was detected on plasma 
membranes and in cytoplasmic compartments of NOS-immunopositive myenteric plexus 
(MP) neurons of both mouse ileum and colon (Figures 4.1 A1, B1). Immunoreactivity for 
TWIK- 1 was also observed in the longitudinal smooth muscle (LM) cells in both ileum and 
colon, as demonstrated by co-localisation with the smooth muscle cell marker α-actinin 
(Figures 4.1 A2, B2). Immunoreactivity for the TASK-2 channel protein was significantly 
enriched in the cell membranes of NOS-immunopositive MP neurons (Figures 4.1 C1, D1), 
but was not detectable in LM cells of either mouse ileum or colon (Figures 4.1 C2, D2). 
These data indicate that TWIK-1 and TASK-2 channels are widely distributed across 
neuronal and smooth muscle tissues and correlates with the abundant transcript 
expression observed in both ileum and colon.  
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Figure 4.1: TWIK-1 and TASK-2 channels are distributed in myenteric plexus inhibitory 
neurons and longitudinal smooth muscle layers of the mouse ileum and colon. Panels show 
overlays of cell specific markers (green) and individual K2P channel markers (red) 
throughout. For clarity, panels A1, A2, B1, B2, E1, E2, F1 and F2 (ileum) and C1, C2, D1, D2, 
G1, G2, H1 and H2 (colon) show the individual images from corresponding merges in A3, 
B3, C3, D3, E3, F3, G3 and H3.  Scale bars represent 10 μm. 
151 
 
4.2.2 TREK-1 expression in ileum and colon 
Our qPCR and RT-PCR indicated that the TREK subfamily channel gene transcripts (TREK-1, 
TREK-2 and TRAAK) are present in both mouse ileum and colon, but their levels were 
relatively low and may be suggestive of cell specific expression patterns. Given the proposal 
that a TREK-like conductance may underlie an important stretch-activated current in the GI 
smooth muscle, we therefore utilised TREK family channel specific antibody 
immunolabeling to characterise the specific distribution of TREK channels in muscle and 
nervous tissue of the mouse GI tract. For consistency with planned organ bath 
pharmacology studies, we firstly focused on their expression profiles in LM layers and MP 
neurons. Immunoreactivity for the TREK-1 channel protein indicated it was widely 
distributed across LM cells in both ileum and colon (Figure 4.2 A, B), as visualised by 
overlapping immunoreactivity with the smooth muscle cell marker α-actinin. In contrast, 
TREK-1 immunoreactivity was not detected in NOS-immunopositive MP neurons and 
submucosal plexus neurons (Figure 4.2 C, D). I also performed duplicate experiments to 
look at the expression in circular smooth muscle layers and neighbouring submucosal 
plexus (SP) neurons in both ileum and colon. TREK-1 channel protein was also detected 
throughout circular smooth muscle (CM) layers, as demonstrated by co-localisation with 
the smooth muscle cell marker α-actinin, but TREK-1 immunoreactivity was again not 
detected in NOS-immunopositive SP neurons (Figure 4.3 A, B). 
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Figure 4.2: TREK-1 channel are expressed in longitudinal smooth muscle tissue of both 
mouse ileum and colon. Panels A3, and C (ileum) and B3 and D (colon) show overlays of 
cell specific markers (green) and the TREK-1 channel marker (red). For clarity, panels A1 
and A2 (ileum) and B1 and B2 (colon) show individual images from corresponding positive 
merges in smooth muscle. Panels (C) and (D) show overlays for NOS immunoreactive 
myenteric plexus neurons and the TREK-1 channel in ileum and colon, respectively. Scale 
bars represent 10 μm.  
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Figure 4.3: TREK-1 channels are expressed in circular smooth muscle of both mouse ileum 
and colon. Images show the expression of NOS immunoreactive submucosal plexus 
neurons (blue, A1 and B1), TREK-1 channel (red, A2 and B2) and α-actinin immunoreactive 
smooth muscle cells (green, A3 and B3) in mouse ileum and colon as indicated. (A4) and 
(B4) are overlays of (A1-3) and (B1-B3) respectively. Scale bar represents 20 μm (A1-A4) 
and 50 μm (B1-B4). 
 
4.2.3 TREK-2 expression in ileum and colon 
In both mouse ileum and colon, I was unable to detect immunoreactivity for the TREK-2 
channel protein in LM cell layers (Figure 4.4 A, B) and CM cell layers (Figure 4.5 A, B). 
Conversely, strong TREK-2 labelling was observed within NOS-immunopositive MP neurons 
(Figure 4.4 C, D) and SP neurons (Figure 4.5 A, B). Moreover, TREK-2 was also detected in 
a number of NOS-negative enteric neurons, and thus I also investigated TREK-2 expression 
in other types of neurons including cholinergic neurons and interneurons. TREK-2 was 
detected in interneurons (Figure 4.6 A, B) and excitatory neurons (Figure 4.6 C, D), as 
visualised by co-labelling with the calcium binding protein, calretinin and ACh synthesizing 
enzyme, choline acetyltransferase (ChAT) respectively.  
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Figure 4.4: TREK-2 channels are expressed in myenteric plexus neurons of both mouse 
ileum and colon. Panels A, and C3 (ileum) and B and D3 (colon) show overlays of cell specific 
markers (green) and the TREK-2 channel marker (red). For clarity, panels C1 and C2 (ileum) 
and D1 and D2 (colon) show individual images from corresponding positive merges in 
enteric neurons. Panels (C3) and (D3) show overlays for NOS immunoreactive myenteric 
plexus neurons and the TREK-2 channel in ileum and colon respectively. Scale bars 
represent 10 μm (A, B) and 20 μm (C1-C3, D1-D3).  
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Figure 4.5: TREK-2 channels are expressed in submucosal plexus of both mouse ileum and 
colon. Images show the expression of NOS immunoreactive submucosal plexus neurons 
(green, A1 and B1), TREK-2 channel (red, A2 and B2) and α-actinin immunoreactive smooth 
muscle cells (blue, A3 and B3) in mouse ileum and colon as indicated. (A4) and (B4) are 
overlays of (A1-3) and (B1-B3) respectively. Scale bar represents 20 μm (A1-A4) and 20 μm 
(B1-B4). 
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Figure 4.6: TREK-2 channels are expressed in ChAT-positive and calretinin-positive 
myenteric plexus neurons in mouse ileum and colon. Panels A3 and C3 (ileum) and B3 and 
D3 (colon) show overlays of cell specific markers (green) and the TREK-2 channel marker 
(red). For clarity, panels A1 and A2 (ileum) and B1 and B2 (colon) show the individual 
images from corresponding merges in A3 and B3, panels C1 and C2 (ileum) and D1 and D2 
(colon) show the individual images from corresponding merges in C3 and D3. Overlays 
shown in A3 and B3. Scale bars represent 20 μm (A1-A3), 40 μm (B1-B3), 30 μm (C1-C3) 
and 40 μm (D1-D4). 
 
4.2.4 TRAAK expression in ileum and colon 
TRAAK channel specific antibody immunolabeling was utilised to characterise the 
distribution of the TRAAK channel protein in muscle and nervous tissue of the mouse GI 
tract. Similar to TREK-2, I could find no evidence for TRAAK expression in LM cells (Figure 
4.7 A, B) and CM cells (Figure 4.8 A, B) in either mouse ileum or colon. The pattern of TRAAK 
protein labelling observed in the MP neurons (Figure 4.7 C, D) and SP neurons (Figure 4.8 
C, D) of ileum and colon were analogous to that observed for TREK-2, displaying a wide 
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distribution across both NOS-immunopositive and NOS-immunonegative cell types of 
enteric neurons. Furthermore, TRAAK protein was also detected in interneurons (Figure 4.9 
A, B) and cholinergic neurons (Figure 4.9 C, D), as visualised by co-labelling with the 
calretinin and ChAT respectively. 
 
Figure 4.7. TRAAK channels are expressed in myenteric plexus neurons of both mouse 
ileum and colon. Panels A, and C3 (ileum) and B and D3 (colon) show overlays of cell specific 
markers (green) and the TRAAK channel marker (red). For clarity, panels C1 and C2 (ileum) 
and D1 and D2 (colon) show individual images from corresponding positive merges in 
enteric neurons. Panels (C3) and (D3) show overlays for NOS immunoreactive myenteric 
plexus neurons and the TRAAK channel in ileum and colon respectively. Scale bars 
represent 20 μm (A, B, C1-C3) and 40 μm (D1-D3). 
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Figure 4.8: TRAAK channels are expressed in submucosal plexus of both mouse ileum and 
colon. Images show the expression of NOS immunoreactive submucosal plexus neurons 
(green, A1 and B1), TRAAK channel (red, A2 and B2) and α-actinin immunoreactive smooth 
muscle cells (blue, A3 and B3) in mouse ileum and colon as indicated. (A4) and (B4) are 
overlays of (A1-3) and (B1-B3) respectively. Scale bar represents 10 μm (A1-A4) and 20 μm 
(B1-B4). 
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Figure 4.9: TRAAK channels are expressed in ChAT-positive and calretinin-positive 
submucosal/ myenteric plexus neurons in mouse ileum and colon. Panels A3 and C3 (ileum) 
and B3 and D3 (colon) show overlays of cell specific markers (green) and the TRAAK channel 
marker (red). For clarity, panels A1 and A2 (ileum) and B1 and B2 (colon) show the 
individual images from corresponding merges in A3 and B3, panels C1 and C2 (ileum) and 
D1 and D2 (colon) show the individual images from corresponding merges in C3 and D3. 
Scale bars represent 20 μm (A1-A3), 20 μm (B1-B3), 20 μm (C1-C3) and 10 μm (D1-D4). 
 
4.2.5 Expression of other K2P subtypes in ileum and colon 
Our qPCR data indicated that TASK-1 and TWIK-2 genes also displayed high relative 
expression levels in both ileum and colon. TASK-3 genes had been previously reported in 
rat colon (Kim et al., 2000), although they were barely detectable in my qPCR studies. Taken 
together, I thought it pertinent to classify the precise cellular locations of these three K2P 
channel subtypes in the mouse intestine, as determined by immunohistochemistry and 
confocal microscopy. Expression of TASK-1 protein was detected on plasma membranes 
and in NOS-immunopositive MP neurons of both mouse ileum and colon (Figures 4.10 A1, 
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B1). Immunoreactivity for TASK-1 was also observed in the cytoplasmic compartments of 
LM cells in both ileum and colon, as demonstrated by co-localisation with the smooth 
muscle cell marker α-actinin (Figures 4.10 A2, B2). Immunoreactivity for TASK-3 channel 
subunits was located on MP neurons. Clustered immunoreactivity for the TASK-3 protein 
was evident on NOS-immunopositive MP neurons (Figures 4.10 C1, D1), but was not 
detectable in LM cells of either mouse ileum or colon (Figures 4.10 C2, D2). Similar to TREK-
2 and TRAAK, we could find no evidence for TWIK-2 expression in LM cells in either mouse 
ileum or colon (Figure 4.10 E2, F2). The expression pattern of TWIK-2 channel labelling 
displays an evident in the NOS-immunopositive MP neurons of both ileum and colon 
(Figure 4.10 E1, F1).  
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Figure 4.10: TASK-1, TASK-3 and TWIK-2 channels are distributed in enteric plexus 
inhibitory neurons and smooth muscle layers of the mouse ileum and colon. Panels show 
overlays of cell specific markers (green) and individual K2P channel markers (red) 
throughout. (A1) and (B1) show overlays for NOS immunoreactive submucosal plexus 
neurons and the TASK-1 channel in ileum and colon respectively. Panels (C1) and (D1) show 
overlays for NOS immunoreactive myenteric plexus neurons and the TASK-3 channel in 
ileum and colon respectively. Bottom panels (E1) and (F1) show overlays for NOS 
immunoreactive myenteric plexus neurons and the TWIK-2 channel in ileum and colon 
respectively. Scale bars represent 5 μm (C1), 10 μm (A1; A2; B1; B2; D1; D2; E1; E2; F1; F2), 
20 μm (C2). 
 
Since TWIK-1 and TASK-2 exhibit protein expression pattern in both enteric neurons and 
smooth muscle, we also investigate whether these two channels also expressed in other 
cell types such as glia cell. The glia cell also play an essential role in GI function which 
providing structural and metabolic support for neurons, although there is no previous 
research which indicated that these channels might be expressed in glial. We could find no 
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evidence for both TWIK-1 and TASK-1 expression in SOX-10-immunopositive enteric glial 
cells in either mouse ileum or colon, only observed their expression pattern in NOS-
immunopositive MP neurons (Figure4.11).  
 
 
Figure 4.11: TASK-1 and TWIK-1 channels are not expressed in enteric glia in both mouse 
ileum and colon. Images show the expression of SOX10 immunoreactive enteric glia 
neurons (green, A1, B1, C1, D1), TASK-1 channel (red, A2 and C2), TWIK-1 (red, B2 and D2) 
and NOS immunoreactive myenteric plexus neurons (blue, A3, B3, C3, D3) in mouse ileum 
and colon as indicated. (A4, B4, C4, D4) are overlays of (A1-3), (B1-B3), (C1-C3) and (D1-
D3) respectively. All scale bar represents 10 μm. 
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4.2.6 K2P subtypes expression in isolated smooth muscle cells 
From the whole tissue mounts it was evident that TREK-1, TWIK-1 and TASK-1 proteins were 
present in smooth muscle layers, and the K2P channel subtypes TREK-2 and TRAAK were 
not. To reinforce these K2P channel protein expression profiles, I also determined the 
expression of the K2P channel proteins in isolated colonic smooth muscle cells by using 
immunocytochemistry and confocal microscopy.  Immunoreactivity for TREK-1, TWIK-1 and 
TASK-1 proteins was detected in the isolated intestinal smooth muscle cell preparations, as 
demonstrated by overlapping fluorescence with the smooth muscle cell marker α-actinin 
(Figure 4.12 A, D, E). In contrast, I could find no evidence for TREK-2 and TRAAK expression 
in isolated single smooth muscle cells (Figure 4.12 B, C). Collectively, these data confirmed 
the smooth muscle specific distribution of TREK-1, TWIK-1 and TASK-1 in mouse ileum and 
colon.  
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Figure 4.12: K2P channel expression in isolated colonic smooth muscle cells. Double 
immunofluorescence labelling for TREK-1, TREK-2, TRAAK, TWIK-1 and TASK-1 (red, A1, B1, 
C1, D1 and E1) and the smooth muscle marker α-actinin (green, A2, B2, C2, D2 and E2) The 
co-expression appears yellow in the overlays (A3, B3, C3, D3 and E3). All scale bar 
represents 10 μm. 
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4.3 Discussion  
The cell specific expression and localisation of K2P channel subtypes in the GI tract is poorly 
understood. A physiological role for a mechano-gated K2P channel has been proposed. 
Previous functional characterisation along with transcript expression profiles point toward 
TREK-1 as the molecular correlate of the stretch-dependent potassium (SDK) conductance 
in colonic myocytes (Koh and Sanders, 2001), although direct protein localisation and 
conclusive pharmacological evidence is lacking. The immunohistochemical results shown 
in this chapter reveal that K2P channel subtypes are expressed throughout the mouse 
intestine and distributed across different cell types. TREK-1 channels displayed a primarily 
smooth muscle cell expression, with TREK-2, TRAAK, TASK-2 and TASK-3 channels being 
limited to the circuitry of the enteric nervous system, whereas TWIK-1 and TASK-1 channels 
were shown to be widely distributed across neuronal and smooth muscle tissues. These 
novel findings provide a new perspective on the distinctive expression of K2P channel 
subtypes in enteric neurons and intestinal smooth muscle cells, and implies an important 
yet uncharacterised functional role for these different channels in specific populations of 
cells.  
 
4.3.1 Antibody Validation  
Antibodies raised against proteins are among the most frequently used research tools for 
studying the expression of ion channels and receptors. To validate an antibody, it must be 
shown to be specific, selective, and reproducible in the context for which it is to be used. 
Although there are no universally accepted guidelines or standardized methods for 
determining the validity of these reagents, there have been a number of previous 
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publications on the subject, and an assortment of recommendations is available in the 
literature and online resources. Ideally, a negative control could be a cell line or tissue that 
is known not to express the protein of interest, such as the knock-out mice. Similarly, non-
expressing cells, transfected with the protein of interest, provide the best positive controls. 
Although I did not provide either negative or positive control for the antibodies used in this 
chapter due to lack-of K2P knock-out mice, the specific protein labelling and distinct 
expression within neuron cells and smooth muscle cells in mouse intestine confirm the 
specificity of the Alomone Lab K2P antibodies I have used in my immunohistochemistry 
studies.  
 
It has been previously shown by immunohistochemistry that TWIK-1, TREK-1 and TASK-1 
are expressed in hippocampal astrocytes (Zhou et al., 2009). Moreover, pre-incubation in 
the blocking peptide completely abolished K2P channel immunolabelling in hippocampal 
tissue sections (Zhou et al., 2009), indicating the specificity of these antibodies from 
Alomone Lab. In later studies, Immunohistochemical staining of TREK-1 have been shown 
in both cultured astrocytes (Banerjee et al., 2016) and mouse brain sections (Woo et al., 
2018). In addition, lack of TREK-1 staining in TREK-1 knock-out mice confirms antibody 
specificity (Woo et al., 2018). Previous Immunohistochemical studies show TREK-2 
expression in DRG neurons from rat brain, antibody recognizes heterologously expressed 
TREK2 but not the structurally closely related TREK1 or any of the other K2P channels tested 
(TWIK1, TASK3, THIK2, THIK1), indicating very high selectivity for TREK2 (Acosta et al., 
2014).  Moreover, the specificity of TREK-2 antibody was also confirmed by western blot of 
DRG tissue (Acosta et al., 2014).  The specificity of the TRAAK channel antibody had been 
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confirmed in a previous immunocytochemical studies in mouse oocytes (Hur et al., 2012), 
and western-boot studies in mouse hippocampal tissue (de la Pena et al., 2012). TASK-2 
channel has been previously shown by immunohistochemistry in HEK 293 cells, and 
blocking peptide was added to the primer reaction as the negative control, demonstrating 
the specificity of TASK-2 antibody (Gonczi et al., 2006). Thus, previous studies provide 
strong evidence for the specificity of K2P channel antibodies that I have used in this chapter.  
 
4.3.2 Distinctive GI expression of TREK family  
Previous studies have indicated that TREK-like channels underlie a SDK in colonic smooth 
muscle cells, based on the biophysical phenotype and similarity to cloned murine TREK-1 
channels, including mechano-sensitivity, insensitivity to classical potassium channel 
blockers, and regulation by nitrergic stimulation (Koh and Sanders, 2001, Koh et al., 2001, 
Park et al., 2005). Immunohistochemical analysis of all three mechano-gated K2P channel 
proteins in the murine GI tract revealed a distinct expression pattern of these channels. I 
found evidence for TREK-1 channel expression in longitudinal and circular smooth muscle 
tissues, but not in nitrenergic enteric neurons of the myenteric and submucosal plexuses, 
whereas TREK-2 and TRAAK channel proteins were only observed in enteric neurons and 
were not detected in smooth muscle layers. This distinctive expression pattern is analogous 
to previous observations in airway, where TREK-1 channels show expression in smooth 
muscle cells of mouse lung tissue, while TRAAK channels show expression in nerve endings 
located in different layers of intrapulmonary airways (Lembrechts et al., 2011), and in 
bladder where TREK-1 displays labelling in single freshly dispersed human bladder smooth 
muscle cells (Lei et al., 2014). Furthermore, my protein localisation findings contrast TREK-
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1 and TRAAK expression in the central nervous system, where they show overlapping 
expression in a variety of neurons, and are thought to form functional heterodimers (Blin 
et al., 2016). Furthermore, there is no evidence to date for TREK-2 protein localisation in 
smooth muscle cells of any other organs, with TREK-2 being largely confined to expression 
in neurons of the CNS and PNS (Viatchenko-Karpinski et al., 2018, Talley et al., 2001a), 
which again is analogous to the specific expression of TREK-2 channels in enteric neurons 
of the gut.  
 
In addition, I found TREK-1 channel protein expression in isolated intestinal smooth muscle 
cells by using immunocyctochemical studies, whereas TREK-2 and TRAAK channels protein 
were absent from these smooth muscle cells, which further confirmed their distinct cellular 
localization in intestine tissue.  However, I have only looked their protein expression in 
single cell, further studies in quantification of proportion of cells showing signal could be 
investigated in the future.  
 
Given that my project is ultimately concerned with the functional role of K2P channels in GI 
motility, the pacemaker cells of the gut, the Interstitial Cells of Cajal (ICC) are an import 
subset of cells that should be investigated. ICC are important regulators of GI function, 
communicating with enteric neurons and smooth muscle cells, inducing propagating 
electrical slow wave potentials and thus helping to regulate phasic contractile activity of GI 
smooth muscle (Al-Shboul, 2013). However, in preliminary experiments, the low specificity 
of the ICC antibody I used restricted further investigation. Given the importance of the ICC 
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in regulating motility, further experiments are required to detail the expression of K2P 
channels in these pacemaker cells of the gut. 
 
4.3.3 Distinctive GI expression of TWIK family  
The novel finding from our qPCR was the high expression of TWIK-1 and TWIK-2 mRNA in 
both murine ileum and colon. Detailed immunohistochemical analysis for these proteins 
demonstrated a wide distribution pattern across smooth muscle and neuronal cell types in 
ileum and colon and may be suggestive of important roles in GI physiology. Although TWIK-
1 and TWIK-2 genes are widely expressed in many region of the CNS and in a number of 
peripheral tissues such as stomach, pancreas, spleen and uterus (Medhurst et al., 2001, 
Kew and Davies, 2010), their role as background K+ channels is still speculative. This is 
because there is no TWIK-1 or TWIK-2 channels have yet been recorded from any native 
tissues. Previous studies in TWIK-1 knock-out mice suggest that TWIK-1 may contribute to 
K+/water transport in proximal tubule and medullary collecting duct of kidney (Nie et al., 
2005). In the human heart, TWIK-1 gene is strongly expressed in the atria, the Purkinje 
fibers and the ventricles (Ordog et al., 2006, Ellinghaus et al., 2005, Gaborit et al., 2007, 
Lesage et al., 1996), but whether TWIK-1 plays a functional role in heart has not yet been 
reported. In addition, recent studies found TWIK-1 deficiency caused a depolarizing shift in 
the resting membrane potential of dentate gyrus granule cells (DGGCs) and enhanced their 
firing rate in response to depolarising current injections, suggesting TWIK-1 channel is 
involved in the intrinsic excitability of DGGCs in mouse hippocampus (Yarishkin et al., 2014). 
There is currently a distinct lack of available evidence for expression of TWIK-1 and TWIK-
2 channels in GI tract, and so my findings that the TWIK-1 channel protein not only localised 
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in enteric neurons but also in smooth muscle layers, and TWIK-2 channel proteins are only 
observed in enteric neurons greatly enhances the knowledge within this field of research. 
Although TWIK-1 channels are widely expressed, the physiological significance of TWIK-1 
channels has been questioned due to the difficulties encountered in demonstrating 
functional currents in heterologous systems. It has been proposed that TWIK-1 channels 
are present at the cell membrane but it is normally silent and requires modulation by SUMO 
(Rajan et al., 2005). However, a later study failed to show sumolyation of TWIK-1 and 
suggest that TWIK-1 is lack functional due to it is present in the cytosolic which do not 
trafficked to the membrane (Feliciangeli et al., 2007).  
 
TWIK-1 were reported to form heterodimeric channels with TASK channel subunits (TASK-
1 or TASK-3), and these heterodimeric channels exhibit acid-sensitive and halothane-
sensitive outwardly rectifying K+ currents in cerebellar granule neurons (Plant et al., 2012, 
Ma et al., 2012). Also, recent studies showed that TWIK-1 were associate with TASK-3 in 
DGGCs of mouse hippocampus when both genes were overexpressed in the cells, and this 
complex displayed outwardly rectifying currents and involves in the intrinsic excitability of 
DGGCs (Choi et al., 2018). My immunohistochemical staining data showed that TASK-3 
proteins were localised in the MP neurons, and TASK-1 proteins were detected in both 
smooth muscle cells and neurons, and this localization is similar to the expression pattern 
of TWIK-1 where localised in both smooth muscle cells and MP neurons, although whether 
those two channels were expressed in the same cells stills remains unknown. Furthermore, 
TWIK-1 was also reported to form a functional channel with TREK-1, which contribute to 
mediate astrocytic passive conductance and cannabinoid-induced glutamate release from 
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astrocytes proteins (Hwang et al., 2014). TREK-1 was exhibited predominately pattern in 
both circular and longitudinal smooth muscle cells in my data. Therefore, all these co-
expression pattern indicates TWIK-1 may form functional heterodimers with other K2P 
channels (TASK-1, TASK-3 and TREK-1 channels) and contribute to the GI physiology such 
as regulating intestinal smooth muscle contractility. However, along with a current lack of 
pharmacological tools for TWIK family, the physiological importance of these two channels 
in the GI system remains to be conclusively determined. 
 
4.3.4 Distinctive GI expression of other K2P subunits  
TASK-1 and TASK-2 were previously identified to be expressed in smooth muscle cells of 
murine small and large intestine by analysis of mRNA distribution (Cho et al., 2005). In 
addition TASK-2 channel proteins have also been shown in both smooth muscle layers and 
enteric neurons. Furthermore a TASK-2-like conductance has been proposed as a potential 
contributor to resting membrane potential in smooth muscle cells, although the 
pharmacological tools used to assess this, including lidocaine, were used at concentrations 
too high to be TASK-2 specific  (Cho et al., 2005). This report is in contrast to my findings 
here where I show expression of TASK-2 in enteric neurons of the GI tract, but no detectable 
expression in smooth muscle cell layers of either the ileum or colon. Due to the lack of 
double staining with a smooth muscle cell marker and good control experiments it is not 
possible to decipher from their data whether the channel protein staining was due to non-
specific binding. Functional corroboration of these current data will depend on the 
identification of specific pharmacological tools for TASK-2 channels. Previous studies have 
not only indicated the positive immunohistochemical expression of TASK-2 channel in 
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uterine circular muscle of mouse, but also showed that TASK-2 inhibitors such as quinidine, 
lidocaine, and extracellular acidosis produced smooth muscle contraction in uterine (Hong 
et al., 2013). Moreover, both gene and protein expression of TASK-1 channel have been 
detected in pulmonary artery smooth muscle cells (Gurney et al., 2003). The arterial 
conductance (Gurney et al., 2003) showed similar pH-sensitivity as the conductance 
observed in intestinal muscles (Cho et al., 2005), suggesting that TASK family channels may 
be generally important in visceral smooth muscles as regulators of membrane potential. 
My studies identified that TASK-1 protein is located in longitudinal muscle and a small 
portion of neuronal cells in MP, and TASK-3 protein was only expressed in enteric neurons. 
These findings are in good accordance with previous immunohistochemical studies in rat 
proximal colon, which TASK-1 was localized in the LM layer and MP and TASK-3 was 
localised in MP (Kubota et al., 2015). In the same studies, authors also detected TASK-3 
protein expression in ICC cells in the MP layer. Although both TASK-1 and TASK-3 exhibit 
NOS-immunopositive in MP neurons, it is hard to distinguish whether they were expressed 
in the same cells. Notably, TASK-1 and TASK-3 can form functional heterodimers exhibiting 
properties distinct from TASK-1 and TASK-3 alone, which showed intermediate pH 
sensitivity and ruthenium red insensitivity (Czirjak and Enyedi, 2002). Moreover, recent 
studies reported that TASK-3 was localized at the plasma membrane of isolated 
cardiomyocytes, but single channel recording observed a TASK-1/TASK-3 complex channel 
conductance, suggesting TASK-1/TASK-3 may form heteromeric complexes in human atrial 
cardiomyocytes (Rinne et al., 2015). Therefore, TASK-1 and TASK-3 may also form 
functional heterodimers in enteric neurons to play an important role in GI physiology, but 
further experiments are required to identify the co-expression details of TASK-1 and TASK-
3 channels in MP neurons. 
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4.4 Summary and Conclusions 
The key finding of this chapter is that both enteric neurons and smooth muscle cells 
differentially express K2P channels. Whole-mount preparations, rather than cross-sections 
of the tissue preparations were used. This therefore technically restricted the inspection of 
the epithelial layers of the GI microscopically, precluding the verification of K2P subunits 
localisation in mucosal elements. Thus, this could be an interesting set of experiments in 
the future to further characterise the localisation of K2P channels in epithelial layers of the 
intestine, since the pathophysiological mechanisms of IBS also include the alterations in the 
epithelial barrier and secretory properties of the gut (Camilleri and Ford, 2017).  
 
In summary, these data provide new information on the cell type specific expression of 
mechano-gated TREK family channels in GI tract, with the novel finding that TREK-1 
expression is limited specifically to smooth muscle layers were as expression of TREK-2 and 
TRAAK channels was confined to enteric neurons. The high expression of TWIK-1 mRNA in 
the GI tract correlated with combined protein expression observed across both smooth 
muscle and enteric neurons and is suggestive of important roles in GI physiology.  The 
physiological function of TREK family channels in GI smooth muscle and neurons is 
unknown, but given their pattern of cellular localisation in the various layers of the GI tract 
in both ileum and colon supports a hypothesis for a potential role in regulating enteric 
neuronal excitability and neurochemical signalling and intestinal smooth muscle 
contractility. Therefore, the next step was to directly assess the functional contribution of 
TREK channels to smooth muscle contractility using organ bath pharmacology 
methodologies.  
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Chapter 5 – Functional role of 
Potassium Channels in GI smooth 
muscle contractility 
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5.1 Introduction and Aims 
There is a great deal of molecular and functional evidence describing the various ionic 
conductance’s responsible for GI smooth muscle contraction, including transient receptor 
potential channels and voltage-dependent calcium channels. However, comparably little is 
known about the underlying K+ channels responsible for suppressing smooth muscle 
contractility and promoting GI tract relaxation, a mechanism that could be exploited 
therapeutically to treat hypermotility disorders, such as IBS. In chapter 3, I demonstrated 
that several different K+ transcripts (e.g. Kv4.3, Kv7.1, Kir 6.1, & mechano-gated K2P channels) 
are prominently expressed throughout the murine intestine. In this chapter, I utilised 
pharmacological techniques to dissect the distribution and contribution of various 
subtypes of K+ channels in regulating intestinal motility in the mouse. Moreover, in chapter 
4 I revealed the precise cellular location of K2P channel subtypes within both ileum and 
colon, and suggested a potential role for the mechano-gated TREK channel family in 
ENS/smooth muscle medicated GI function. Historically, specific pharmacological tools 
targeting K2P channels have been rather limited, therefore direct pharmacological 
validation of TREK channel activity in GI smooth muscle has been difficult to confirm. 
Recent reports have begun to highlight multiple chemical modulators of TREK family 
channels, in order to to support our immunohistochemical findings I sought further 
pharmacological evidence for mechano-gated K2P functional expression in murine ileum 
and colon using an organ bath preparation. 
 
177 
 
5.2 Results 
5.2.1 Potassium channel blockers alter muscle tension 
To broadly assess the expression and contribution of potassium channels to  gut contractile 
activity,  the broad spectrum K+ channel inhibitors TEA, Ba2+ and 4-AP were exposed to both 
mouse ileum and colon segments under basal conditions at 32 °C and changes in muscle 
tension monitored (Figure 5.1).  The cholinergic agonist carbachol (CCh) and potassium 
chloride (KCl) were firstly applied to tissues to confirm the functionality of the tissues. As 
expected, both CCh and KCl induced significant increases in the basal tension of the ileum 
and colon (n = 6 each condition). TEA at a bath concentration of 10 mM induced a significant 
increase in the tension of ileum and colon tissues (Figure 5.1). The induced contraction was 
non-significantly different between ileum and colon (0.52 ± 0.1 g vs 0.52 ± 0.4 g 
respectively; n = 6; p = 0.9872, un-paired Student’s t-test). Ba2+ at a bath concentration of 
10 mM also promoted a significant increase in tension in both ileum and colon (1.13 ± 0.3 
g vs 0.45 ± 0.3 g respectively; n = 6). However, the amplitude of Ba2+ induced contractions 
were significantly less in colon versus ileum (p = 0.0035, un-paired Student’s t-test). 
Conversely, exposure to 4-AP (5 mM) did not markedly effect tension in either ileum or 
colon (n = 6 each condition). Together, these results suggest that potassium channels, 
especially the K2P channels are expressed and play a direct functional contribution to the 
contractile physiology of longitudinal muscle in both mouse ileum and colon, since K2P 
channel is the only K+ channels stay opening when cells at rest. The K+ channel blockers, 
which inhibit K2P channels, caused contraction of smooth muscle cells result in inhibition of 
currents around the resting membrane potential and depolarized membrane potential.    
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Figure 5.1. Top panels, representative traces showing the time course of the addition of 
classical K+ channel blockers 10mM tetraethylammonium (TEA) (A1) and 10mM barium 
(Ba2+) (A2) to mouse ileum. Scale bars represent 0.2g (vertical) and 30 seconds (horizontal). 
(B) Bar graph showing mean change in tension induced by carbachol (CCh), potassium 
chloride (KCl) and broad spectrum K+ channel inhibitors TEA, 4-amino pyridine (4-AP) and 
Ba2+  and in both mouse ileum and colon (n = 6 each condition). **indicates p = 0.0035, 
unpaired t-test.  
 
5.2.2 Activation of Kv channels induces relaxation in ileum and colon 
Due to the high relative expression levels of Kv7.1 and Kv4.3 transcripts observed in my 
qPCR data and the significant contraction effects caused by the classic K+ channel blockers 
TEA and Ba2+, the functional role of Kv channels in smooth muscle tone were investigated 
using more selective Kv channel modulators. Application of increasing concentrations of 
CCh where first utilised to measure ascertain concentration-responses of longitudinal 
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smooth muscle in both ileum and colon to determine the functional viability of the tissues 
and to gauge contraction amplitudes of each tissue. Sub-maximal concentrations of CCh 
could then be chosen to assess the impact of Kv channel activation in CCh pre-contracted 
tissues. Figure 5.2 shows mean data collated from experiments were ascending 
concentrations of the parasympathomimetic drug CCh (from 10-9  to 10-5 M) were applied 
to both ileum and colon resulting in  concentration-dependent contractions, which when 
approximated with a non-linear curve revealed an EC50 of 1.83 ± 0.22 μM in ileum and 5.76 
± 0.73 μM in colon (n = 9) . 
 
 
Figure 5.2: Carbachol induced concentration-response curve of the mouse ileum (A) and 
colon (B), n = 9 each. Data is displaced as mean percentage (%) contraction ± SD and 
approximated with a non-linear curve. EC50 = 1.83 ± 0.22 μM (ileum); 5.76 ± 0.73 μM 
(colon). HillSlope is 0.77 ± 0.04 (ileum); 0.95 ± 0.10 (colon).  
 
Submaximal concentrations of CCh were applied to tissues and tonic contractions allowed 
to stabilise. To assess the contribution of potassium channels to GI tract smooth muscle 
contractility, various Kv channel activators were applied to the CCh pre-contracted tissues 
and smooth muscle relaxation was monitored.  Firstly, isolated ileum and colon segments 
were pre-contracted with CCh (10 μM) and the generated tension allowed to reach steady 
180 
 
state before the addition of the Kv7 activator, retigabine (Figure 5.3 A1, A2). Changes in 
tension induced by addition of activators were normalised to steady-state pre-contracted 
tension in each individual experiment and are reported as percentage. On average 10 μM 
CCh generated a tension of 1.2 ± 0.03 g in ileum and 1.3 ± 0.05 g in colon (both n = 100). 
Retigabine (1-100 µM) induced a concentration-dependent decrease in muscle tension in 
both ileum and colon. Relaxation induced by 100 µM retigabine was not maximal but 
differed significantly between ileum and colon (54.3 ± 1.9 % vs 35.4 ± 3.1 %, p =0.0004; see 
Figure 5.3 B1, B2). To further clarify the functional presence of Kv7 channels, the broad 
spectrum Kv7 inhibitor, XE991, was applied at baseline tension at a bath concentration of 
100 µM. XE991 induced a small contractile response and generated a tension of 0.33 ± 0.1 
g in ileum and 0.17 ± 0.2 g in colon (both n = 6, Figure 5.3 C). However, addition of the Kv7.1 
specific blocker, Chromanol 293B, which does not modulate Kv7.2-7.5 channels, at a bath 
concentration of 100 µM did not significantly affect tension in either ileum or colon (n = 6; 
p = > 0.05, see Figure 5.3 C).  
 
To assess the functional expression of Kv4.3 channels in ileum and colon, a single 
concentration of the selective Kv4.3 channel activator NS5806 (50 µM) was used (Lundby 
et al., 2010). NS5806 induced a marked but limited relaxatory effect in CCh pre-contracted 
ileum and colon tissues [Figure 5.3 D; 27.5 ± 3.7 % (ileum) and 14.4 ± 3.5 (colon); both n = 
6]. Comparatively, relaxation induced by NS5806 in ileum was significantly greater than 
effect in colon (p =0.0393, un-paired Student’s t-test).  
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Taken together, these results suggest that Kv7.2-7.5 and Kv4.3 channels have a functional 
role in regulating the GI contractility. In contrast, Kv7.1 channel does not appear to 
functionally contribute to contractility of GI longitudinal smooth muscle.  
 
Figure 5.3: Top panels, exemplar traces showing relaxation induced by the Kv7 channel 
agonist retigabine (1 µM) (A1) and retigabine (100 µM) (A2) in mouse ileum. Scale bars 
represent 0.2g (vertical) and 30 seconds (horizontal). Mean concentration-response 
relationships for retigabine in mouse ileum (B1) and colon (B2) are shown below the 
corresponding traces, n = 6 each. Both plots were fitted with non-linear regression. (C) Bar 
graph showing mean change in tension induced by Kv7 channel inhibitors XE991 and 
chromanol 293B (n = 6 each). (D) Mean normalised relaxation in CCh pre-contracted ileum 
and colon in response to Kv4.3 activator NS5806 (n = 6). Error bars represent standard 
deviation (SD), * p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001, student’s paired t-test 
(B1 & B2), student’s un-paired t-test (C & D).  
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5.2.3 Activation of KCa channels induced relaxation in ileum and colon 
Of 8 KCa genes analysed, IK and BK transcripts showed the largest relative expression within 
mouse ileum and colon. Therefore, the impact of KCa channel activation in CCh pre-
contracted tissues was probed by directly measuring changes in both ileum and colon 
muscle tension during application of a range of specific KCa activators including SKA-31 and 
NS 309 (activators of IK / SK channels) (Sankaranarayanan et al., 2009, Strobaek et al., 2004, 
Morimura et al., 2006), and specific activator of BK channels, NS 19504 (Nausch et al., 
2014). Single concentration additions of the SKA-31 (100 µM) and NS 309 (50 µM) both 
induced marked relaxations of CCh pre-contracted ileum and colon tissues [Figure 5.4 A, B; 
SKA-31, 68.9 ± 8.9% (ileum) and 48.6 ± 12.6% (colon); NS 309, 41.6 ± 14.9% (ileum) and 
33.5 ± 8.1% (colon)]. SKA-31 produced a significantly greater magnitude of relaxation in 
ileum compared to colon (n = 6, p = 0.0093, Student’s unpaired t-test), whereas NS 309 
effects were not significantly different between ileum and colon (n = 6, p = 0.4373, 
Student’s unpaired t-test).  
 
Tissue exposure to the selective BK channel agonist NS19504 produced a concentration 
dependent relaxation in CCh pre-contracted ileum (IC50 = 57.5 ± 2.4 µM, n = 6, Figure 5.4, 
C1). Relaxation to NS 19504 in colon was also concentration dependent (IC50 = 25.85 ± 3.1 
µM, n = 6, Figure 5.4 C2), however the relaxations at all effective concentrations were 
significantly larger than those observed in ileum (n = 6, p = 0.0182, Student’s unpaired t-
test). The relaxation induced by NS 19504 was also investigated in 60 mM KCl pre-
contracted ileum and colon segments. 100 µM NS 19504 produced a significantly greater 
relaxation when the ileum was pre-contracted with KCl compared to CCh (Figure 5.4 D; 
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106.5 ± 17.0% vs. 73.8 ± 12.4%, n = 6, p = 0.0021, Student’s unpaired t-test). A robust 
relaxation effect was similarly observed in KCl pre-contracted colon with NS 19504,  but 
was not significantly different from the relaxation observed during CCh pre-contraction 
(Figure 5.4 D; 100.8 ± 15.8% vs. 87.3 ± 5.2%, n = 6, p = 0.0748, Student’s unpaired t-test). 
The classic K+ channel blocker TEA has been shown to effectively inhibit BK channels at a 
concentration of 10 mM (Sun et al., 1999).  We therefore tested the ability of the BK 
activator NS 19504 to relax CCh pre-contracted ileum and colon in the presence of 10 mM 
TEA. As would be predicted, addition of 10 mM TEA significantly attenuated the relaxatory 
response to NS 19504 in colon, but interestingly, not in ileum (Figure 5.4 E). In ileum, 10 
μM NS 19504 induced a mean normalised relaxation of 24.0 ± 5.6% which was only slightly 
reduced to 19.2 ± 13.0% in the presence of TEA (n = 5 each, p = 0.5176, Student’s paired t-
test). However in colon, 10 μM NS 19504 induced a mean normalized relaxation of 31.1 ± 
6.7% compared to 7.3 ± 10.6% in the presence of TEA (n = 5 each, p = 0.0091, Student’s 
paired t-test).  
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Figure 5.4: Bar graph showing the relaxatory effects induced by the IK channel agonists 
SKA-31 (A) and NS 309 (B) in CCh pre-contracted mouse ileum and colon (n = 6 each), ** 
indicates p = 0.0093, student’s un-paired t-test. Mean concentration-response 
relationships for NS19504 in CCh pre-contracted mouse ileum (C1) and colon (C2), n = 6 
each. Both plots were fitted with non-linear regression. (D) Bar graph illustrating the BK 
channel agonists NS 19504 induced a differential relaxation in CCh (yellow bar) and KCl 
(green bar) pre-contracted ileum and colon (n = 6 each condition), **indicates p = 0.0005, 
two-way ANOVA.  (E) Bar graph showing relaxation (%) in ileum and colon to 10 µM NS 
19504 in the absence (pink bar) and presence (yellow bar) of 10 mM TEA (n = 5 each 
condition), **indicates p = 0.008, student’s un-paired t-test 
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5.2.4 Activation of Kir6.1 channels induced a modest relaxation in ileum and 
colon 
Kir6.1 had the highest relative expression of the 15 KIr genes examined. To clarify any 
potential functional role of Kir6.1 in GI motility, I exposed CCh pre-contracted tissues to the 
known Kir6.1 activators, diazoxide (Cui et al., 2001) and cromakalim (Gopalakrishnan et al., 
1999). 100 µM diazoxide caused a small but significant relaxation of both CCh pre-
contracted ileum (14.8 ± 6.9 %, n = 6, p = 0.0034, Student’s paired t-test) and colon (15.2 ± 
2.5 %, n = 6, p = 0.0002, Student’s paired t-test) (Figure 5.5 A). 20 µM cromakalim also 
induced a significant relaxation of CCh pre-contracted ileum (43.9 ± 8.5 %, n = 6, p = 0.0002, 
Student’s paired t-test) and colon (17.4 ± 4.8 %, p = 0.0002, Student’s paired t-test), and 
the observed relaxations to cromnakalim were significantly greater in ileum than in colon 
(Figure 5.5 B, n = 6, p < 0.0001, Student’s unpaired t-test).  
 
 
Figure 5.5: Bar graph showing that mean normalised relaxation in CCh pre-contracted ileum 
and colon in response to Kir6.1 activators diazoxide in 100 µM (A) and cromakalim in 20 µM 
(B). n = 6 each condition, error bars represent standard deviation (SD), ****indicates P < 
0.0001, student’s un-paired t-test.  
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5.2.5 Activation of mechano-gated TREK channels induces relaxation in 
ileum and colon 
Across 14 mouse K2P genes, TWIK-1 and TASK-2 transcripts showed the greatest relative 
expression in ileum and colon, with the TREK-1 transcript prominent in ileum but not colon. 
My immunohistochemical analysis showed wide distribution of TWIK-1 and TASK-2 across 
gut tissues, but revealed the unique expression of TREK-1 in smooth muscle only, whilst 
other members of the TREK subfamily, TREK-2 and TRAAK, were confined to neurons of the 
enteric nervous system. Given a paucity of specific pharmacological modulators for TWIK-
1 and TASK-2, I focussed on characterising the functional contribution of mechano-gated 
K2P channels in CCh pre-contracted tissues, employing the organ bath system to directly 
monitor changes in both ileum and colon muscle tension during application of a range of 
specific mechano-gated K2P activators including the cyclooxygenase (COX) inhibitor BL-1249 
and the lipoxygenase inhibitor cinnamyl 1-3,4-dihydroxy-alpha-cyanocinnamate (CDC) 
(Veale et al., 2014, Danthi et al., 2004).  
 
Isolated ileum and colon segments were pre-contracted with CCh (10 µM) and the 
generated tension allowed to reach steady state before the addition of K2P activators 
(Figure 5.6 A1, B1). Bath exposure to the caffeic acid derivative and lipoxygenase inhibitor 
CDC produced a relaxation in ileum, the magnitude of which was concentration dependent 
(IC50 = 8.5 ± 1.0 µM, n = 6, Figure 5.6 A2), resulting in a 88.5 ± 1.2 % relaxation at 30 µM 
(illustrated in the exemplar trace in Figure 5.6 A1). Relaxation to CDC in colon was also 
concentration dependent (IC50 = 18.6 ± 3.5 µM, n = 6, Figure 5.6 A2), however the 
relaxations at all effective concentrations were significantly smaller than those observed in 
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ileum, only reaching a maximally observed relaxation of 57.1 ± 3.4 % at 60 µM CDC (Figure 
5.6 A2). I propose that the relaxation induced by CDC did not occur through inhibition of 
lipoxygenase, as application of an alternative lipoxygenase inhibitor, Zileuton (10 μM), did 
not induce a significant change in tension in either CCh pre-contracted ileum (4.8 ± 1.3 %, 
n = 6, p = 0.70, Student’s paired t-test) or colon (6.2 ± 1.4 %, n = 6, p = 0.058, Student’s 
paired t-test) as shown in Figure 5.6 C1, C2. 
 
Similar to CDC, the TREK subfamily activator and COX inhibitor BL-1249 induced a 
concentration dependent decrease in muscle tension in both CCh pre-contracted ileum and 
colon (Figure 5.6 B2), with a predicted IC50 of 13.7 ± 1.4 µM (ileum, n = 6) and 60.8 ± 4.2 
µM (colon, n = 6).  Although relaxation induced by the highest concentration of BL-1249 
used (60 µM) was not maximal, it differed significantly between ileum and colon tissues 
(93.1 ± 1.2 % versus 56.1 ± 4.2 % respectively, n = 6, p <0.0001, two-way ANOVA followed 
by a Bonferroni multiple comparisons test).  
 
As BL-1249 induced a strong and significant relaxation effect in both ileum and colon, the 
mechanism of this drug became of interest. BL-1249 has been reported as a COX inhibitor, 
leading to enhanced intracellular arachidonic acid (AA) accumulation, and AA is a potent 
activator of TREK/TRAAK channels (Patel et al., 1998). To confirm whether the BL-1249 
activation of TREK subfamily channels and subsequent muscle relaxation was direct or due 
to enhancement of intracellular AA levels, I applied the broad spectrum COX-inhibitor 
aspirin (100 µM). Aspirin did not cause a significant change in tension in either CCh pre-
contracted ileum (5.3 ± 1.6 %, n = 6, p = 0.88, Student’s paired t test) or colon (2.0 ± 2.3 %, 
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n = 6, p = 0.95, Student’s paired t test) as shown in Figure 5.6 C1, C2, indicating that BL-
1249 activity was direct to reinforce this argument, I also assessed the effects of melittin, 
a PLA2 activator. Phospholipase A2 catalyses the hydrolysis of glycerophospholipids to 
liberate AA (Gijon and Leslie, 1999). Application of 10 µM melittin did induce a small and 
significant relaxation in ileum (21.4 ± 9.0 %, n = 6, p = 0.0054, Student’s paired t test, Figure 
5.6 C1), but not in colon (6.6 ± 5.4 %, n = 5, p = 0.38, Student’s paired t test, Figure 5.6 C2). 
Finally, I assess the effects of directly applying AA to CCh pre-contracted ileum and colon. 
Unexpectedly, application of 100 µM AA did not induce a significant relaxation in either 
ileum (0.85 ± 0.2 %, n = 6, p = 0.95, Student’s paired t test, Figure 5.6 C1) or colon (1.25 ± 
0.2 %, n = 6, p = 0.33, Student’s paired t test, Figure 5.6 C2).  
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Figure 5.6: Top panels, representative traces showing the time course of the addition of 
mechano-gated K2P channel activators 30 µM CDC (A1) and 60 µM BL-1249 (B1) to mouse 
ileum, pre-contracted with 10 µM carbachol (CCh). Scale bars represent 0.4g (vertical) and 
1 min (horizontal). Mean concentration-response relationships in CCh pre-contracted ileum 
(red triangles) and colon (blue circles) for Cinnamyl 1-3,4-dihydroxy-alpha-cyanocinnamate 
(CDC) (A2) and the fenamate BL-1249 (B2) are shown below the corresponding traces. All 
data was fitted with non-linear regression giving predicted IC50 of CDC (8.516 ± 0.97 μM in 
ileum versus 18.67 ± 3.539 μM in colon); BL-1249 (13.68 ± 1.372 μM in ileum versus 60.82 
± 4.18 μM in colon). Lower panels, Bar graph illustrating the relaxatory effects of mechano-
gated K2P channel activator arachidonic acid (AA), the phospholipase A2 activator melittin, 
COX inhibitors aspirin, and zileuton in both ileum (C1) and colon (C2), All data represents n 
= 6 animals, error bars represent standard deviation (SD), * p < 0.05, **p < 0.01, ****p < 
0.0001, two-way ANOVA followed by the Bonferroni post hoc test (A2 and B2), student’s 
paired t test (C1 and C2). 
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5.2.6 Relaxation induced by TREK activator BL-1249 can be attenuated by 
barium 
There is currently a lack of well characterised, specific TREK-1 inhibitors. However the non-
selective potassium channel pore blocker, barium chloride (Ba2+), has been shown to 
effectively inhibit TREK-1 channels with an IC50 of ~1 mM (Ma et al., 2011). I therefore 
tested the ability of the TREK-1 activator BL-1249 to relax CCh pre-contracted ileum and 
colon in the presence of 1 mM Ba2+. As might be predicted, addition of 1 mM Ba2+ 
significantly attenuated the relaxatory response to BL-1249 in both ileum (Fig. 5.7 A1) and 
colon (Fig. 5.7 A2). In ileum, 10 µM BL-1249 induced a mean normalised relaxation of 63.2 
± 12.3 % which was reduced almost by half to 32.1 ± 7.7 % in the presence of Ba2+ (p = 
0.0003, Student’s paired t-test). A similar effect was observed in colon were 30 µM BL-1249 
induced a mean normalised relaxation of 42.8 ± 5.3 % compared to 29.9 ± 5.0 % in the 
presence of 1 mM Ba2+ (p = 0.0143, Student’s paired t-test). To further  reinforce the notion 
that TREK-1 currents formed a significant component of the smooth muscle conductance 
in ileum and colon, I  investigated the ability of BL-1249 to relax CCh pre-contracted tissue 
in the presence of spadin, a proposed blocker of TREK-1 channels. Spadin has been recently 
described to exhibit high selectively to TREK-1 channels with an IC50 of ~100 nM (Mazella 
et al., 2010). Interestingly, the relaxation of CCh pre-contracted tissues induced by BL-1249 
(10 µM) persisted in the presence of 1 µM spadin; in ileum (Figure 5.7 B1), 59.8 ± 11.1 % 
(without spadin) vs. 54.8 ± 21.5 % (with spadin), n = 6, p = 0.3689, Student’s paired t-test. 
In colon (Figure 5.7 B2), 40.8 ± 2.0 % (without spadin) vs. 33.2 ± 8.5 % (with spadin), n = 6, 
p = 0.1259, Student’s paired t-test. 
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Figure 5.7: (A1) mean normalised relaxation in ileum to 10 µM BL-1249 in the absence (red 
bar) and presence (grey bar) of 1 mM barium chloride (Ba2+). (A2) mean normalised 
relaxation in colon to 30 µM BL-1249 in the absence (Blue bar) and presence (grey bar) of 
1 mM barium chloride (Ba2+). (B1) mean normalised relaxation in ileum to 10 µM BL-1249 
in the absence (red bar) and presence (grey bar) of 1 µM Spadin. (B2) mean normalised 
relaxation in colon to 30 µM BL-1249 in the absence (Blue bar) and presence (grey bar) of 
1 µM Spadin. All data represents n = 6 animals. Error bars represent standard deviation 
(SD), * indicates p = 0.0143, *** indicates p = 0.0003, student’s paired t test. 
 
5.2.7 Relaxation induced by mechano-gated K2P activators occurs via smooth 
muscle mechanisms  
To investigate further whether the activation of mechano-gated K2P channels influences 
intestinal contractions, we also applied the antidepressant drug riluzole and fenamate 
flufenamic acid (FFA) to CCh pre-contracted tissues. Both these compounds have been 
reported previously as activators of TREK channels (Duprat et al., 2000, Veale et al., 2014). 
Single concentration additions of the FFA (100 µM) and the riluzole (100 µM) induced 
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marked relaxations in CCh pre-contracted ileum and colon tissues, although to a lesser 
degree than those observed with BL-1249 and CDC (Figure 5.8 A; FFA, 63.3 ± 6.2% (ileum) 
and 41.1 ± 3.4 % (colon); riluzole, 37.1 ± 4.7 % (ileum) and 18.9 ± 4.0 % (colon). Consistent 
with our data obtained with CDC and BL-1249, the observed relaxations to FFA and Riluzole 
were significantly greater in ileum versus colon (Figure 5.8 A, n = 6, p <0.05, Student’s 
unpaired t-test). 
 
On the whole, data from all these functional pharmacological studies demonstrated a clear 
contribution of TREK-like channels to GI tract smooth muscle contractility. However, it was 
unclear whether the observed relaxations induced by K2P activators occurred at the level of 
the smooth muscle (via TREK-1) or potentially through modulation of neuronal input to 
smooth muscles, thus involving TREK-2/TRAAK. To clarify this, I performed drug additions 
in two separate experiments; (1) in tissues pre-contracted with potassium chloride (60 mM 
KCl) and (2) in tissues pre-contracted with CCh in the presence of tetrodotoxin (TTX).  
 
Isolated ileum and colon segments were pre-contracted with 60 mM KCl and the generated 
tension allowed to reach steady state before the addition of K2P activators. Changes in 
tension induced by addition of TREK-1 activators were normalised to steady-state pre-
contracted tension in each individual experiment and are reported as percent. On average 
60 mM KCl generated a tension of 0.6 ± 0.04 g in ileum and 0.8 ± 0.05 g in colon (both n = 
50). All mechano-gated K2P channel activators applied (riluzole, BL-1249, FFA and CDC) 
induced robust relaxations of KCl pre-contracted ileum and colon tissues (Figure 5.8 B) with 
BL-1249 and FFA producing significantly greater magnitudes of relaxation in ileum 
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compared to colon (n = 6, p = <0.05, Student’s unpaired t-test). In ileum, the extent of the 
relaxation induced by BL-1249, FFA and CDC was independent of the manner of pre-
contraction, however riluzole produced a significantly greater relaxation when the ileum 
was pre-contracted with KCl compared to CCh (72.1 ± 3.6 % versus 37.1 ± 3.9 %, n = 6, p < 
0.0001, Student’s unpaired t-test). This phenomenon was similarly observed in colon with 
riluzole (78.3 ± 5.2 %, KCl versus 18.9 ± 4.4 %, CCh, n = 6, p < 0.0001, Student’s unpaired t-
test) and CDC (76.2 ± 6.9 % in KCl versus 57.1 ± 3.3 % in CCh, n = 6, p = <0.01, Student’s 
unpaired t-test). 
 
These data are consistent with a direct smooth muscle effect. To reinforce this hypothesis 
I assessed the effects of a K2P activator in the presence of tetrodotoxin (TTX). TTX is a 
voltage-gated sodium channel blocker, which in this preparation has been previously 
shown to block neuronal action potentials and prevent ENS activity (Seifi et al., 2014). The 
relaxation of CCh pre-contracted tissues induced by BL-1249 (60 µM) persisted in the 
presence of TTX (1 µM); in ileum (Figure 5.8 C1), 91.1 ± 2.0 % (without TTX) versus 98.2 ± 
3.7 % (with TTX), n = 6, p = 0.038, Student’s paired t-test; in colon (Figure 5.8 C2), 63.6 ± 
2.9 % (without TTX) versus 64.8 ± 5.0 % (with TTX), n = 6, p = 0.74, Student’s paired t-test. 
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Figure 5.8: Bar graph showing mean normalised relaxation of CCh (A) and KCl (B) pre-
contracted ileum (red bars) and colon (blue bars) by Riluzole (100 µM), BL-1249 (30 µM), 
fluflenamic acid (FFA) (100 µM) and CDC (30 µM). (C1) mean normalised relaxation in ileum 
to 30 µM BL-1249 in the absence (red bar) and presence (grey bar) of 1 µM tetrodotoxin 
(TTX). (C2) mean normalised relaxation in colon to 60 µM BL-1249 in the absence (Blue bar) 
and presence (grey bar) of 1 µM tetrodotoxin (TTX). Error bars represent standard deviation 
(SD). All data represents n = 6 animals. * p< 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001, 
student’s unpaired t-test. 
 
 
5.2.8 Potassium channel modulators regulate the force but not frequency of 
spontaneous contractions 
Finally, in order to understand whether the activation or inhibition of potassium channels 
is able to directly influence physiological intestinal contractions, I applied the classical K+ 
channel blocker (TEA, Ba2+), KCNQ channel blocker/activator (XE991/retigabine), TASK 
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channel blocker (ML-365), and mechano-gated K2P channel activators (riluzole, BL-1249) to 
isolated mouse ileum and colon segments using the organ bath system and measured 
changes in the force and frequency of spontaneous contractions. Table 5.1 summarises the 
effects of the modulators used in regulating both frequency and force of spontaneous 
contractions. None of the compounds displayed a significant effect on the frequency of 
spontaneous contractions in ileum or colon. Furthermore, the TASK-1 channel blocker 
ML365 (Zou et al., 2010), only induced a significant increase in the force of spontaneous 
contractions in colon (0.04 ± 0.02 g versus 0.07± 0.01 g, n = 5, p = 0.0082, Student’s paired 
t-test) but not in ileum (0.13 ± 0.07 g versus 0.24± 0.13 g, n = 5, p = 0.07, Student’s paired 
t-test). 
 
Table 5.1: Summary table showing the effects of different K+ channel blockers and 
activators on both ileum and colon spontaneous contraction (n = 6 each condition). Key: 
↓=currents inhibited. ↑=currents increased. X =no effect 
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Riluzole (100 µM), significantly decreased the force of spontaneous contractions in ileum 
(0.19 ± 0.04 g versus 0.07 ± 0.01 g, n = 6, p = 0.0216, Student’s paired t-test, Figure 5.9, A2) 
and in colon (0.07 ± 0.01 g versus 0.03 ± 0.01 g, n = 6, p = 0.0074, Student’s paired t test, 
Figure 5.9 B2) and produced a noticeable reduction in basal tone as illustrated in the 
exemplar traces shown in Figure 5.9 A1, B1. Likewise, addition of BL-1249 (30 µM) 
significantly reduced the force of spontaneous contractions in ileum (0.14 ± 0.02 g versus 
0.06 ± 0.01 g, n = 7, p = 0.0030, Student’s paired t-test) but not colon (0.06 ± 0.02 g versus 
0.05± 0.02 g, n = 7, p = 0.0917, Student’s paired t-test) as shown in Figure 5.9 C2, D2 
respectively. Neither Riluzole nor BL-1249 had any significant effect of the frequency of 
spontaneous contractions in ileum or colon (Figure 5.9 A3, B3, C3 and D3).  
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Figure 5.9: Spontaneous contractions were recorded in the presence and absence of 100 
μM Riluzole (A and B panels) and 30 μM BL-1249 (C and D panels) in ileum (left) and colon 
(right) as indicated. Upper panels, representative traces show the effects of 100 μM 
Riluzole on the spontaneous contractile responses obtained from mouse ileum (A1) and 
colon (B1). Arrows signify reduction in basal tone. Mean data for force of contraction and 
frequency is displayed in chart form below the corresponding traces for ileum (A2 and A3) 
and for colon (B2 and B3). Lower panels, representative traces show the effects of 30 μM 
BL-1249 on the spontaneous contractile responses obtained from mouse ileum (C1) and 
colon (D1). Arrows signify reduction in basal tone. Mean data for force of contraction and 
frequency is displayed in chart form below the corresponding traces for ileum (C2 and C3) 
and for colon (D2 and D3). For traces, scale bars represent 0.2 g (vertical) and 30 s 
(horizontal) for panels A1 and C1, and 0.1 g (vertical) and 30 s (horizontal) for panels B1 
and D1. For bar charts, error bars represent standard deviation (SD); n = 6 animals. * p < 
0.05, **p < 0.01, student’s paired t-test. 
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5.3 Discussion  
The expression of specific potassium channel subunits, especially the mechano-gated K2P 
channels, on distinct cell types (smooth muscles and enteric neurons) of the mouse ileum 
and colon suggested a role for distinct potassium channel subtypes in modulating intestinal 
motility (Chapter 3 & 4). Functional and pharmacological evidence presented in this 
chapter reinforces this notion. The application of variety of specific potassium channel 
modulators induced contrasting effects on both force and frequency of spontaneous 
contraction and in pre-contracted tissues of the ileum and colon in organ bath experiments. 
Results showed that potassium channel activation was sufficient to induce significant 
relaxatory effects, whereas inhibition of potassium channel activity induced significant 
increases in tension in both ileum and colon. The implications are that multiple potassium 
channel subtypes play functional role in determining GI contractility.  
 
5.3.1 Kv channel subtypes have contrasting effects on the intestinal 
contractility 
Kv7 channels are appearing as major regulators of muscle contractility, particularly in 
cardiac muscle and vascular smooth muscle (Greenwood and Ohya, 2009). To date, 
research on the expression profile of Kv7 channels in smooth muscle has revealed that Kv7.4 
and Kv7.5 transcripts show abundant expression   and functionally are key regulators of 
smooth muscle contractility in the  vasculature of the stomach and intestine (Jepps et al., 
2009, Ipavec et al., 2011, Yeung et al., 2007). Since Kv7.1 channel transcripts displayed the 
highest relative expression of all Kv7 subfamily members in both ileum and colon, I focused 
my attention on the potential functional roles for these channels by using pharmacological 
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tools in organ bath preparation. Previously, retigabine has been reported as a potent 
agonist of Kv7 channels, specifically activating Kv7.2-7.5 but not Kv7.1 channels (Stott et al., 
2014, Schenzer et al., 2005). In contrast, Chromanol 293B blocks only Kv7.1 channels and 
not Kv 7.2-7.5 (Lerche et al., 2007), while XE991 blocks all heterologously expressed Kv7 
channels (Yeung et al., 2007). The combined influence of these three compounds on GI 
contractility suggests that Kv7.1 does not play a major functional role in mouse intestinal 
contractility. Indeed, Schroeder et al. (2000) previously highlighted Kv7.1 expression in the 
epithelium, and expression in murine colonic epithelium has been noted (Jepps et al., 
2009). In this same study, the authors utilised retigabine and XE991, demonstrating direct 
regulation of spontaneous contraction of the circular smooth muscle in mouse distal colon, 
and combined with immunohistochemical characterisation suggested Kv7.4 and Kv7.5 are 
important in regulating contractile activity in the GI tract. This correlates directly with my 
data revealing Kv7 channels, but not Kv7.1, also play an essential role in regulating the 
contraction of longitudinal smooth muscle in both mouse ileum and colon. Given that the 
accessory subunit transcript for KCNE3, encoding MiRP2, shows high expression in gut 
tissue, and when in complex with Kv7.1 forms a leak conductance, it is likely that the 
physiological role of Kv7.1 channels in GI tissue is in intestinal and tracheal chloride 
transport. 
 
It has been suggested that the  A-type currents in the GI smooth muscle are generated by 
Kv4 channels, and their inhibition increases smooth muscle excitability and contractility 
(Amberg et al., 2003). Consequently, the activation of A-type currents should have opposite 
effects, inducing smooth muscle relaxation. Recently, NS5806 has been reported as an 
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activator of Kv4 channels, and modulate channel gating depending on the presence of 
KChIP2 accessory subunit (Calloe et al., 2010, Lundby et al., 2010). NS5806 had little effects 
on current density and current decay of Kv4.2 and Kv4.3 in the absence of KChIP2, whereas 
it significantly increased current density and slowed the current decay for channel co-
expressed with KChIP2 (Lundby et al., 2010, Calloe et al., 2010). Moreover, co-expression 
of Kv4.3 with and without KChIP2 with DPP6, DPP10, KCNE2 or KCNE3 β-subunits 
corroborated that NS5806 only slowed current decay of channel complexes containing 
KChIP2 (Lundby et al., 2010). In contrast, for Kv4.1, the slowing of current decay by NS5806 
was independent of the KChIP2 subunit (Lundby et al., 2010, Witzel et al., 2012). The EC50 
of NS5806 in Kv4.3/KChIP2 was 25.4 ± 1.1 µM (Lundby et al., 2010), but at concentration 
over 100 µM an inhibition effect of current amplitude was observed in HEK293 cells (Witzel 
et al., 2012). Therefore, 50 µM NS5805 was selected for my organ bath preparation, and 
induced significant relaxation in both ileum and colon, although the relaxatory effect was 
smaller than that previously observed with Kv7 activator retigabine. The smaller effect 
could be due to a lower potency or efficacy of the Kv4 compound or a lower functional 
expression of Kv4 channels and therefore contribution to contractility. NS5806 has also 
been shown to inhibit Kv1.4 channel currents, and to a lesser extent, Kv1.5 channel currents 
(Lundby et al., 2010). Blockade of these Kv channels would promote contraction and 
counterbalance the relaxatory effect of Kv4 channel activation, thus partially masking the 
full impact of Kv4 channel currents to GI tract contractility. Moreover, both Kv1.4 and Kv1.5 
transcripts were shown to be expressed in ileum and colon as shown by my qPCR data. 
However, the combination of high transcript expression for Kv4.3, and ability for Kv4 
activator, NS5806, to induce relaxation in both ileum and colon, and previous studies in 
colonic myocytes by Amberg et al, 2002, strongly infer that Kv4.3 channels form a 
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physiologically important current in GI smooth muscle cells. However, given their lesser 
impact on relaxation compared to other channel subtypes, argues they are not first choice 
potential therapeutic targets for GI tract motility disorders. 
 
5.3.2 Both BK and SK channels play a role in the regulation of GI smooth 
muscle 
 Previous studies have revealed that SK protein are expressed in the GI muscular layer 
(Chen et al., 2004), whereas IK protein are mainly expressed in enteric neurons, in which 
they mediate the slow afterhyperpolarization (Neylon et al., 2004). To investigate the 
functional role of calcium-activated potassium channels in GI tract I studied the effects of 
the SK/IK channel openers [SKA-31 (Sankaranarayanan et al., 2009) and NS306 (Strobaek 
et al., 2004)] on murine intestinal contractility using the organ bath technique. The results 
presented in this chapter revealed that both SKA-31 and NS309 caused a significant 
reduction in CCh-induced contraction amplitude and muscle tone, suggesting that 
activation of the SK/IK channels is able to repolarise smooth muscle potential preventing 
further Ca2+ influx and therefore contraction. Both drugs were higher selectivity for IK over 
SK, and show no effect on BK channel activity (Strobaek et al., 2004, Sankaranarayanan et 
al., 2009), but the concentration I used was in the range to activate both IK and SK channels. 
Given the inability to distinguish the functional contributions of SK and IK channels here, it 
is difficult to identify how each channel contributes to smooth muscle relaxation. However 
a previous report by Ipavec & Curro (2015) reported that NS309 produced relaxatory 
effects in the pre-contracted proximal stomach smooth muscle which were not affected by 
the selective IK channel blocker TRAM-34, but were greatly inhibited by the selective SK 
202 
 
channel blocker UCL-1684. A similar phenomena was exhibited in human bladder smooth 
muscle  were the selective SK channel blocker apamin readily reversed the relaxatory effect 
induced by SKA-31, suggesting that SKA-31 inhibits bladder smooth muscle contractions 
mainly by its action on the SK channels (Soder et al., 2013). Thus, the role of IK/SK in 
intestinal smooth muscle may be similar to other types of smooth muscle in that IK/SK 
activators likely relaxes the GI contractility via SK activation. However, further studies using 
a similar pharmacological approach would have to be conducted in ileum and colon to 
conclusively determine the contribution of SK and IK channels individually to GI tract 
motility. 
 
Previous studies have revealed that activation of large conductance, calcium activated K+ 
channels (BK) channels reduced the spontaneous motor activity of the mouse ileum (Dela 
Pena et al., 2009), while inhibition of this channel increased the spontaneous contractile 
activity of ileum longitudinal muscle (Hong et al., 1997). Therefore, BK channels are 
proposed to have an important physiological role in regulating the smooth muscle 
contractility in the GI tract. My data presented here demonstrates that BK channel activator 
NS19504 could induce an almost complete relaxation of pre-contracted colon, and less so 
in ileum. This strong impact of BK channels in controlling contractile responses in smooth 
muscle tissues have also been recognised previously in bladder smooth muscle contraction 
(Nausch et al., 2014). The observed differences in relaxation effects of BK activation 
between ileum and colon could be explained by the differential transcript expression level 
along the GI tract, since I revealed the levels of BK transcript was higher in colon than in 
ileum (Chapter 3).  
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In order to provide evidence that the relaxatory effect of BK channel activation originated 
at the level of the smooth muscle I pre-contracted the tissue with potassium chloride (KCl). 
Increasing external KCl concentration shifts the reversal potential of potassium channel 
currents, as predicted by the Nernst equation to more depolarise potentials, thereby 
adjusting the resting membrane potential to amore depolarised potential. The 
depolarisation of the cell membrane directly activates plasma membrane L-type voltage-
gated Ca2+ channels, causing an influx of calcium to induce smooth muscle contraction. This 
mechanism is receptor independent, and therefore by passes neuronal input and any G 
protein coupled signalling pathways that normally determine cell contractile state. 
NS19504 caused a significant relaxation of ileum and colon tissues pre-contracted with KCl, 
suggesting that BK channel activation likely occurred at the level of the smooth muscle. To 
further reinforce the suggestion that the observed relaxation occurred via activation of BK 
channels, I investigated the impact of the known, but not specific, BK channel inhibitor TEA 
on the ability of the BK activator NS19504 to induce relaxation in both ileum and colon.  
TEA was chosen due to a lack of suitable alternative BK blockers. Charybdotoxin is a potent 
blocker of BK channels (Gribkoff et al., 1996), however it also inhibits the IK channel 
(Anderson et al., 1988). Iberiotoxin is another potent BK blocker, but it has been shown 
that it does not affect the resting membrane potential of colonic circular smooth muscle 
cells and does not induce contraction of the basally quiescent gastric fundus smooth muscle 
(Carl et al., 1995). Although TEA is not specific for BK, it does not inhibit SK and IK channels 
(Kew and Davies, 2010). Pre-exposure of TEA significantly attenuated the relaxatory 
response to the BK channel activator, NS 19504 in colon, providing further support for the 
suggestion that NS19504 likely relaxes the GI smooth muscle via BK activation. However, 
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that this response was not observed in ileum may suggest that NS19504 has modulatory 
effects on other channels other than BK.   
 
5.3.3 KATP channels may play a functional role in intestinal contractility 
In smooth muscle cells, intracellular ATP can directly regulate the activity of Kir6 (KATP) 
channels (Vogalis, 2000). Therefore, the open probability of these KATP channels is directly 
linked to the metabolic activity of the smooth muscle cells. A number of studies have 
confirmed the presence of KATP channels in GI smooth muscle. Koh et al. (1998) reported 
that the KATP channel agonist, cromakalim hyperpolarized membrane potential and 
reduced spontaneous contractility of mouse intestine. Together with the RT-PCR analysis 
the authors suggests that KATP channels are functionally expressed in mouse intestine and 
are formed by Kir6.2 and SUR2B subunits. Another study in muscle strips of mouse gastric 
fundus suggested that the relaxation induced by opening of KATP channels occurred mainly 
via smooth muscle cells and did not involve ENS input, since KATP channel agonists caused 
relaxation in KCl pre-contracted tissue (Sun and Benishin, 1994, Richardson et al., 1992, 
McPherson and Angus, 1990). In my study here using mouse ileum and colon, I found that 
KATP agonists (diazoxide & cromakalim) caused a small but significant relaxation in both pre-
contracted ileum and colon tissues and is consistent with these previous observations. It 
also parallels a previous study in rat, where another KATP opener, H2S was shown to cause 
a modest relaxation of small intestine and colonic smooth muscle (Lu et al., 2014). In the 
same study, the authors also provided immunohistochemical analysis revealing that both 
Kir6.1 and Kir6.2 were localised in smooth muscle layers.  
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The KATP agonist, cromakalim, has been shown to directly and reversibly activate KATP 
channels but has also been reported to activate Kv channels (McHugh and Beech, 1995) and 
inhibit L-type Ca2+ channels (Post et al., 1991), and would provide an explanation for the 
stronger relaxation to cromakalim compared to diazoxide in both ileum and colon. In 
addition, although not specific, Ba2+ is a potent blocker of KATP channel (Quayle et al., 1988).  
Application of Ba2+ in this study not only induced significant contraction, but also increased 
the force of smooth muscle spontaneous contraction. Together, this and previous data 
provide further support for the suggestion that KATP channels may play a functional role in 
intestinal contractility. However, the lack of selectivity makes the currently available KATP 
channel modulators unsuitable for the treatment of GI disorders.   
 
5.3.4 Pharmacological modulators of TREK family channels regulate 
intestinal contraction  
In chapters 3 and 4, I revealed the transcripts for all three mechano-gated TREK family 
channels, TREK-1, TREK-2 and TRAAK are expressed in the ileum and colon and that their 
channel proteins are localised in distinct cell types within the different layers of the wall of 
the GI tract. In support of my findings, I sought further pharmacological evidence for 
mechano-gated K2P function in intestinal contractility. I therefore assessed the repolarising 
power of documented mechano-gated K2P channel activators in pre-contracted tissues and 
during spontaneous contractile activity. This approach yielded strong evidence for a 
functional role of smooth muscle TREK-1 in murine GI tract, both under basal conditions 
and during smooth muscle relaxation. 
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Available data suggests all utilised compounds are potent activators of mechano-gated K2P 
channels. Riluzole has been shown to directly activate TREK-1, TREK-2 and TRAAK channels 
(Duprat et al., 2000), and CDC to activate TREK-1 (Danthi et al., 2004) at micromolar 
concentrations. Fenamates, non-steroid anti-inflammatory drugs, including BL-1249 and 
flufenamic acid (FFA) have been revealed to directly and reversibly activate TREK-1, TREK-
2 and TRAAK channels (Takahira et al., 2005, Veale et al., 2014). All four compounds 
produced comparable effects on pre-contracted ileum and colon tissues and have 
previously been used to describe functions of mechano-gated K2P channels in native tissues 
including sympathetic neurons (Cadaveira-Mosquera et al., 2011), dorsal root ganglion cells 
(Han et al., 2016), the blood brain barrier (Bittner et al., 2013), bladder (Tertyshnikova et 
al., 2005), and adrenocortex (Enyeart et al., 2002, Danthi et al., 2004).  
 
The relaxatory effect of BL-1249 after pre-contraction was stronger than that observed 
from exposure to FFA in both tissues, and is consistent with data from Veale et al. (2014) 
who revealed that BL-1249 is the most potent of the fenamates compounds for activating 
TREK-1 channel. However, fenamates are not ion channel specific compounds. Guinamard 
et al. (2013) provided an overview of different ion channels targeted by FFA to aid in 
interpreting its effects, including inhibition of L-type Ca2+ channels, chloride channels, 
transient receptor potential (TRPC) channels and activation of several types of potassium 
channels including Kv7.1 and BK, all of which are known to be expressed in GI tissues 
(Guinamard et al., 2013). For example, FFA has been shown to activate TRPC6 (Foster et 
al., 2009) and TRPA1 channels (Hu et al., 2010). TRPC channels are Ca2+-permeable non-
selective cation channels implicated in diverse physiological functions, including smooth 
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muscle contractility and synaptic transmission (Montell et al., 2002). Deletion of TRPC6 
channels in mice impairs smooth muscle contraction and intestinal motility in vivo 
(Tsvilovskyy et al., 2009). Therefore, the differential relaxatory effect between BL-1249 and 
FFA could also be potentially explained by FFA activation of TRPC6 channels which would 
resist the relaxatory response induced by activation of TREK channels. However, given that 
BL-1249 is a structurally-related drug to FFA, it may also affect other channels including TRP 
channels. Furthermore, the mechano-gated K2P activator AA was largely without impact, 
confounding the functional role of TREK channels in modulating GI contractility. However, 
AA is also not a selective compound and although a highly potent activator of TREK family 
channels, it also modulates a number of other ion channels and cellular targets including 
members of the Kv4 family. AA has been demonstrated to inhibit the A-type K+ currents 
formed by Kv4.2 when expressed in oocytes, and also native hippocampal A-type currents 
(Villarroel, 1993, Meves, 2008).  Given the prominent function of A-type currents in GI 
tissues, thought to be carried by Kv4 channels, it is plausible that the depolarising effect of 
AA inhibition of Kv4 channels would counterbalance the repolarising effects of activating 
TREK family channels, resulting in a minimal functional effect on GI tract contractility.  
 
Although the specificity of Riluzole, FFA, BL-1249 and CDC can be debated, it is clear that 
all four compounds have qualitatively similar effects on GI tract contractility that likely arise 
from modulation of a common target. In order to further reinforce the suggestion that the 
observed relaxations occur via activation of TREK channels, I took the further step of 
investigating the impact of the known TREK channel inhibitor barium and the proposed 
TREK-1 channel blocker, spadin, on the ability of the TREK activator BL-1249 to induce 
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relaxation in both ileum and colon. These blockers were chosen based on previously 
highlighted flaws with other characterised TREK channel blockers. For example, the 
proposed TREK-1 inhibitor, L-methionine, was used to demonstrate the functional 
presence of TREK channels in colonic myocytes (Park et al., 2005). However, it has since 
been argued that the effects of L-methionine in native tissue do not involve TREK-1 (Gil et 
al., 2012). Fluoxetine is another potent blocker of TREK-1 (Kennard et al., 2005), however 
its activity as a serotonin (5-hyroxytryptamine) reuptake inhibitor would modulate 
contractile activity in the GI tract through mechanisms independent of TREK-1 and 
therefore precluded its use. So even though barium is not a specific blocker of TREK 
channels, its mechanism of action is well characterised, its potency for TREK channels is 
reasonable (IC50 for TREK-1 block is ~ 1 mM (Ma et al., 2011) and given its mechanism is 
likely to only affect potassium channel activity, thus minimising the likelihood of off target 
effects. Pre-exposure of ileum and colon tissues to 1 mM barium attenuated the relaxatory 
response to the TREK activator, BL-1249, by 50 and 30% respectively, in line with what 
might be predicted, and provides further support for the suggestion that BL-1249 likely 
relaxes the GI smooth muscle via TREK channel activation. Interestingly, the relaxation 
induced by BL-1249 persisted in the presence spadin, which is a proposed TREK-1 blocker 
(Mazella et al., 2010). However, Gil et al. (2012) utilised spadin and observed no effect on 
colonic membrane potential or spontaneous motility. Mechanistically, it has currently only 
been shown to block AA-activated TREK-1 currents, and the specific molecular mechanism 
of action has not been described. Therefore its ability to prevent TREK-1 activation by 
riluzole, FFA, CDC and BL-1249 has not been established or confirmed.   
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5.3.5 Relaxation by mechano-gated TREK activators occurs via smooth 
muscle 
In spontaneous contraction studies, I found BL-1249 and riluzole both reduced the force of 
spontaneous contractions, without affecting their frequency. The frequency of 
spontaneous contraction in GI tract is mainly controlled by ICC (Yoneda et al., 2001) and I 
have no evidence that TREK channels are expressed here, but the ineffectiveness of TREK 
channel activators on frequency suggests they are not likely expressed in ICC. However, 
TREK compounds affect the force of contraction suggests it may take place to modulate the 
intestinal contractions via multiple and distinct mechanism. For example, it may either be 
acting directly on enteric neurons or regulating the amount of calcium allowed to enter the 
cell to change the amplitude of the contractions. Since, I demonstrated in previous chapter 
that TREK channel subtypes localised in different cell types, it would be beneficial to 
understand which particular cellular pathway of TREK channels modulates the contractile 
process. 
 
In order to investigate whether the relaxatory effect of the activators originated at the level 
of the smooth muscle we pre-contracted with potassium chloride. In the case of Riluzole, 
the relaxatory effect was stronger than that previously observed with CCh pre-contraction. 
This differential effect could be explained by activation of nitrenergic neurons as I revealed 
TREK-2 and TRAAK expression in enteric neurons in Chapter 4, which would counteract the 
relaxatory response at the smooth muscle. This would also provide an explanation for the 
enhanced relaxation to BL-1249 observed during neuronal action potentials blockade via 
TTX. Alternatively, the mechanism of pre-contraction could also be influential. Carbachol, 
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a parasympathomimetic, activates metabotropic muscarinic receptors inducing 
contraction via: (1) transmembrane calcium influx through TRPC channels, (2) subsequent 
transmembrane calcium influx via voltage-dependent calcium channels (VDCC) and (3) SR 
calcium release (Ambudkar, 2009). When using KCl as the contractile stimulus, only 
transmembrane calcium influx via VDCC occurs and calcium influx through TRPC channels 
and SR calcium release would not occur. Thus the use of TREK activators would be expected 
to modulate the membrane potential driven calcium influx through VDCC (receptor 
independent) and therefore might appear less efficacious in CCh pre-contracted tissues. 
 
5.4 Summary and Conclusions 
Overall, these data suggest that the relaxation induced by activation of mechano-gated K2P 
channels is independent of enteric neuron input and therefore likely occurs at the level of 
the smooth muscle. Given that the localisation studies I presented in Chapter 4 clearly 
highlight that TREK-1 was the only TREK family channel member expressed in smooth 
muscle layers, strongly suggests that pharmacological modulators of mechano-gated TREK 
channels likely act on TREK-1 to regulate the GI smooth muscle contractility. Therefore 
TREK-1 channels represent a favourable pharmacological/therapeutic target for treating 
hypermotility disorders. 
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Chapter 6 – Biophysical and 
pharmacological characterisation of 
TREK channels 
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6.1 Introduction and Aims 
In Chapter 5, I provided evidence that TREK-1 channels may play an important functional 
role in mouse intestine, with their pharmacological activation resulting in smooth muscle 
relaxation. However, verification was constrained by a lack of well-defined K2P modulators 
and species specific pharmacology. I utilised a number of defined TREK family activators, 
however a number of these have been shown to modulate other ion channels, some of 
which may be expressed in GI tissues. Likewise, demonstrating the specificity of the 
activators in the GI tract was hampered by a lack of specific TREK family channel blockers. 
For example, BL-1249 induced a potent GI tract relaxation in pre-contracted ileum and 
colon, and has been shown previously to activate all mechano-gated TREK  channels 
(including TREK-1, TREK-2 and TRAAK), although BL-1249 external application exhibit 
different selectively with different EC50 to  members of the TREK subfamily (Pope et al., 
2018). Spadin has been proposed to be a specific TREK-1 blocker (Mazella et al., 2010), but 
I observed no effect on either spontaneous contractility or in inhibiting relaxation induced 
by BL-1249 in my organ bath studies. This brought into question whether spadin is indeed 
a blocker of TREK-1 and whether its mechanism of block would be expected to prevent the 
activity of BL-1249. Further to this, the inhibitory effects of spadin have only been studied 
in AA-activated TREK-1 currents, and its impact on TREK channel currents activated by other 
chemical compounds are currently lacking. Therefore, the aim of this chapter was to 
investigate the pharmacological specificity and the inhibition activity of spadin in the 
presence of different chemical activators of the mechano-gated K2P channels TREK-1, TREK-
2 and TRAAK. Channels were overexpressed in Xenopus oocytes and ion channel mediated 
potassium currents measured using the two-electrode voltage clamp technique. 
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Furthermore, given that mouse tissue had been used through my whole project, for 
consistency the mouse homologues of the three TREK channels were used to allow direct 
comparison to other data in my thesis. However, the cloned mouse channels have not been 
described previously and so in the first instance, their biophysical phenotypes were sought.  
 
6.2 Results 
6.2.1 Biophysical characterisation of mouse TREK-1, TREK-2 and TRAAK 
channels 
Xenopus laevis oocytes were injected with 2-10 ng of cRNA encoding the mTREK-1 and 
mTREK-2 channels and 20 ng of cRNA encoding the mTRAAK and assessed using TEVC. To 
obtain a comprehensive picture of mTREK-1, mTREK-2 and mTRAAK channels, I measured 
currents in response to 1-s voltage steps (from -120 to +60 mV). Robust ionic currents were 
recorded in standard bath solution containing 4 mM K+ from both mTREK-1 (Figure 6.1, A1) 
and mTREK-2 (Figure 6.1, B1) expressing oocytes, but were very small in mTRAAK (Figure 
6.1, C1) expressing oocytes. In addition, significant currents were not observed in un-
injected oocytes. The phenotype of all three channel currents resembled that of 
characterised human K2P channels, displaying no time-dependent activation, strong 
outwardly rectifying currents in physiological solutions, with minimal inward currents 
observed in 4 mM K+. However, when the external K+ concentration ([K+]out) was increased 
to 20 mM, 100 mM and 140 mM K+ respectively, the I-V curves were shifted rightwards, 
and prominent inward currents were revealed upon hyperpolarization below EK for all 
three channels (Figure 6.1, A2, B2 & C2). The experimental data aligns with that predicted 
by the Goldman Hodgkin-Katz current equation at different [K+]out concentrations, a 
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phenomenon described previously in other cloned K2P channels. Increasing extracellular 
K+ concentration from 4 mM to the highest concentration of 140 mM induced a shift in the 
voltage threshold at which outward ionic currents could be observed. A plot of the reversal 
potential as a function of [K+]out  is shown for each channel in Figure 6.1 (A3, B3 and C3). 
showed that the slope was  47.3 ± 2.2 mV (mTREK-1; n = 7), 49.4 ± 0.4 mV (mTREK-2; n = 8) 
and 45.3 ± 3.5 mV (mTRAAK; n = 8), which all close to the calculated Nernst value of 58 mV 
at 20°C, indicating these three channels continue to permit the passage of K+ ions as 
expected for a highly selective K+ channel. 
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Figure 6.1. Biophysical characterisation of mTREK-1 (A1-A3), mTREK-2 (B1-B3) and mTRAAK 
(C1-C3). Currents of mTREK-1 (A1), mTREK-2 (B1) and mTRAAK (C1) elicited by voltage 
pulses from -120 to +60 mV in 10 mV steps, 1 s in duration, from a holding potential of -80 
mV, in low K+ solutions (4 mM) or high K+ solutions (140 mM). In each panel, scale bars 
represent 2 μA and 100 ms. The 0 mV current level is indicated by red dashed line.  Mean 
current-voltage (I-V) relationships taken from steady-state currents in the presence of 
differing concentrations of extracellular K+; 4 mM (blue), 20 mM (red), 100 mM (green) and 
140 mM (purple) for mTREK-1 (A2, n = 7), mTREK-2 (B2, n = 8) and mTRAAK (C2, n = 8). 
Reversal potentials of mTREK-1 currents (A3), mTREK-2 currents (B3) and mTRAAK currents 
(C3) were plotted as a function of [K+]out  (mean ± SD). Data points are fitted with a linear 
relationship (red line). Dashed line represents Nerstian theoretical linear relationship of EK 
with changing [K+]o as calculated using the Nernst equation assuming [K+]i is 140 mM (slope 
= -58.2 mV).   
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6.2.2 Mutation of predicted SUMOylation sites in mTRAAK channel did not 
increase channel activity 
mTRAAK generated only very small ionic currents at the voltages test, at cRNA 
concentrations of 20 ng/23 nl and incubation duration of up to 72 hours. Low activity of 
human TRAAK when expressed heterologously has been described previously (Soussia et 
al., 2018). The related K2P channel, TWIK-1, has also been shown to be problematic when 
overexpressed in Xenopus oocytes or mammalian cells and its activity at the plasma 
membrane has been proposed to be influenced by sumoylation of a critical lysine residue 
in its C-terminus. Mutation of K274 to either an arginine, glutamine, tyrosine or cysteine, 
prevents sumoylation by SUMO protease (Rajan et al., 2005) and generates robust, 
functional currents. Thus, I hypothesised whether mTRAAK activity was also similarly 
controlled by sumoylation in Xenopus oocytes. Analysis of the mTRAAK sequence using 
sumolyation prediction software (GPS-SUMO) highlighted positions K38 (p = 0.072) and 
K330 (p = 0.047) respectively as highly probably sumoylation sites. Both sites were 
independently mutated to glutamine (Q) and expressed in oocytes. However, neither K38Q 
(0.80 ± 0.17 μA versus 0.97 ± 0.40 μA, p = 0.2314, Student’s paired t-test, Figure 6.2 A2) or 
K330Q (0.80 ± 0.17 μA versus 0.79 ± 0.38 μA, p = 0.9512, Student’s paired t-test, Figure 6.2 
B2) mutation produced a significant increase in channel currents, even after prolonged 
expression durations (up to 72 hours) and injection of high cRNA concentrations (up to 20 
ng/23 nl). Given the low functional activity of mTRAAK channels and the inability to increase 
activity through mutations, it was decided that mTRAAK channel currents would not be 
used further in this study. However, given time it would be useful in the future to address 
the low functional expression of this channel. I would be particularly interested to label 
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mTRAAK channel proteins and to assess their expression levels at the surface of the cell 
membrane using biotinylation and Western blot techniques. 
 
 
Figure 6.2. Exemplar currents of sumoylation mutations of mTRAAK channel; in the N-
terminus K38Q (A1) and the c-terminus K330Q (B1). Currents were elicited by voltage 
pulses from -120 to +60 mV in 10 mV steps, 1 s in duration, from a holding potential of -80 
mV, in recording solution with concentration 4 mM K+. In each panel, scale bars represent 
0.4 μA of current and 100 ms time. The red dashes line indicated the current at -80 mV to 
point zero current. A2 and B2 indicate mean steady-state current-voltage (I-V) relationship 
for WT mTRAAK (black) and K38Q mutation and K330Q mutation (red) respectively.  
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6.2.3 Pharmacological characterisation of mTREK-1 and mTREK-2 channels 
Given the pharmacological results from my previous organ bath investigations, I felt it 
pertinent to establish a clear pharmacology profile of mTREK-1 and mTREK-2 channels, and 
therefore decided to expose mTREK-1 and mTREK-2 channels heterologously expressed in 
Xenopus oocytes to previously characterised human TREK family pharmacological agents 
(e.g. activators AA, BL-1249, CDC, and the blocker Ba2+). AA is a well-established activator 
of mammalian K2P channels, having been shown to activate currents in all TREK family 
subtypes (Fink et al., 1996, Bang et al., 2000, Lesage et al., 2000). BL-1249 has been shown 
to greatly increase hTREK-1 currents at 1 μM (Veale et al., 2014), whereas CDC has been 
shown to be a potent activator of bTREK-1 channels at a concentration of 10 μM (Danthi et 
al., 2004). It was important to establish whether extracellular application of these 
regulators would elicit a response in mouse homologues of TREK channels. Figure 6.3 
shows representative whole-cell current traces and I-V relationship curve of mTREK-1 in 
both control (4K+ solution) alone and in the presence of 10 μM AA (Figure 6.3 A), 1 μM BL-
1249 (Figure 6.3 B), 10 μM CDC (Figure 6.3 C) and 1mM Ba2+ (Figure 6.3 D). mTREK-1 
currents at 0 mV were significant increased by application of AA (256.8 ± 6.7 %, n = 8, p = 
0.0005, Student’s paired t-test), BL-1249 (392.9 ± 29.5 %, n = 9, p = 0.0003, Student’s paired 
t-test) and CDC (307.8 ± 10.1 %, n = 8, p < 0.0001, Student’s paired t-test) respectively 
(Figure 6.5 A). Application of 1 mM Ba2+  exhibited a significant reduction of mTREK-1 
currents, with an inhibition of 56.1 ± 1.4 % at 0 mV compared to control (n = 7, p < 0.0001, 
Student’s paired t-test; Figure 6.5 A).  
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Figure 6.3: TEVC measurements of mTREK-1 in different TREK pharmacological modulators. 
(A1-D1) Whole-cell current measurements taken from Xenopus laevis oocytes in 4 mM KCl 
(Control) and AA (10 μM), BL-1249 (1 μM), CDC (10 μM) and Ba2+ (1 mM). (A2-D2) Mean 
steady-state current-voltage (I-V) relationship for mTREK-1 control (Black) and drug (Red).  
 
Similar activation and inhibition effects were observed in mTREK-2 channel. Figure 6.4 
shows representative whole-cell current traces and I-V relationship curve of mTREK-2 in 
both control (4K+ solution) alone and in the presence of 10 μM AA (Figure 6.4 A), 3 μM BL-
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1249 (Figure 6.4 B), 10 μM CDC (Figure 6.4 C) and 1mM Ba2+ (Figure 6.4 D) respectively. 
Application of 10 μM AA induced a significant augmentation of mTREK-2 currents 
compared to control at 0 mV, with an increase of 265.77 ± 6.5 % (n = 6, p < 0.0001, Student’s 
paired t-test; Figure 6.5 B). Application of 3 μM BL-1249 exhibited a significant activation 
in mTREK-2 currents, with an increase of 378.2 ± 42.5% (n = 9, p = 0.005, Student’s paired 
t-test; Figure 6.5 B). Measurement of the concentration-response curves for BL-1249 
activation of mTREK-1 and mTREK-2 channels is displayed in Figure 6.6 A. Concentration-
response curves did not saturate and therefore EC50 was not estimated. The data suggest 
that extracellular application of BL-1249 activates both mechano-gated TREK-1 and TREK-
2 channels, having a more potent effect on TREK-1. Application of 10 μM CDC exhibited a 
significant enhancement of mTREK-2 currents, with an increase of 333.7 ± 19.3 % at 0 mV 
compared to control (n = 6, p = 0.0006, Student’s paired t-test; Figure 6.5 B). Construction 
of concentration-response curves for mTREK-1 and mTREK-2 to extracellular application of 
CDC (Figure 6.6 B) revealed similar effects with currents size augmentation at the highest 
concentration of CDC (30 μM) being 3.3 ± 0.4 μA and 3.7 ± 0.5 μA for mTREK-1 and mTREK-
2, respectively. Similar to mTREK-1, mTREK-2 currents recorded at 0 mV exhibited 
significant decrease in the presence of 1 mM Ba2+ (55.5 ± 3.4 %  of inhibition, n = 7, p = 
0.0004, Student’s paired t-test; Figure 6.5 B). These results demonstrated that mTREK-1 
and mTREK-2 possess a similar pharmacological phenotype as their human counterparts, 
and can be activated by AA, BL-1249 and CDC, and inhibited by barium. 
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Figure 6.4: TEVC measurements of mTREK-2 in different TREK pharmacological modulators. 
(A1-D1) Whole-cell current measurements taken from Xenopus laevis oocytes in 4 mM KCl 
(Control) and AA (10 μM), BL-1249 (1 μM), CDC (10 μM) and Ba2+ (1 mM). (A2-D2) Mean 
steady-state current-voltage (I-V) relationship for mTREK-2 control (Black) and drug (Red). 
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Figure 6.5: Mean normalized activation (%) of AA, BL-1249, CDC and Ba2+ in mTREK-1 (A) 
and mTREK-2 (B) currents measured at 0 mV. Dashes line indicated the basal line, data 
below the line means the inhibition effects. Error bars represent SD. All data represents n 
> 6 oocytes.  ***P < 0.001, ****P < 0.0001, Student’s paired t-test.  
 
 
 
Figure 6.6: External application of BL-1249 and CDC selectively activates mechano-gated 
TREK channels. (A) BL-1249 dose-response curves for mTREK-1 (blue circles), mTREK-2 
(green triangles), (n=9 in both). (B) CDC dose-response curves for mTREK-1 (blue circles), 
mTREK-2 (green triangles). (n=8 and 6 respectively). 
 
 
 
223 
 
6.2.4 Spadin does not block baseline or AA-activated mTREK-1 channels 
Spadin has been proposed to be a blocker of TREK-1 channels, with 100 nM spadin 
apparently blocking 63 ± 12 % of the hTREK-1 current after stimulation by AA (Mazella et 
al., 2010). However, application of 1 μM spadin exhibited no effects in my previous organ 
bath study and led me to speculate whether the published effects were possibly species 
specific or channel specific and what the mechanism of action of this compound might be. 
Therefore, the effects of spadin were studied on the mTREK-1 channel expressed in 
Xenopus oocytes using TEVC. Firstly, I wanted to see if I could recapitulate previous findings 
using the mouse homologue, so mTREK-1 channels were activated with 10 μM AA and 
when the current amplitude stabilised I measured the ability of 1 μM spadin to inhibit the 
mTREK-1 channel activity (time scale of this effect shown in Figure 6.7 A1). Spadin did not 
significantly affect the amplitude of AA-activated mTREK-1 measured at 0 mV (Figure 6.7 
A2). Values of current density were 1.9 ± 0.1 μA (AA activated current, n = 8) and 2.1 ± 0.1 
μA (AA activated current + spadin, n = 8). Furthermore, mTREK-1 basal channel activity was 
also insensitive to spadin, with channel currents at 0 mV measured as 1.4 ± 0.1 μA (control 
mTREK-1 current, n = 12) versus 1.5 ± 0.1 μA (in the presence of 1 μM spadin, n = 12) (Figure 
6.7 B2). 
 
6.2.5 Spadin specifically antagonises AA-activation of mTREK-1 channels 
Given that spadin was not a blocker of mTREK-1, I decided to investigate whether spadin 
could antagonise AA-activation of mTREK-1 channels. Oocytes were incubated for 5-10 
mins in bath solution containing 1 μM spadin before subsequent addition of 10 μM AA 
(time scale of this experiment shows in Figure 6.7 B1). Pre-application of 1 μM spadin 
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significantly perturbed the activation of mTREK-1 channels by AA by 52.2 ± 14.7% (n = 12, 
p < 0.0001, one-way ANOVA) (Figure 6.7 B2). Full activation of mTREK-1 channels was 
observed after removal of spadin. These data suggest that spadin does not block mTREK-1 
channels, but rather antagonises its activation by AA. 
 
In order to further investigate the action of spadin on mTREK-1 channels, I wanted to assess 
the effects of spadin in the presence of another PUFA to assess the specificity of spadin 
activity.  DHA is a related PUFA and has been reported activated TREK-1 channels (Patel et 
al., 2001). Application of 10 μM DHA exhibited a significant enhancement of mTREK-1 
currents, with an increase of 2.3 ± 0.2-fold at 0 mV compared to control (n = 6, p = 0.0003, 
one-way ANOVA; Figure 6.7 C). However, 1 μM spadin did not affect the current amplitude 
measured at 0 mV of the DHA-activated mTREK-1 currents (Figure 6.7 C 2.6 ± 0.2 μA (DHA 
activated current, n = 6) versus 2.9 ± 0.3 μA (DHA activated current + spadin, n = 6, p = 0.53, 
one-way ANOVA). Moreover, spadin did not prevent the DHA stimulation of mTREK-1 
currents (Figure 6.7 D). At membrane potential of 0 mV, currents were 3.0 ± 0.3 μA versus 
3.3 ± 0.2 μA in the presence (n = 7) and absence respectively of spadin (n = 7, p = 0.88, one-
way ANOVA).  
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Figure 6.7: Effects of spadin on the mTREK-1 channel activity. (A1, B1) show time series 
plot of currents at 0 mV evoked from oocytes by adding spadin (1 μM) before the AA-
activation and after the AA-activation. (A2, B2) I-V plots for effects of spadin in mTREK-1 
currents. A2, currents were recorded after mTREK-1 AA-activation by 10 μM arachidonic 
acid (AA) and AA + spadin (1 μM) (n = 8). B2, currents were recorded in absence (control) 
and in presence of spadin (1 μM), followed by AA (10 μM) + spadin (1 μM) and then AA (10 
μM) (n = 12). (C-D) Mean current amplitudes recorded at 0 mV with bath conditions 
(control; 4 K+) and following treatment with the agents spadin (1 μM), DHA (10 μM) and 
DHA + spadin (1 μM). The effects of spadin after DHA-activation shows in (C, n = 6), before 
shows in (D, n = 7). Error bars represent SD, ***P < 0.001, ****P < 0.0001, one-way ANOVA 
followed by Tukey’s multiple comparisons test. 
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Given the clear results and the conflict with previous findings I decided to investigate 
whether spadin shows same activity in human TREK-1 channels under the same conditions. 
Similar effects were observed in hTREK-1 channel (Figure 6.8), application of 1 μM spadin 
did not inhibit AA-activated currents at 0 mV; 3.6 ± 0.3 μA (AA-activated current, n = 8) and 
3.9 ± 0.5 μA (AA-activated current + spadin, n = 8, p = 0.16, one-way ANOVA; Figure 6.8 A). 
Nor did 1 uM spadin block the hTREK-1 channel basal current at 0 mV, which were 
measured as 2.4 ± 0.3 μA (without spadin, n = 10) and 2.4 ± 0.4 μA (with spadin, n = 10, p = 
0.99, one-way ANOVA; Figure 6.6, B).Furthermore, pre-application of 1 uM spadin 
significantly antagonised AA-activation of hTREK-1 at 0 mV by 67.9 ± 18.6% (n = 10, p < 
0.0001, one-way ANOVA; Figure 6.8 B).  Therefore, I conclude that the mechanism of action 
of spadin involves antagonism of AA-activation of TREK-1 channels, a mechanism that 
appears to be lipid specific. 
 
Figure 6.8:  Effects of spadin on hTREK-1 channel activity. Mean currents were recorded at 
0 mV. (A) shows the effect of 1 μM spadin applied after AA-activation of hTREK-1 currents 
(n = 8). (B) displays the effect of 1 μM spadin applied before AA-activation of hTREK-1 
currents (n = 10). Error bars represent SD, ****P < 0.0001, one-way ANOVA followed by 
Tukey’s multiple comparisons test. 
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6.2.6 Spadin does not affect AA-activation of mTREK-2 channels 
Given the effects of spadin on human and mouse TREK-1 channels, and the close 
biophysical phenotypes of TREK-1 and TREK-2, the effects of spadin were tested on mTREK-
2 channels. Figure 6.9 shows that 1 μM spadin was unable to block mTREK-2 channel 
activated by AA (Figure 6.9 A2); currents measured at 0 mV were 3.1 ± 0.1 μA and 3.3 ± 0.1 
μA in the absence (n = 7) or presence of spadin (n = 7) respectively. Again, spadin alone 
failed to inhibit mTREK-2 currents under standard bath conditions. The current densities 
measured at 0 mV were 2.2 ± 0.1 μA (control mTREK-2 current, n = 10) and 2.3 ± 0.1 μA (in 
the presence of spadin, n = 9, p = 0.99, one-way ANOVA; Figure 6.9 B2). Furthermore, it 
was observed that the antagonistic effect of spadin on AA-activation in mTREK-1 channels 
was absent in mTREK-2 channels (Figure 6.9 B1, B2). Pre-application of 1 μM spadin showed 
a small antagonization of the AA activation of mTREK-2 at 0 mV by 25.8 ± 23.11 %, but this 
is not statistically significant (n = 9, p = 0.99, one-way ANOVA; Figure 6.9 B2).  
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Figure 6.9. Effects of spadin on the mTREK-2 channel activity. (A1, B1) show time series 
plot of currents at 0 mV evoked from oocytes by adding spadin (1 μM) before the AA-
activation and after the AA-activation. (A2, B2) I-V plots for effects of spadin in mTREK-2 
currents. A2, currents were recorded after mTREK-2 AA-activation by 10 μM arachidonic 
acid (AA) and AA + spadin (1 μM) (n = 7). B2, currents were recorded in absence (control; 4 
K+) and in presence of spadin (1 μM), followed by AA (10 μM) + spadin (1 μM) and then AA 
(10 μM) (n = 9). Error bars represent SD, *P < 0.05, ****P < 0.0001, one-way ANOVA, 
followed by Tukey’s multiple comparisons test. 
 
6.2.7 Spadin does not antagonise other known activators of TREK channels 
To investigate whether spadin also influences the activation of mTREK-1 and mTREK-2 
channels induced by other TREK family agonists, I applied spadin to mTREK-1 and mTREK-2 
before the addition of the cyclooxygenase (COX) inhibitor BL-1249 or CDC. Neither 
activation of mTREK-1 nor mTREK-2 currents by BL-1249 were significantly antagonised by 
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pre-exposure to 1 μM spadin. Values of current density recorded at 0 mV were [Figure 6.10 
A; mTREK-1, 3.3 ± 0.2 μA (1 μM BL-1249 with spadin) and 3.5 ± 0.2 μA (1 μM BL-1249 
without spadin), n = 10, p = 0.74, one-way ANOVA; Figure 6.10 B; mTREK-2, 2.8 ± 0.1 μA (3 
μM BL-1249 with spadin) and 2.9 ± 0.2 μA (3 μM BL-1249 without spadin), n = 10, p = 0.93, 
one-way ANOVA]. Consistent with our data obtained with BL-1249, the observed activation 
of CDC (10 μM) recorded at 0 mV was not antagonised by spadin in either mTREK-1 currents 
(Figure 6.10 C) or mTREK-2 currents (Figure 6.10 D). The mean values of currents in mTREK-
1 channel were measured as 3.4 ± 0.1 μA (10 μM CDC with spadin, n = 10) and 3.7 ± 0.2 μA 
(10 μM CDC without spadin, n = 10, p = 0.35, one-way ANOVA). The mean values of currents 
in mTREK-2 channel were measured as 2.8 ± 0.2 μA 10 μM CDC with spadin, n = 8) and 3.1 
± 0.3 μA (10 μM CDC without spadin, n = 8, p = 0.56, one-way ANOVA). Therefore, I conclude 
that neither BL-1249 nor CDC activation of mTREK-1 and mTREK-2 channels was 
antagonised by spadin.  
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Figure 6.10. Effects of spadin on BL-1249/CDC-activation of mTREK-1 and mTREK-2 
channels activity. Mean currents of mTREK-1 (A, n = 10) and mTREK-2 (B, n = 10) measured 
at 0 mV with bath conditions (control; 4 K) and following treatment with the agents spadin 
(1 μM); BL-1249 (1 μM in mTREK-1 and 3 μM in mTREK-2) + spadin (1 μM); and BL-1249 on 
its own (1 μM in mTREK-1 and 3 μM in mTREK-2). As above, currents of spadin + CDC (10 
μM) at 0 mV were recorded before the activation of 10 μM CDC in mTREK-1 (C, n = 10) and 
mTREK-2 (D, n = 8). Error bars represent SD, **P < 0.01, ****P < 0.0001, one-way ANOVA. 
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6.2.8 Ba2+ blocks both AA and BL-1249 activation of mTREK-1 and mTREK-2 
channels 
To confirm that activated TREK-1 channels could be inhibited I applied Ba2+ to AA and BL-
1249 activated mTREK-1 and mTREK-2 currents. As expected, in mTREK-1 currents 
measured at 0 mV, 1 mM Ba2+ significantly blocked AA-activated currents by 46.2 ± 5.3% 
(currents from 2.23 ± 0.1 μA reduced to 1.23 ± 0.1 μA, n = 8, p < 0.05, Student’s paired t-
test; Figure 6.11 A1) and BL-1249 activation by 39.1 ± 3.0 % (currents from 2.6 ± 0.1 μA 
reduced to 1.6 ± 0.1 μA, n = 10, p < 0.05, Student’s paired t-test; Figure 6.11 A2). In mTREK-
2 currents measured at 0 mV, 1 mM Ba2+ significantly blocked AA-activation in 37.2 ± 5.5% 
(currents from 2.81 ± 0.1 μA reduced to 1.8 ± 0.1 μA, n = 6, p < 0.05, Student’s paired t-test; 
Figure 6.11 B1) and BL-1249 activation in 35.5 ± 4.2% (currents from 2.1 ± 0.2 μA reduced 
to 1.3 ± 0.1 μA, n = 9, p < 0.05, Student’s paired t-test; Figure 6.11 B2). These data confirm 
that the known pore blocker Ba2+ is able to block both AA and BL-1249 activated mTREK-1 
and mTREK-2 currents and helps to reinforce the notion that spadin is not a blocker of 
mTREK-1 channels. 
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Figure 6.11. Effects of Ba2+ on the mTREK-1 and mTREK-2 channel activity. Mean currents 
of Ba2+ + AA and Ba2+ + BL-1249 were measured at 0 mV after pre-activation of mTREK-1 by 
10 μM AA (A1, n = 8) and 1 μM BL-1249 (A2, n = 10). Mean currents for mTREK-2 at 0 mV 
showing effects of 1 mM Ba2+ after 10 μM AA (B1, n = 6) and 3 μM BL-1249 (B2, n = 9) 
activation. Error bars represent SD. * P < 0.05, ***P < 0.001, ****P < 0.0001, Student’s 
paired t-test. 
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6.2.9 Spadin antagonism does not involve the C-terminus of mTREK-1 
Gating stimuli detected by sensors in various parts of the channel converge on the K2P 
selectivity filter C-type gate (Schewe et al., 2016, Lolicato et al., 2017). Previous evidence 
suggests the C-terminal domain is the sensor for TREK-1 activation by both physiological 
and chemical activators (Honore et al., 2002, Lotshaw, 2007, Chemin et al., 2007). Notably, 
previous research infers AA binds on the proximal c-terminus to activate the TREK channels 
(Patel et al., 1998). Therefore, we hypothesised spadin may share the same/similar binding 
site as AA in order to specifically antagonise AA activation of TREK-1 channels. Given the 
insensitivity of mTREK-2 channels to spadin, I generated a mTREK-2/TREK-1 chimera 
construct consisting the N-terminus and 4 transmembranes of mTREK-2 and C-terminus of 
mTREK-1 (Figure 6.12 A). The hypothesis was that if spadin bound to the c-terminus of 
TREK-1 to antagonise AA-activation, transfer of this domain to the insensitive mTREK-2 
channel should also transfer spadin sensitivity.  TEVC experiments showed that this chimera 
formed a functional channel generating robust currents analogous to the parental mTREK-
1 and mTREK-2 channels (Figure 6.12 B, C). Plotting reversal potential in different external 
K+ concentrations generated a Nernstian slope of 43.7 ± 2.9 mV (n = 6), which was close to 
that predicted by the Nernst equation for a highly selective K+ channel. As expected, this 
chimera construct generated currents that were still significantly activated by 10 μM AA; 
1.63 ± 0.1-fold (n = 7, p < 0.0001, one-way ANOVA; Figure 6.12 D) at 0mV. Similar to their 
parental channels, 1 μM spadin did not inhibit the pre-activated AA currents in this 
chimera, which were measured as 3.7 ± 0.2 μA (AA-activated current, n = 7) and 4.0 ± 0.2 
μA (AA-activated current + spadin, n = 7; Figure 6.12 D). In addition, application of 1 μM 
spadin did not affect this chimera basal channel activity, with no significant change in 
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currents measured at 0 mV; 2.1 ± 0.2 μA (control, n = 8) and 2.2 ± 0.2 μA (in presence of 
spadin, n = 8; Figure 6.12 E). In contrast to mTREK-1 channels, 1 μM spadin failed to 
antagonise AA-activation of the mTREK-2-mTREK-1 c-terminal chimera currents with 
currents measuring at 0 mV; 4.2 ± 0.4 μA (AA activated current + spadin, n = 8) and 4.5 ± 
0.4 μA (AA alone, n = 8, p = 0.67, one-way ANOVA; Figure 6.12 E). As AA activation is 
preserved, but spadin no longer antagonises AA activation I suggest that the C-terminal 
domain does not contribute directly to spadin activity.  
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Figure 6.12. (A) shows the cartoon structure of the mTREK-2-mTREK-1-c-terminal chimera 
construct. (B) Mean current-voltage (I-V) relationships taken from steady-state currents in 
the presence of differing concentrations of extracellular K+; 4 mM (blue), 20 mM (red), 100 
mM (green) and 140 mM (purple), n = 6. Currents of the chimera elicited by voltage pulses 
from -120 to +60 mV in 10 mV steps, 1 s in duration, from a holding potential of -80 mV, in 
low K+ solutions (4 mM) or high K+ solutions (140 mM). Reversal potentials of chimera 
currents (C) were plotted as a function of [K+]out  (mean ± SEM). Data points are fitted with 
the Goldman-Hodgkin-Katz voltage equation (lines). Currents were measured in K+ 
solutions respectively 4 mM, 20 mM, 100 mM and 140 mM. Data points are fitted with a 
linear relationship (red line). Dashed line represents Nerstian theoretical linear relationship 
of EK with changing [K+]o as calculated using the Nernst equation assuming [K+]i is 140 mM 
(slope = -58.2 mV).  (D, E) I-V plots for effects of spadin in chimera currents. D, currents 
were recorded after chimera AA-activation by 10 μM arachidonic acid (AA) and AA + spadin 
(1 μM) (n = 7). E, currents were recorded in absence (control) and in presence of spadin (1 
μM), followed by AA (10 μM) + spadin (1 μM) and then AA (10 μM) (n = 8). Error bars 
represent SD, ****P < 0.0001, one-way ANOVA. 
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Overall, these data suggest that spadin is an allosteric antagonist of mTREK-1 channels, 
preventing AA-activation. This antagonism is specific to TREK-1 channels and is specific to 
AA-activation.  Moreover, the mechanism of spadin antagonism does not involve the C-
terminus of mTREK-1.  
 
6.3 Discussion 
In my previous chapters, I demonstrated that mechano-gated TREK subfamily channels not 
only exhibit distinctive expression patterns in mouse intestinal smooth cells and enteric 
neurons, but also play a function role in regulating the mouse intestinal smooth muscle 
contractility. Hence, pharmacological manipulation of TREK subfamily channels could be a 
vital new therapeutic target for treating GI motility disorders. In order to understand the 
physiological roles of TREK channels in the mouse model, a pharmacological profile of 
different mouse TREK channels needs to be established, at least initially, through the 
application of known TREK channels activators and inhibitors, to isolated heterologously 
expressed mouse channels. These important details are currently lacking in the literature. 
So to allow comparison of TREK-1, TREK-2 and TRAAK channel properties in mouse tissue 
to previous reports, mouse homologues of TREK-1, TREK-2 and TRAAK were expressed in 
Xenopus oocytes and their biophysical properties and pharmacological phenotypes 
assessed through TEVC analysis. However, mTRAAK was failed to produce robust currents 
despite varying concentrations of cRNA, expression durations and creating de-sumoylated 
mutants. The data within this chapter show both TREK-1 and TREK-2 channels are sensitive 
to pharmacological activators of the mechano-gated K2P channels, with particular potency 
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exhibited by the fenamate, BL-1249. Investigation into the activity and specificity of spadin 
towards TREK-1 and TREK-2 channels suggested a structural component, such as the C-
terminus, may be responsible for the mechanism of action of antagonism of AA-activation 
of TREK-1 channels. Transplant of the c-terminus from the spadin sensitive m TREK-1 
channels to the spadin insensitive mTREK-2 channel failed to transfer spadin activity, 
suggesting spadin does not bind on the C-terminus to antagonise AA action in TREK-1 
channels.  
 
6.3.1 Heterologous expression of mTRAAK in Xenopus laevis oocytes 
Injection of individual cloned mouse TREK channel cRNAs into Xenopus oocytes resulted in 
robust, measurable currents from mTREK-1 and mTREK-2 but not for mTRAAK, despite 
various attempts using altered concentrations and incubation times. There could be several 
reasons as to why mTRAAK failed to elicit substantial currents; 1) proteins were not 
efficiently translated; 2) proteins were translated but not efficiently trafficked to the cell 
membrane; 3) proteins may form functional expression by requiring accessory or 
regulatory subunits, such as SUMO, analogous to the K2P channel TWIK-1 (Rajan et al., 
2005), or Mtap2, like the K2P channel TREK-1 (Sandoz et al., 2008); 4) channels have a low 
open probability; 5) TRAAK channels have a low single channel conductance (Soussia et al., 
2018, Blin et al., 2016). Previous studies revealed that the silent K2P channel, TWIK-1, could 
be awakened by perturbing sumoylation via mutation of the binding site at K274 to either 
an arginine, glutamine, tyrosine or cysteine (Rajan et al., 2005, Plant et al., 2005). To test 
the hypothesis that sumoylation was involved in low TRAAK activity, high probability SUMO 
sites in TRAAK were mutated. Mutations at sites K38 and K330 failed to elicit a substantial 
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increase in currents suggesting mTRAAK activity is not regulated by sumoylation. 
Regulatory partners or accessory proteins play an important role in mammalian and plant 
K2P channel trafficking and regulation (Noel et al., 2011). Unlike TRAAK, TREK-1 and TREK-2 
have protein partners regulating their channel activity, such as A-kinase-anchoring protein 
(AKAP150) and Microtubule-associated protein 2 (Mtap2) (Noel et al., 2011). AKAP150 
binds to a major regulatory domain located in the C-terminus of TREK-1, promoting a 
drastic increase in channel currents which are unable to be further enhanced by 
polyunsaturated fatty acids, acidic pH, or stretch but can still be regulated by protein kinase 
(Sandoz et al., 2006). Mtap2 is another identified constituent protein of TREK channels in 
the brain, binding to TREK-1 and TREK-2 does not affect channel activity directly but 
increases channel surface expression and current density (Sandoz et al., 2008). The beta-
coatomer protein complex (β-COP) as another interacting partner of TREK-1 binding on the 
N-terminus by enhancing the TREK-1 channel surface expression (Kim et al., 2010). It is not 
known if β-COP interacts with TREK-2 and TRAAK, however, this does present a potential 
probability for future investigation.  
 
All these three TREK subfamily channels have a similar unitary conductance in physiological 
conditions (Fink et al., 1998, Patel et al., 1998), however, TREK-1 and TREK-2 display larger 
currents than TRAAK, when they are in the same expression conditions (Levitz et al., 2016), 
indicating differences in the number of channels at the membrane or open probability of 
individual channels. In this same study, it was demonstrated that co-assembly of TREK 
channels could occur, forming functional heterodimers (Levitz et al., 2016). When TREK-1 
is co-expressed with TREK-2, heterodimers display voltage-dependent gating and open 
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probability similar to TREK-1 homodimers (Blin et al., 2016). TRAAK can form heterodimers 
with both TREK-1 and TREK-2 (Levitz et al., 2016). TREK-1/TRAAK heterodimers exhibit 
functional, regulatory and pharmacological differences from TRAAK homodimers. TREK-
1/TRAAK heterodimers are stimulated by both intracellular acidification and alkalinisation, 
and regulated by the enzyme phospholipase D2 (Levitz et al., 2016). Activation of protein 
kinase A (PKA) down-regulates TREK-1 and TREK-1/TRAAK, although displays no effect to 
TRAAK (Blin et al., 2016). Moreover, heterodimerization also impacts channel 
pharmacology in TREK-1/TRAAK. TREK channels modulators such as fluoxetine and ML67 
display different sensitivities towards TREK1/TRAAK heterodimers versus TREK-1 or TRAAK 
homodimers (Blin et al., 2016). This may suggest that TRAAK preferentially assembles with 
other TREK subfamily channels in-vivo rather than forming a homodimer. Given the distinct 
expression profiles of TREK-1 and TRAAK in mouse GI tract, functional studies of TREK-
1/TRAAK heterodimers were not pursued.  
 
Recently, the proximal C-terminal domain (pCt) of TREK channels has been reported as a 
key element in regulating the channel basal currents (Soussia et al., 2018). Notably, this pCt 
region exhibits opposite effects in TREK-1 and TRAAK, which stimulate activity in TREK-1 
and impairs TRAAK activity. Deletion of this region dramatically decreased TREK-1 current 
amplitude whereas increased TRAAK current by 13-fold. Moreover, the same effects were 
observed when the two pCt were swapped (Soussia et al., 2018). Therefore, this could be 
another reason to explain why TRAAK is less active than other two channels and produces 
small currents in basal conditions.  
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6.3.2 mTREK-1 and mTREK-2 display comparable biophysical and 
pharmacological phenotypes as their human orthologues 
To compare the properties of TREK-1 and TREK-2 channels in mouse tissue to previous 
organ bath studies, mouse homologues of TREK-1 (mTREK-1) and TREK-2 (mTREK-2) were 
characterised after expression in Xenopus oocytes. Expression of mTREK-1 in oocytes 
resulted in a conductance with similar electrophysiological properties as the human TREK-
1 (hTREK-1) and a previously characterised colonic conductance postulated to be TREK-1 
(Fink et al., 1996, Koh et al., 2001). There is no previous research documenting the 
properties of mouse TREK-2, therefore the results presented in this chapter provides new 
insight. My data reveals that mTREK-2 channels share very similar biophysical properties as 
its rat TREK-2 (rTREK-2) and human TREK-2 (hTREK-2) counterparts (Bang et al., 2000, 
Lesage et al., 2000).  
 
Polyunsaturated fatty acids, including arachidonic acid (AA) have been revealed to activate 
all mechano-gated K2P channels (TREK-1, TREK-2 and TRAAK) (Fink et al., 1998, Bang et al., 
2000, Kim et al., 2001a). BL-1249, a non-steroid anti-inflammatory drug has been shown to 
directly and reversibly activate TREK-1, TREK-2 and TRAAK channels (Veale et al., 2014, 
Pope et al., 2018), and the caffeic acid derivative, CDC, to activate TREK-1 (Danthi et al., 
2004). All three compounds produced activation effects on both mTREK-1 and mTREK-2 
channel currents. In addition, BL-1249 produced more potent activation of mTREK-1 than 
mTREK-2 echoing a previous study (Pope et al., 2018). However, a novel finding from my 
experiments was the activation of mTREK-2 by CDC, which displays a similar potency as 
mTREK-1. However, the mechanism of action of CDC has not been elucidated, and future 
241 
 
studies describing the binding site and mechanism of action should be sought. Furthermore, 
given the number of research studies conducted in mice, and their use as a model for many 
physiological processes and pathologies, the biophysical and pharmacological 
characterisation of two cloned mouse TREK channels here provides useful and timely 
information for future studies in this model. 
 
6.3.3 Spadin specifically antagonizes the activation of TREK-1 channels by 
AA, but not other pharmacological activators 
Recently, a new antidepressant peptide, spadin, was described as a blocker of TREK-1 
channels, and a new potential therapeutic treatment for depression (Mazella et al., 2010, 
Borsotto et al., 2015). The authors showed that spadin was able to block TREK-1 activation 
stimulated by 10 μM AA (IC50 = 71 nM) in COS-7 cells. The action of spadin on TREK-1 was 
also confirmed in brain slices by directly recording hippocampal CA3 pyramidal cells. 
Moreover, this inhibitory effect of spadin on AA stimulated current in CA3 neurons was 
absent in the same experimental conditions in the TREK-1 knock-out mice, which confirmed 
the specificity of spadin for TREK-1 channels (Mazella et al., 2010). However, I was unable 
to reproduce these findings in my oocyte expression system with either human or mouse 
TREK-1 channels. On the contrary, data from my study indicates that spadin does not block 
mTREK-1 currents under basal conditions, but rather antagonises mTREK-1 activation by 
AA. Given the stark contrast to previous findings, my experiments characterised the activity 
of spadin when applied after AA addition and also before AA addition, experiments not 
described in previous studies.  
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Taken together my data suggested spadin to be an antagonist of TREK-1 channel activation, 
rather than a “blocker” as previously perceived. In order to help understand the 
mechanisnm of action of spadin, and how it may act as an antagonist, it was important to 
establish whether this antagonism was modulator specific, i.e. prevented TREK-1 channel 
activation by any chemical modulator, or whether this was specific to lipid activation.  My 
results clearly show that spadin was unable to antagonise the activation of TREK-1 channels 
by BL-1249 or CDC, or indeed by other lipid modulators such as DHA (Fink et al., 1998). 
These data led me to propose that spadin specifically antagonises the activation of mTREK-
1 channels by AA, and not other pharmacological activators. 
 
6.3.4 How does spadin antagonise TREK-1 channel activation by AA? 
Spadin may antagonise AA-activation in TREK-1 channels by allosteric or orthosteric 
antagonism, meaning it may have a different binding site from AA on the channel protein 
and induce a change in the conformation of the protein that affects subsequent AA binding, 
or it may bind to the same site as AA and prevent AA activity directly. A recent set of studies 
investigating the state-depending binding of fluoxetine in TREK channels could possibly 
explain any potential allostery. Crystal structures of TREK-1 (Lolicato et al., 2017), TREK-2 
(Dong et al., 2015) and TRAAK (Brohawn et al., 2012) channels in the up and down 
conformations have been reported, and suggest different conformational gating states, but 
provide no firm consensus about the structure of the active open state. The crystal 
structures of the hTREK-2 channel in complex with its inhibitor norfluoxetine suggests that 
conformational changes induced by drug binding can modulate channel activity (Dong et 
al., 2015). The authors proposed a gating mechanism of TREK-2 in which movement of the 
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pore-lining helices converts channel between ‘‘down’’ and ‘‘up’’ functional states. The 
‘‘down’’ state represents a closed and poorly conductive state stabilized by inhibitors such 
as norfluoxetine binding within the fenestrations, whereas the ‘‘up’’ state can be induced 
by membrane stretch or AA activation and represents an open and more conductive state 
(Dong et al., 2015). Moreover, many physiological TREK activators, such as AA, PIP2 and 
intracellular acidification, are thought to act on C-terminus and influence C-type gate 
through M4 (Dong et al., 2015, Bagriantsev et al., 2012, Lolicato et al., 2014), and shift the 
channel confirmation from outward rectifier mode to an ohmic ‘‘leak mode’’ (Schewe et 
al., 2016). In addition, norfluoxetine would access its binding site only when the TREK-2 
channel is in the ‘‘down’’ state. TREK-2 shifts to the ‘‘up’’ functional state when activated 
by AA, and becomes resistant to norfluoxetine (as shown in Figure 6.13 below) 
(McClenaghan et al., 2016). Indeed, the inhibitory ability of norfluoxetine can been 
markedly reduced by the mutation Y315A locates in channel M4, which promotes a 
conformation of pore-lining the TREK-1, TREK-2 and TRAAK channel subfamily are thought 
to be similar, and thus like TREK-2, TREK-1 is proposed to be only sensitive to fluoxetine 
when it is in the ‘‘down’’ conformation, but not when TREK-1 is stimulated by AA and in the 
up state (Soussia et al., 2018). Both norfluoxetine and fluoxetine are clinically effective 
antidepressants which also have been reported as a blocker of TREK channel (Heurteaux et 
al., 2006). Interestingly, spadin has also been proposed to work as a potential 
antidepressant peptide for treating the depression. Therefore, I propose that spadin could 
possibly act in a similar way to fluoxetine, which only being effective when applied before 
AA. Spadin only binds to TREK-1 channels when the channel is in the so-called ‘‘down’’ 
conformation, and as such would inhibit subsequent activation by AA. Similarly, when pre-
activated by AA and channel will change its confirmation to the “up” state, spadin is no 
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longer able to bind, and so this model would predict no activity of spadin in AA activated 
TREK-1 channels. 
 
Figure 6.13: Expanded gating model for TREK-2 activation. This cartoon illustrates how 
structurally distinct open states (e.g., O1 and O2) can be produced by different activatory 
stimuli. The model allows for the filter to gate independently in both the up and down 
conformations. The dotted line illustrates how the major conformational changes in the 
TM helices caused by, e.g., membrane stretch and temperature can also influence the filter 
gating mechanism. The model also shows how the channel can interconvert between 
different open states in response to membrane stretch (McClenaghan et al., 2016). 
 
Notably, TRAAK displays opposite activity to TREK-1 and TREK-2 in the state-depending 
binding of fluoxetine. TRAAK is not sensitive to fluoxetine when in the ‘‘down’’ 
conformation, whereas it becomes sensitive once activated by AA (Soussia et al., 2018). 
The authors suggest that this opposing behaviour of TRAAK and TREK-1 are due to their 
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proximal c-terminus (pCt), as swapping this section of the C-terminus between TRAAK and 
TREK-1 induces an exchange of their activity regarding fluoxetine sensitivity in the 
stimulated state. In addition, these new findings highlight the significance of the pCt 
(Soussia et al., 2018). These data suggest that the C-terminal domain plays an important 
role in influencing the conformational state of TREK-1 and TRAAK channels, and implies the 
pCt may critical to spadin sensitivity in TREK-1 channel.  
  
6.3.5 The role of the C-terminus in AA sensitivity 
The finding that spadin does not antagonise other known activators of TREK channels, 
implied that spadin may share the same binding site as AA in order to specifically 
antagonise AA activation of TREK-1 channels. A previous report identified that a charge 
cluster (RVISKKTKEE) in the C-terminal region (Arg297-Glu306) of TREK-1 was a critical 
binding site for AA sensitivity (Patel et al., 1998, Honore et al., 2002). Interestingly, 
progressive deletion of the C-terminal domain of TREK-1 reduced sensitivity to AA, but 
replacing the C-terminal region of TASK-1 and 3 (not stimulated by AA) with TREK-1 do not 
have any significant effect to AA  (Patel et al., 1998, Honore et al., 2002). TREK-2 has been 
also reported that consist a region of 25 amino-acid between position Arg323 and Thr348, 
containing a charge cluster (KKTKEE), which are thought to be critical to AA sensitivity (Kim 
et al., 2001b). However, there is also evidence to suggest the C-terminus plays a less 
important role, as shown in TRAAK channel, where substitution of a homologous charge 
cluster results fails to effect of AA sensitivity (Kim et al., 2001a). Taken together with the 
significance of pCt in TREK-1, I predicted that the C-terminus of TREK-1 would be important 
in providing the sensitivity to spadin. Replacing the mTREK-2 C-terminal domain with that 
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from mTREK-1 creates a fully functional channel with biophysical attributes expected of a 
potassium selective channel, and similar to its parental channels, retains significant AA 
sensitivity. However, spadin did not antagonise AA stimulated chimera currents indicating 
that the C-terminal region of TREK-1 is not sufficient nor necessary to mediate the selective 
action of spadin.   
 
6.3.6 Locating the binding site of spadin in TREK-1 
It is possible that AA also binds to other regions in TREK-1 and not just in the c-terminus as 
previously suggested, as TRAAK also contains a cluster of charged amino acids (KVISKKTKEE) 
in its c terminus, but replacing it with that from TASK-1 or 3 channels still leaves AA 
sensitivity intact (Kim et al., 2001a). Spadin does not antagonise the effects of BL-1249, and 
so it is unlikely that spadin binds at this site. Veale et al., (2014) identified M1 (W44A), M2 
(L174A) and M4 (W275S and W284A) mutations in TREK-1 affect fenamate activation 
(including BL-1249). Pope et al., (2018) suggest the M2/M3 transmembrane helix interface 
as a key site of BL-1249 sensitivity (Pope et al., 2018), but acknowledge a role for the c-
terminus in BL-1249 activation, inferring co-operatively between the pore and c-terminus 
in determining gating states of the channel. I can rule out spadin as a classical pore blocker 
given its ineffectiveness on basal or activated currents, which were clearly demonstrated 
with the classical pore blocker barium. Spadin could possibly share a similar binding site as 
fluoxetine, since it may become accessible when the pore lining M4 helix adopts a ‘‘down’’ 
conformation as fluoxetine does. The molecular modelling data of TREK-2 with 
norfluoxetine shows that this inhibitor binds in a pocket underneath the P2 helix of the 
selectivity filter at a site that is framed by the M2, M3 and M4 transmembrane helices 
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(Dong et al., 2015). Notably, disruption of the binding site by the L320W mutation located 
in M4 helices, reduces the inhibition of TREK-2 by norfluoxetine. Furthermore, the 
structural data indicates that the primary amine of norfluoxetine is near to the lower side 
of the selectivity filter where it could influence ion conductivity by disturbing the 
electrostatic environment of the pore (Dong et al., 2015). These recent findings suggest 
transmembrane M4 or the channel modulator pocket could be a possible binding site of 
spadin, although to date no co-crystal structure of TREK with spadin have been studied. To 
further understand the mechanism action of spadin in TREK-1 channels two approaches 
could be undertaken; 1) the generation of a chimera by replacing the M2, M3 and M4 of 
TREK-2 by TREK-1 respectively, 2) utilise molecular modelling of the TREK-1 structure in 
complex with spadin to identify the highest probable binding site and use mutagenesis to 
demonstrate proof of principle. To this end, I am currently collaborating with Dr Paul Cox, 
University of Portsmouth, to identify the binding site of spadin in TREK-1 using molecular 
modelling technology.  
 
In summary, application of known mechano-gated TREK activators, AA, BL-1249 and CDC 
resulted in the activation of both mTREK-1 and mTREK-2 channels. The previously proposed 
blocker of TREK-1 channels, spadin, was found to specifically antagonise AA-activation of 
TREK-1. Spaidin did not antagonise AA activation of mTREK-2, nor did it antagonise 
activation by other known TREK activators. Substitution of the C-terminus of mTREK-2 with 
that of mTREK-1 failed to transfer spadin sensitivity, suggesting its mechanism of action 
does not likely involve the C-terminus. Further definition of the action site of spadin 
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through chimera and molecular modelling studies will be crucial for defining how spadin 
controls TREK-1 activity. 
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Chapter 7 – General discussion 
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7.1 Summary and key findings 
The overall aim of this thesis was to provide an insight into potassium ion channel 
expression in the GI system and to understand the physiological contribution and function 
of mechano-gated K2P subtypes TREK-1, TREK-2 and TRAAK in intestinal smooth muscle. 
Smooth muscle plays an important role in controlling GI motility, forming mechanical and 
electrical junctions with neighbouring cells creating a functional syncytium that stimulates 
coordinated contractions, forcing the food, water and waste to move though the gut 
(Sanders et al., 2012b). The key findings within this thesis show; 1) many different 
potassium channel subtypes from Kv, Kir and K2P subfamilies are heterogeneously expressed 
along mouse ileum and colon; 2) K2P channels, TWIK-1 and TASK-2, transcripts and proteins 
are expressed at high levels across multiple cell types in the GI tract; 3) mechano-gated K2P 
channel proteins are differentially expressed in GI tract with TREK-1 exclusive to smooth 
muscle whereas TREK-2 and TRAAK are expressed only in enteric neurons; 4) 
pharmacological activation of mechano-gated channels is sufficient to induce significant 
relaxation of pre-contracted ileum and colon, suggesting an important role in GI physiology; 
5) cloned mouse TREK-1, TREK-2 and TRAAK channels exhibit similar biophysical properties 
as their human homologues, with sensitivity to well-known K2P activators AA, CDC and BL-
1249; 6) spadin is not a blocker of mTREK-1 or mTREK-2 channels, but specifically 
antagonises the activation of mTREK-1 channels by AA, and not that of other 
pharmacological activators; 7) the mechanism of action of spadin does not involve the C-
terminus directly, and likely works via an allosteric mechanism distinct from the AA binding 
site. This study has provided a new insight into the potassium channel subtype expression 
profile and function in mouse intestine, and highlights the mechano-gated K2P channel 
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TREK-1 as a potential target for future drug development treating hypermotility GI 
disorders.  
 
7.2 Could K+ channels be a potential target for treating IBS? 
Potassium channels are intimately involved in almost all aspects of physiology and play a 
critical role in diverse processes such as nerve and muscle relaxation, sensory transduction, 
regulation of blood pressure, and cell proliferation (Hille, 2001, Kew and Davies, 2010). 
Therefore, potassium channels have been reported as therapeutic targets for treating a 
wide range of diseases that include cardiac disorders (Diness et al., 2015, Doshi and Marx, 
2009), neuropathic pain (Busserolles et al., 2016, Tsantoulas and McMahon, 2014), skeletal 
muscle disorders (Zhu et al., 2014) and kidney failure (Grgic et al., 2009, Mene and Pirozzi, 
2013). Their membrane expression makes these proteins easy to target chemically, and 
their ability to establish and maintain an electrical membrane potential is key for 
controlling many aspects of cell physiology. L-type calcium channels have been previously 
targeted in GI tract to treat motility issues including IBS related diarrhoea by promoting 
relaxation of GI smooth muscle (Wegener et al., 2006, Radulovic et al., 2015). Alternatively, 
comparably little is known about the underlying potassium channels responsible for 
suppressing smooth muscle contractility and promoting GI tract relaxation, and represents 
and as yet unexplored mechanism for treating a range of GI motility disorders including IBS.  
 
IBS is a disorder of the brain-gut axis causing disruption to the physiological process of 
motility involving the coordinated contractions of the circular and longitudinal smooth 
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muscle cells. Current treatments for IBS are often selected sympomatically, whether 
involving diarrhoea or constipation, while the treatment of pain remains a significant 
unmet need (Camilleri and Ford, 2017). Therefore, novel effective therapeutic targets are 
required which are able to target both motility and pain symptoms and improve prognosis. 
 
Identification of distinct expression patterns and functional contributions of K+ channel 
families in Chapter 3, 4 and 5 respectively within the mouse intestine, reveal the K2P 
channel family could become increasingly seen as valid therapeutic targets. For example, 
specific smooth muscle and ENS neuron expression patterns of different K2P subunits were 
apparent from my data. Given the finding that TREK-1 appears to be expressed only in 
smooth muscle and TREK-2 and TRAAK only in enteric neurons, the two main symptoms of 
IBS, motility and pain, could be targeted independently depending on the patients’ 
presentation. A picture emerges of TREK-2, TRAAK, TASK-2/3 and TWIK-2 subunits being 
located only in ENS neurons and thus suggest they could be potential targets for treating 
visceral pain symptoms. Notably, both TREK-2 and TRAAK exhibits ChAT-immunopositive 
MP neurons labelling, which thought to be a primary afferent neurons as the sensor of the 
pain pathway (Furness, 2000). Indeed, TREK-2 has been reported as a major background K+ 
current in dorsal root ganglion (DRG) neurons, which serves such an important role in 
limiting pain sensation (Kang and Kim, 2006). Moreover, molecules that activate TREK-2 
channels have been found to stimulate K+ currents in DRG neurons and limit calcium influx 
in order to reducing neuropathic pain (Dadi et al., 2017, Veale and Mathie, 2016). However, 
from my data presented here, I am not able to confirm whether these channels are directly 
involved in controlling abdominal pain sensation. Furthermore, ChAT positive neurons also 
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include excitatory motor neurons and interneurons which are involved in motility reflexes 
(Furness, 2000, Rao and Gershon, 2018, Costa et al., 2000), therefore TREK-2 could also be 
a target for indirectly treating contractile dysfunction. TREK-1 and TRAAK have also been 
shown to have strong immunoreactivity in small-sized DRG neurons (Viatchenko-Karpinski 
et al., 2018), and TREK-1 KO mice haven been found to be more sensitive to painful heat 
sensations compared to WT (Alloui et al., 2006). Thus, I believe further 
immunohistochemistry experiments of K2P subunits within specific ENS sensory neurons 
are required,  for example using the calcium-binding proteins calbindin (CB) as a marker for 
identifying the sensory neurons in both MP and SP (Furness, 2000, Megias et al., 2003) and 
subsequent overlapping expression of TREK-2 and TRAAK. 
 
On the basis of the combination of the immunolocalisation and organ bath pharmacology, 
I can conservatively conclude that since TREK-1 is exclusively expressed by smooth muscle, 
this channel is likely to be principally involved in the contractile functions of intestinal 
smooth muscle. Indeed, the block of neuronal action potentials by TTX suggests the 
relaxation induced by activation of mechano-gated K2P channels is independent of enteric 
neuron input. However, specific pharmacological modulators of TREK-1 channels are still 
lacking, and is an area of research that requires significant input if K2P channels are to be 
realised as therapeutic targets for various pathologies. Based on my pharmacology 
characterisation of K2P channels in Chapter 6, the potency of BL-1249 for different TREK 
subtypes was identified, thereby suggesting the relaxation induced by BL-1249 may also 
related to effects across enteric neurons though TREK-2 and TRAAK channels. Importantly, 
TREK-2 and TRAAK exhibit expression patterns in both inhibitory and excitatory enteric 
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motor neurons, as GI motility is directly controlled by those two motor neurons that 
innervate the layers of smooth muscle (Brookes, 1993). Thus, I believe that subunit-specific 
KO mice will need to be employed in future experiments. For instance, repeating organ 
bath experiments of BL-1249 using tissue from TREK-1, TREK-2 and TRAAK KO mice should 
be assessed.  
 
Furthermore, GI motility involves co-ordinated activity between GI longitudinal and circular 
muscles. However, in my organ bath preparation, I essentially only measured longitudinal 
muscle activity. This was simply due to the availability of recording equipment. Therefore, 
repeating the experiments using the myograph preparation (Jepps et al., 2009) would allow 
direct analysis of circular muscle function and analysis of K2P pharmacology would address 
their roles in circular muscles.  
 
7.3 Could K+ channel as a cause of IBS 
My results from Chapter 3 demonstrated, for the first time, the expression profile of whole 
potassium families within WT mouse intestine, and from Chapter 4 further focused on the 
localisation and physiological role of K2P subfamily channels. However, how this expression 
level of K+ channel subtypes changes in GI disease (such as IBS & IBD) is remains to be 
elucidated. Although on the organ bath studies I identified several K+ subtype channel play 
a functional role in regulating the intestinal contractility, I am not able to determine 
whether there is a cause-effect relationship from these channels. In addition, determining 
the onset of IBS could be important to human health and wellbeing. If particular K+ subtypes 
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are found to have a direct role in GI disorder development, then early diagnoses and 
therapy with specific K+ channel modulators are likely to offer clinical benefits. Therefore, 
to further investigate this, I will need to repeat these experiments in different animal 
models (such as IBS, stress or Parkinson’s) or samples from patients to take this research 
to the next level.  
 
To date little is known about the changes in expression level of the K+ channels in GI disease 
model, especially in IBS model. TREK-1 expression has been recently reported to be down-
regulated in Hirschsprung’s disease (Tomuschat et al., 2016), which is an intestinal 
obstruction disease with symptoms characterised by the absence of ganglion cells in the 
colon. This disease presents similar symptoms with IBS, such as constipation. Apart from 
the K+ channels, Ca2+ channels has been well-studied in IBS and as a target of current 
treatment using otilonium bromide (OB) resulting in reducing abdominal pain frequency 
(Camilleri and Ford, 2017). In IBS patients, the T-type calcium channel Cav 3.2 channels 
exhibits higher expression in colon compared to control (Scanzi et al., 2016). Furthermore, 
neither the protein nor mRNA expression of L-Type voltage-dependent Ca2+ channel (Cav 
1.2) appears to change in colonic myocytes from IBD mouse whereas the calcium currents 
were reduced by almost 70% by inflammation (Kang et al., 2004c). Thus, various 
experiments in IBS mouse model can be conducted in the future to probe the role of K+ 
channels in causation, quantified by mRNA expression using qPCR and protein levels by 
using western-blot, as well as recording isolated smooth muscle cell from an IBS model to 
observe changes in current density.  
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Recently, information suggests that association of IBS and psychiatric disorders may be 
more fundamental than was previously believed (Lydiard, 2001). A comprehensive body of 
research indicates that the mental disorders such as stress, anxiety and depression play an 
important role in the development, onset and symptom exacerbation of IBS (Wood, 2002, 
Drossman, 2004). In addition, on a functional level, stress leads to the inhibition of gastric 
emptying which is accompanied by an increase in the colonic motility, mucosal electrolyte 
secretion and faecal pellet discharge (Tache et al., 1999, Maillot et al., 2000). Furthermore, 
various clinical studies have shown as many as 30-40% IBS patients have co-morbid 
depression or anxiety disorder (Lydiard and Falsetti, 1999, Kabra and Nadkarni, 2013). 
Within the CNS, various types of K+ channels are abundantly expressed and their activities 
are suggested to be altered during depression (Lodge and Li, 2008). In general, when 
activated, potassium channels inhibit excitability of cells and lower the effectiveness of 
excitatory inputs by hyperpolarizing cell membrane potential. For instance, K2P channels 
(such as TREK-1 and TASK-3) have been identified as a target for the treatment of 
depression (Borsotto et al., 2015). Moreover, deletion of the TREK-1 gene leads to 
resistance to depression in animal models (Heurteaux et al., 2006), and thus suggests this 
gene plays an important role in onset of depression. Notably, both TREK-1 and TASK-3 
subunits exhibit specific localisation in smooth muscle and NOS neurons respectively in 
mouse intestine. Nevertheless, whether the stress-specific alterations in the expression of 
specific K+ subunits are compensatory or pathological remain unclear. If such experiments 
were to be conducted in the future, the stress or depression animal model would be a 
useful model to utilise. Moreover, tracking motility directly through assessing faecal pellet 
transit through the gut in TREK-1 KO mice compared to WT would also be another approach 
to assess whether the TREK-1 channel plays an essential role in the symptomology of IBS. 
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Given the link between stress, anxiety and GI motility disorders, it may also be fruitful to 
conduct further immunohistochemistry studies of K+ channel expression and corticotropin-
releasing hormone (CRH) receptors in the gut. CRHRs are important mediators in the stress 
response. For example, exposure of rats to early life stress, in form of maternal separation, 
leads to an increase in CRH1 and CRH2 receptors within the colon at protein levels 
(O'Malley et al., 2010). Importantly, increase in CRH1 receptor expression within certain 
disorders of the GI tract such as IBS has been reported (Tache et al., 2004, Tache and 
Perdue, 2004).  
 
IBS is one of the most commonly encountered functional GI disorders in the elderly 
(Bennett and Talley, 2002), but whether advancing age impacts on IBS remains unknown. 
Interestingly, an onset of IBS after the age of 65 years (elderly) is extremely rare, as in most 
cases, the incidence increases during adolescence and young adulthood (Kurniawan and 
Kolopaking, 2014). This information suggest ageing may act as an important role in onset 
of IBS, and thus whether changes in the expression of K+ during ageing within the intestine 
could be conducted in the future. However, it is very difficult to relate the development or 
existence of IBS to ageing due to the usual co-existence of GI disorders with other age-
related diseases such as Parkinson’s disease (PD).  Moreover, K+ channels have been 
thought to be a new therapeutic target for PD, as K+ channels such as Kv7 (Sander et al., 
2012), KATP (Dragicevic et al., 2015), SK (Dolga et al., 2014, Mourre et al., 2017) and A-type 
K+ (Kv4) (Subramaniam et al., 2014) are widely expressed in the basal ganglia (especially in 
DAergic neurons) which play crucial roles in the pathophysiology of PD. Notably, these K+ 
channels  also exhibit high level expression within mouse intestine, as revealed from my 
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qPCR results. Thus, this interesting finding regarding expression patterns of specific K+ 
subunits in both DAergic and intestine could provide the impetus for a new programme of 
work investigating the contributions of individual subunits to IBS/PD development and 
ageing.  
 
7.4 Clinical implications of findings 
Differential pharmacology between species, or speciation, is a common problem 
encountered during the course of drug discovery that can severely hamper efficient 
advancement of clinical candidates. However, in Chapter 6, mouse homologues of K2P 
channels display similar pharmacology as their human orthologues. More recently, K2P 
channels have been suggested as targets for treating CNS disorders especially depression 
(Borsotto et al., 2015, Mathie and Veale, 2007, Djillani et al., 2017), since activators of TREK 
subfamily have been demonstrated to be neuroprotective, such as riluzole, 
polyunsaturated fatty acids and lysophospholipids. Patients with IBS frequently suffer from 
anxiety and depression. Interestingly, treatments that relieve the mental health symptoms, 
often provide relief from secondary, co-existing GI symptoms (Fadgyas-Stanculete et al., 
2014, Olden, 2005). For example, anti-anxiety drugs such as chlordiazepoxide, which 
belongs to the drug class of benzodiazepines, have also been used in the treatment of IBS. 
However, these drugs have not been very successful due to the unwanted central side-
effects such as drowsiness and dizziness. The K2P channel inhibitor, spadin, displays 
particular antidepressant properties with a rapid onset of action and the absence of 
adverse effects on animal model (Moha Ou Maati et al., 2012, Devader et al., 2015) but 
was not reported to induce any GI side effects such as diarrhoea. Collectively, the data 
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within this thesis provide the scientific rationale for the re-evaluation of such agents with 
a view to reformulating them specifically for delivery to the GI tract.  
 
In conclusion, the results presented in this thesis have achieved my stated aims and 
objectives and my PhD research will thus contribute to the body of knowledge regarding 
the expression and function of K+ channels in gut. Nevertheless, the results created more 
questions than answers. I believe this to be advantageous, since the value of data often 
resides in the previously unknown complexity it unveils. Moreover, my findings lead to 
many further potential avenues of research that may be of interest and importance. The 
next phase of investigations will need to focus on the cause-effect relationship and exact 
roles of K+ channels in these physiological processes and how they can be exploited. The 
thesis provides a solid foundation on which these future investigations can be built with 
the aim of developing therapies targeting the modulation of K+ channels in GI motility 
pathologies.  
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